Modulation of the Gut-Liver Axis in Cirrhosis with Activated Carbon by Macnaughtan, JS
1 
 
 
 
Modulation of the Gut-Liver Axis 
in Cirrhosis with Activated 
Carbon 
 
 
 
Jane Macnaughtan 
 
 
 
PhD Thesis 
 
University College London 
 
 
2 
 
Supervisors 
 
Primary Supervisor  Professor Rajiv Jalan  
     Division of Medicine  
 
Secondary Supervisor  Dr. Rajeshwar Mookerjee (Jan 2014- 
     Division of Medicine 
     Professor Alastair Forbes (June 2010-Dec 
     2013) 
 
Tertiary Supervisor  Dr. Nathan Davies  
     Division of Medicine 
 
 
 
 
 
 
I, Jane Macnaughtan confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my parents 
Olwen and Harry Macnaughtan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Acknowledgements 
 
To the Liver Failure Group ‘family’, who supported me with this project and who will 
always remain lifelong friends: Vikram Sharma, Maria Jover, Naina Shah, Rita Garcia 
Martinez, Abe Habesion, Helen Jones, Rohit Sawhney. To Dr. Junpei Soeda who for 
teaching me flow cytometry analysis. To Dr. Jude Oben for his guidance and support 
for the non-alcoholic fatty liver disease studies. To Professor Alastair Forbes, Dr. 
Nathan Davies and Dr.Raj Mookerjee for their wisdom, support and encouragement 
throughout the project.  
 
My final thanks and acknowledgement is to my primary supervisor Professor Rajiv 
Jalan. I wish to thank him for teaching me by example what it means to be a true 
philosopher of science and for fostering a spirit of intellectual curiosity. I wish to thank 
him for his foresight to identify this as an important research area which 
complements my clinical practice and for which I have developed a great passion 
and enthusiasm. I thank him for developing my skills as a clinician scientist to 
observe both at the bench and the bedside and the ability to marry these two 
together. Finally, I wish to thank him for teaching me that everything we do is from 
patients and for patients and it is to these patients that I give my final word of thanks. 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
“All disease begins in the gut.” Hippocrates 
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Abstract 
 
Introduction 
A substantial body of evidence now exists to implicate bacterial products such as 
endotoxin in the pathogenesis of cirrhosis and determinants of outcome, most 
markedly in advanced disease. Strategies to modulate this process clinically are 
currently limited to antibiotics with the attendant risk of superinfection and resistance. 
Yaq-001, a new, synthetic non-absorbable carbon, has been shown to exhibit a high 
adsorptive capacity for bacterial toxins and thus represent a novel strategy to 
modulate the gut-liver axis. 
 
Methods 
Neutrophil function, cytokine profile and endotoxin concentrations were determined in 
the splanchnic circulation of cirrhotic patients. Gut barrier integrity, innate immune 
function and microbiome analysis was performed in bile duct ligated (BDL) rats 
treated with or without oral Yaq-001. Ob/ob and MCD mice were treated with or 
without Yaq-001. Effects on liver injury, immune function and metabolomic profile 
were determined.  
 
Results 
Portal compartmentalisation of neutrophil dysfunction and endotoxaemia was 
observed and associated with an anti-inflammatory cytokine profile. In vitro Yaq-001 
exhibited a high adsorptive capacity for endotoxin and acetaldehyde without any 
effect on bacterial growth kinetics. Yaq-001 administration in BDL rats significantly 
improved organ injury, portal pressure and innate immune profile along the gut-liver 
7 
 
axis. In vivo and in vitro endotoxin sensitivity was improved. Oral Yaq-001 was found 
to significantly improve liver injury, Kupffer cell function and metabolomic profile in 
NASH models. 
 
Conclusions  
Defects at the gut barrier interface play a key role in driving bacterial translocation 
rates with preserved integrity of hepatic immune surveillance despite advanced 
disease. Oral administration of Yaq-001 in models of cirrhosis and NASH is safe and 
associated with a significant improvement in organ injury, portal pressure, innate 
immune function and endotoxin sensitivity. These studies suggest Yaq-001 
represents a promising new strategy for the management of liver disease. 
  
 
 
 
 
 
 
 
 
 
8 
 
Contents 
 
List of Supervisors               2 
Acknowledgements               4 
Abstract             6 
List of Figures           19 
List of Tables              23 
List of Abbreviations             24 
 
Chapter 1 Introduction 
1.1 Cirrhosis and Acute-on-Chronic Liver Failure       27 
 1.2 Systemic Inflammation; cirrhosis and ACLF 
 1.2.1 Nature of immunological response in cirrhosis and ACLF    29 
  1.2.2 Innate immunity 
  1.2.2.1 Neutrophil Dysfunction       32 
  1.2.2.1 Monocyte/Macrophage Dysfunction      32 
 1.2.3 Acquired immunity         34 
 1.2.4 Other factors modulating immune function      36 
 1.2.5 Role of bacterial ligands in pathogenesis (TLR pathways)     37 
1.3 The role of alterations in the Gut Barrier interface and bacterial translocation on 
pathogenesis of cirrhosis and ACLF 
 1.3.1 Background          39 
 1.3.2 Mechanisms of Bacterial Translocation      41 
 1.3.3 Intestinal Microbiota         42 
  1.3.3.1 How does the microbiota of cirrhosis differ from that of health? 
   1.3.3.1.1 Data from Phylogenic Studies     42 
   1.3.3.1.2 Data from Metagenomic studies     44 
  1.3.3.2 Clinical relevance of bacterial translocation in cirrhosis 
9 
 
   1.3.3.2.1 Hepatic encephalopathy      45 
   1.3.3.2.2 Spontaneous bacterial peritonitis     47 
   1.3.3.2.3 Portal hypertension and circulatory dysfunction   49 
   1.3.3.2.4 Acute-on-chronic liver failure (ACLF)       49 
   1.3.3.2.5 Pre-cirrhotic chronic liver disease     50 
  1.3.3.3 Metabolic sequelae of dysbiosis in cirrhosis 
   1.3.3.3.1 Background        51 
   1.3.3.3.2 Bile acid metabolism and the microbiome in  
   cirrhosis         52 
  1.3.3.4 Aetiology-specific changes in microflora 
   1.3.3.4.1 Alcohol        53 
   1.3.3.4.2 Non-alcoholic fatty liver disease     54 
   1.3.3.4.3 Cholestatic Liver disease      56 
 1.3.4 Intestinal Permeability 
  1.3.4.1 Evidence for alterations in intestinal permeability    56 
  1.3.4.2 Alcohol         58 
  1.3.4.3 Nutritional factors and obesity      59 
  1.3.4.4 Portal Hypertension        60 
1.4 Manipulation of the microbiota as a therapeutic manoeuvre in liver disease 
 1.4.1 Reducing gut bacterial populations: Antibiotics     61 
 1.4.2 Altering Bacterial composition: Probiotics      62 
 1.4.3 Other potential and emerging approaches 
  1.4.3.1 Beta-blockers         63 
  1.4.3.2 Targeting toll-like receptor pathway      63 
  1.4.3.3 Faecal Transplantation       63 
1.5 Nanoporous carbons           65 
 
 
10 
 
Chapter 2 Hypothesis and Aims 
2.1 Hypotheses 
 2.1.1 Hypothesis 1          67 
 2.1.2 Hypothesis 2          67 
 2.1.3 Hypothesis 3          67 
 2.1.4 Hypothesis 4          67 
2.2 Aims  
 2.2.1  Characterisation of the portal-derived neutrophil and cytokine profile 
 and association with markers of bacterial translocation    68 
 2.2.2  Assessment of the integrity of the gut barrier interface and  
  correlation with clinical, immune and pathological characteristics of 
 bile duct ligated rats         69 
 2.2.3  Characterisation of functional, immunological and microbiological 
 changes in the gut-liver axis with oral administration of Yaq-001 in  
  bile duct ligated rats         70 
 2.2.4 Oral administration of Yaq-001 will result in attenuation of liver  
  injury in models of NAFLD        71 
 
Chapter 3 Methods 
3.1 Clinical study  
 3.1.1 Patients           72 
 3.1.2 Patient Management         72 
 3.1.3 Transjugular Intrahepatic Portosystemic Stent Shunt procedure and 
 catheter insertion          73 
 3.1.4 Blood sampling and Measurements       73
 3.1.5 Calculations          74 
 3.1.5 Patient Follow-up         74 
11 
 
3.2 Animal Models 
 3.2.1 Bile duct Ligation Rat Model        75 
 3.2.2 Murine models of Non-Alcoholic Fatty Liver Disease     76 
  3.2.2.1 Leptin deficient mice (ob/ob)       76 
  3.2.2.2 Methionine Choline Deficient Mice      77 
3.3 Cell Culture Experiments  
 3.3.1 HEK-Blue hTLR4 cells         78 
 3.3.2 HEK-Blue IL-1β/IL-18 cells        79 
3.4 Immunology Methods 
 3.4.1 Clinical study          80 
  3.4.1.2 Neutrophil function 
   3.4.1.2.1 Phagoburst Assay       80 
   3.4.1.2.2 Phagotest Assay       81 
 3.4.2 Rodent Studies 
  3.4.2.1 Sample Preparation 
   3.4.2.1.1 Isolation of Non-Parenchymal Cell  
   Fraction from Rodent Liver Tissue      81 
   3.4.2.1.2 Whole Blood Preparation (Arterial and  
   portal venous)         82 
   3.4.2.1.3 Mesenteric Lymph Node Cell Isolation    82 
  3.4.2.2 Population Studies 
   3.4.2.2.1 Kupffer Cell Population studies     83 
   3.4.2.2.2 Cell population assay (Portal Venous  
   and Arterial Blood)        83
  
   3.4.2.2.3 Mesenteric Lymph Node Cell  
   Population Assay        84 
  3.4.2.3 Functional Assays  
12 
 
   3.4.2.3.1 Rat Kupffer Cell and Portal Venous  
   ROS studies         84 
   3.4.2.3.2 Murine Kupffer cell ROS studies     85 
   3.4.2.3.3 Kupffer cell phagocytic function     86 
   3.4.2.3.4 Flow Cytometry Analysis      86 
3.5 Microbiological Methods  
 3.5.1 Bacterial PCR  
  3.5.1.1 Bacterial DNA Isolation from Plasma      86 
  3.5.1.2 DNA Amplification and Sequencing (Plasma samples)   87 
  3.5.1.3 Isolation of DNA from Stool for Pathogen Detection    87 
  3.5.1.4 Sequence-based microbiota composition determination   88 
 3.5.2 Endotoxin measurement        89 
 3.5.3 Mesenteric Lymph Node Culture       89 
3.6 Histological analysis  
 3.6.1 Light microscopy  
  3.6.1.1 Haematoxylin and Eosin Staining      90 
  3.5.1.2 Sirius Red staining        90 
 3.6.2 Electron microscopy         91 
3.7 Biochemical Analysis  
 3.7.1 Standard Biochemical analysis        93 
 3.7.2 Bile acid Analysis         94 
 3.7.3 Lactulose/Rhamnose Test  
  3.7.3.1 General         95 
  3.7.3.2 Electro-Spray Ionization Mass Spectrometry (ESI-MS)   95 
3.8 Protein Expression  
 3.8.1 Protein Extraction Methods        95 
 3.8.2 Tight junction protein expression       96
 3.8.3 Cytokine Studies  
13 
 
  3.8.3.1 Clinical studies        96 
  3.8.3.2 Rodent Studies        96 
3.9 Gene Expression  
 3.9.1 RNA extraction from terminal ileal tissue      97 
 3.9.2 Quantitative PCR         98 
3.9 1Nuclear Magnetic Resonance Spectroscopy       97 
3.10 Carbon Adsorption studies  
 3.11.1 Cytokine adsorption by carbon beads from plasma     98 
 3.11.2 Carbon Adsorption of TNFα from simulated intestinal fluid    98 
 3.11.3 Carbon Endotoxin Adsorption Kinetics      98 
 3.11.4 Carbon Acetaldehyde Adsorption Kinetics      99 
 3.11.5 Determination of the Effect of Direct Contact Incubation of Test  
  Carbon on Bacterial Metabolism       99 
 3.11.6 Determination of the Effect of Carbon Leachate on Bacterial 
 Metabolism         100 
3.11 Statistical Analysis        100
  
Chapter 4  TIPSS Study 
4.1 Introduction         102 
4.2 Aims          103 
4.3 Results 
 4.3.1 Patient Characteristics       104 
 4.3.2 Endotoxin studies       105 
 4.3.3 Neutrophil Function       106 
 4.3.4 Cytokine levels in splanchnic circulation pre-TIPSS insertion  110 
4.4 Discussion 
 4.4.1 Differential intra-splanchnic endotoxin levels    113 
14 
 
 4.4.2 Differential intra-splanchnic neutrophil function   114 
 4.4.3 Differential intra-splanchnic cytokine levels    115 
 4.4.4 The effect of TIPSS insertion      116 
 
Chapter 5 In Vitro Adsorption of Biological Targets in Liver Disease 
5.1 Introduction         118 
5.2 Aims          119 
5.3 Results 
 5.3.1 Studies to determine optimal carbon porosity for in vivo studies 120 
 5.3.2 Studies to determine adsorption kinetics of Endotoxin   121 
 5.3.3 Studies to determine adsorption kinetics of Acetaldehyde  122 
 5.3.4 Studies to determine effects of carbon on bacterial growth kinetics 
  5.3.4.1 Investigating the effect of direct contact incubation of  
   carbons on bacterial metabolism    123 
  5.3.4.2 Studies to determine the effect of carbon leachate on bacterial 
   metabolism       124 
5.4 Discussion  
        126 
Chapter 6 Validation of the Bile Duct Ligated Rat model 
6.1 Introduction         127 
6.2 Aims          127 
6.3 Results 
 6.3.1 Biochemical Profile       128 
 6.3.2 Histological Profile       130 
 6.3.3 Haemodynamic Profile 
  6.3.3.1 Portal Pressure      131 
  6.3.3.2 Mean Arterial Pressure     131 
 6.3.4 Body weight        132 
15 
 
 6.3.5 Markers of Bacterial Translocation     133 
 6.3.6 Other metabolic parameters      134 
 6.3.7 BDL + LPS Model       135 
6.4 Discussion         137 
  
Chapter 7 Characterisation of the Gut-Liver axis in Bile Duct Ligated  
  Rats 
7.1 Introduction         138 
7.2 Aims          138 
7.3 Results 
 7.3.1 Light microscopy 
  7.3.1.1 Duodenum       139 
  7.3.1.2 Jejunum       140 
  7.3.1.3 Ileum        141 
  7.3.1.4 Colon        142 
 7.3.2 Electron microscopy 
  7.3.2.1 Electron Microscopy of the Duodenum   144 
  7.3.2.2 Electron microscopy of the Colon    147 
 7.3.3 Paneth Cell Function       149 
 7.3.4 Intestinal Permeability       150 
 7.3.5 Tight junction Protein expression     151 
 7.3.6 Stool Microbiome Composition 
  7.3.6.1 Phyla Level       155 
  7.3.6.2 Order level       156 
  7.3.6.3 Family level       157 
  7.3.6.4 Genus Level       158 
 7.3.7 Metabolomic Profiling (urinary 1NMR analysis)    159 
 7.3.8 Immunological Profiling 
16 
 
  7.3.8.1 Population Studies 
   7.3.8.1.1 Liver 
    7.3.8.1.1.1 Kupffer cell Populations   160 
    7.3.8.1.1.2 Liver neutrophil Population  161 
   7.3.8.1.2 Portal Venous/Arterial Blood   162
   7.3.8.1.3 Mesenteric Lymph Node Populations  160 
  7.3.8.2 Reactive Oxidant Species (ROS) Production 
   7.3.8.2.1 Liver       163 
   7.3.8.2.2 Portal Venous Populations 
    7.3.8.2.2.1 Portal venous neutrophil ROS  164  
    7.3.8.2.2.2 Portal Venous Monocyte ROS  165
    7.3.8.2.2.3 ROS production by Portal Venous  
    Monocyte Subpopulations    165 
   7.3.8.2.3 Mesenteric Lymph Node populations  162 
  7.3.8.3 Phagocytosis       166 
 7.3.9 Portal Venous Cytokines      167 
7.4 Discussion 
 7.4.1 Structural phenotype       168 
 7.4.2 Gut Microbiota        170 
 7.4.3 Immunological Phenotype      171 
  
Chapter 8 Biological Effects of Oral Administration of Yaq-001 Carbon  
  Therapy in Bile Duct Ligated Rats 
8.1 Introduction         173 
8.2 Aims          173 
8.3 Results 
 8.3.1 Biochemical Profile       174 
 8.3.2 Haemodynamic Profile       175 
17 
 
 8.3.3 Immunological Phenotype       
  8.3.3.1 Population studies 
   8.3.3.1.1 Liver       176 
   8.3.3.1.2 Arterial and Portal Venous blood populations 177 
   8.3.3.2.3 Mesenteric Lymph Node populations  180 
  8.3.3.2 ROS production 
   8.3.3.2.1 Liver 
    8.3.3.2.1.1 Total Liver ROS    183 
    8.3.3.2.1.2 Kupffer cell ROS production  183 
    8.3.3.2.1.3 Liver neutrophil ROS production  184 
   8.3.3.2.2 Portal Venous blood ROS production 
    8.3.3.2.2.1 Monocyte populations   186 
    8.3.3.2.2.2 Monocyte subpopulations  187 
    8.3.3.2.2.3 Neutrophil populations   188 
  8.3.3.2.3 Phagocytosis 
    8.3.3.2.3.1 Kupffer Cell Phagocytosis  189 
    8.3.3.2.3.1 Liver Neutrophil Phagocytosis  189 
  8.3.3.4 Inflammasome activation     194 
  8.3.3.5 Terminal Ileal TNFα gene expression   195 
 8.3.4 Gut Barrier Integrity 
  8.3.4.1 Intestinal Permeability Assays    195 
  8.3.4.2 Paneth Cell Gene Expression Data    196 
  8.3.4.3 Nutrition 
   8.3.4.3.1 Weight      198 
   8.3.4.3.2 Micronutrients and electrolytes   198 
   8.3.4.3.2 Bile acid profile 
    8.3.4.3.2.1 Primary Bile acids   200 
    8.3.4.3.2.2 Secondary Bile acids   202 
18 
 
 8.3.5 Stool Microbiome (Phylogenic Studies)  
  8.3.5.1 Phyla Level       207 
  8.3.5.2 Order level       208 
  8.3.5.3 Family level       209 
  8.3.5.4 Genus Level       210 
 8.3.6 Urinary 1NMR analysis 
  Principal Component Analysis     212 
  BDL/Sham        213 
  Carbon treated BDL/BDL      213 
  Carbon sham/Sham       214 
 8.3.7 Markers of Bacterial Translocation     215 
 8.3.8 ACLF Data        216 
8.4 Discussion         219 
 
Chapter 9 Oral nanoporous carbons attenuate disease pathogenesis  
  in models of non-alcoholic fatty liver disease 
9.1 Introduction         227 
9.2 Aims          228 
9.3 Leptin deficient mice (obob-/-) 
 9.3.1 Markers of liver Injury       229 
 9.3.2 Kupffer Cell Populations      232 
 9.3.3 Kupffer cell ROS production      234 
 9.3.4 Urinary 1NMR Profiling       235 
  9.3.5 Body Weight        235 
9.4 Methionine choline deficient mice      237 
9.5 Discussion         240 
Chapter 10 Conclusions        241 
References          249 
19 
 
List of Figures 
 
Chapter 1 Introduction 
 
Figure 1.1  Role of bacterial translocation in the natural history of cirrhosis 28 
Figure 1.2  Immunopathology of ACLF                                                        29  
Figure 1.3  Inter-relationship of PAMP-sensing pathways in the pathogenesis  
  of ACLF        37  
Figure 1.4   Factors determining Bacterial Translocation Rates   41 
Figure 1.5  Metabolic contributions of the gut microbiome in the pathogenesis  
  of liver disease       52 
 
Chapter 2 Hypothesis and Aims 
 
Figure 2.1 Role of bacterial translocation in disease progression in chronic  
  liver disease        69 
Figure 2.2   Potential role of oral Yaq-001 therapy in prevention of  
  complications of cirrhosis      70 
Figure 2.3  Potential role of oral Yaq-001 therapy in prevention of  
  complications of non-alcoholic fatty liver disease   71 
 
Chapter 3 Methods 
 
Figure 3.1  Experimental Schedule for Bile Duct Ligated Rat Model  75 
Figure 3.2  Experimental Schedule for Yaq-001 treatment in ob/ob mouse  
  Model         77 
Figure 3.3  Experimental Schedule for Yaq-001 treatment in MCD model 77 
 
Chapter 4 TIPSS study 
 
Figure 4.1(a) Endotoxin concentrations in portal and hepatic venous blood 105 
Figure 4.1(b) Endotoxin Fractional extraction rates across liver and intestine 105 
Figure 4.1(c) Arterial endotoxin levels pre- and 1 hour post-TIPSS insertion 105 
Figure 4.1(d)  Hepatic and Intestinal Fractional Extraction Rates of endotoxin- 
  binding molecules       106 
Figure 4.1(e)  Univariate analysis of portal venous endotoxin concentrations and  
  mortality        106 
Figure 4.2(a) Neutrophil ROS production in hepatic venous (HV) and portal  
  venous (PV) blood       108 
Figure 4.2(b) Neutrophil ROS production in hepatic venous blood pre- and post- 
  incubation with portal venous plasma (PVP)    108 
Figure 4.2(c) Neutrophil ROS production in portal venous blood pre- and post- 
  incubation with hepatic venous plasma (HVP)    108 
Figure 4.2(d)  Arterial neutrophil phagocytosis pre- and post-TIPSS insertion 108 
Figure 4.2(e) Correlation between portal pressure gradient and portal venous  
  neutrophil ROS production pre-TIPSS insertion   108  
Figure 4.3(a) Interleukin 6 concentrations in hepatic and portal venous blood 110 
Figure 4.3(b) Interleukin 10 concentrations in hepatic and portal venous blood 110 
Figure 4.3(c) Fractional extraction of IL6 across liver and intestine  110 
Figure 4.3(d) Fractional extraction of IL10 across liver and intestine  110 
Figure 4.3(e) Differential cytokine levels within splanchnic bed   111 
Figure 4.4  Kaplan-Meier Survival Curve post-TIPSS insertion   112 
 
 
20 
 
Chapter 5 In Vitro Adsorption of Biological Targets in Liver Disease 
 
Figure 5.1 Electron micrograph images of Yaq-001 carbon beads  118 
Figure 5.2   Pore size distribution of activated carbons TE3, TE5 and TE7  
  (Yaq-001)         119 
Figure 5.3   TNFα adsorption kinetics      120  
Figure 5.4  IL-6 adsorption kinetics      120  
Figure 5.5  Adsorption isotherm of carbon adsorption of TNFα   121  
Figure 5.6  Adsorption kinetics of carbon for E. coli endotoxin   121 
Figure 5.7 Acetaldehyde removal over time by TE8 carbon   122  
Figure 5.8 Carbon acetaldehyde adsorption kinetics    122  
Figure 5.9   Effect of TE8 carbon on E. coli growth kinetics   123  
Figure 5.10 The effect of TE7 test carbon on Staphylococcus aureus bacterial  
  growth kinetics       123  
Figure 5.11  The effect of TE7 test carbon leachate on E. coli growth kinetics 124  
Figure 5.12  The effect of TE7 test carbon leachate on Bacillus subtilis growth  
  kinetics        124  
 
Chapter 6  Validation of the Bile Duct Ligated Rat model 
 
Figure 6.1 Plasma alanine transaminase concentrations   128 
Figure 6.2(a) Plasma bilirubin concentrations     128  
Figure 6.2(b) Plasma alkaline phosphatase concentrations   128 
Figure 6.3 Plasma albumin concentrations     129  
Figure 6.4 Plasma creatinine concentrations     129  
Figure 6.5 Liver histology (Sirius Red staining)      130  
Figure 6.6  Collagen Proportionate Area of liver tissue    130 
Figure 6.7  Portal haemodynamics at 4 weeks     131 
Figure 6.8 Systemic haemodynamics at 4 weeks    131  
Figure 6.9  Final body weight       132  
Figure 6.10 Percentage body weight increase at 4 weeks   132 
Figure 6.11 Plasma portal venous endotoxin     133  
Figure 6.12 Portal venous plasma bacterial DNA positivity   133     
Figure 6.13 Mesenteric Lymph Node Culture     133  
Figure 6.14 Arterial ammonia concentrations     134  
Figure 6.15  Plasma glucose       134  
Figure 6.16  Plasma lactate concentrations     134  
Figure 6.17  Liver histology (Haematoxylin and Eosin staining)    136  
 
Chapter 7 Characterisation of the Gut-Liver axis in Bile Duct Ligated  
  Rats 
 
Figure 7.1  Light microscopy images of duodenum    139  
Figure 7.2  Light microscopy images of jejunum     140  
Figure 7.3  Light microscopy images of ileum     141  
Figure 7.4  Light microscopy images of colon     142  
Figure 7.5 Electron micrograph of duodenal tissue in sham operated rats 144  
Figure 7.6 Electron micrograph of duodenal tissue in bile duct ligated rats 144  
Figure 7.7 Electron micrograph of duodenal microvilli in sham-operated rats 145  
Figure 7.8 Electron micrograph of duodenal microvilli in BDL rats  145 
Figure 7.9 Electron micrograph of duodenal tissue in sham operated rats 146   
Figure 7.10 Electron micrograph of duodenal microvilli in BDL rats  146  
Figure 7.11 Electron micrograph of colonic tissue in sham operated rats 147 
Figure 7.12 Electron micrograph of colonic tissue in bile duct ligated rats 147  
Figure 7.13 Electron micrograph of colonic tissue in sham operated rats 148 
21 
 
Figure 7.14 Electron micrograph of colonic tissue in bile duct ligated rats 148 
Figure 7.15(a) Relative defensin 8 gene expression in terminal ileum  149 
Figure 7.15(b) Relative defensin 5 gene expression in terminal ileum  149  
Figure 7.15(c) Relative lysozyme gene expression in terminal ileum  149 
Figure 7.16 Urinary Lactulose/creatinine ratio (ESI-MS)     150 
Figure 7.17 Urinary 3OMD/creatinine ratio (ESI-MS)     150 
Figure 7.18  Relative protein expression of claudin-3    152  
Figure 7.19  ZO-1 expression in colon      153  
Figure 7.20  Duodenal connexin-43 protein expression in duodenum  153  
Figure 7.21 Duodenal iNOS expression      154  
Figure 7.22 Duodenal eNOS expression      154 
Figure 7.23 Microbiome composition of stool (phyla level)    155  
Figure 7.24 Microbiome composition of stool (order level)   156  
Figure 7.25  Microbiome composition of stool (family level)    157  
Figure 7.26 Microbiome composition of stool (genus level)    158 
Figure 7.27 Relative urinary concentrations of metabolites   159  
Figure 7.28(a)Kupffer cell populations      159 
Figure 7.28(b)Hepatic neutrophil populations     159  
Figure 7.29 Mesenteric Lymph Node populations     162  
Figure 7.30  Hepatic ROS production      163  
Figure 7.31  Portal venous neutrophil ROS production    164 
Figure 7.32  Portal venous monocyte ROS production    165 
Figure 7.33  Portal venous monocyte subpopulation ROS production  165 
Figure 7.34(a)Kupffer cell phagocytosis      166 
Figure 7.34(b)Liver neutrophil phagocytosis      166 
Figure 7.35 Portal venous cytokine concentrations    167 
 
 
Chapter 8 Biological Effects of Oral Administration of Yaq-001 Carbon  
  Therapy in Bile Duct Ligated Rats 
 
Figure 8.1(a) Plasma alanine transaminase      174  
Figure 8.1(b) Plasma alkaline phosphatase      174  
Figure 8.1(c) Plasma albumin       174  
Figure 8.1(d) Plasma creatinine       174  
Figure 8.2(a) Portal Pressure Response to Yaq-001carbon therapy  175 
Figure 8.2(b) Mean Arterial Pressure Response to Yaq-001carbon therapy 175 
Figure 8.3 CD163+ gated liver non-parenchymal cell fraction   175  
Figure 8.4 Liver neutrophil populations      175  
Figure 8.5 Gating strategy non-parenchymal cell populations   177 
Figure 8.6(a) Absolute leucocyte count in arterial blood    177  
Figure 8.6(b) Absolute leucocyte count in portal venous blood   177  
Figure 8.6(c) Absolute neutrophil count in arterial blood    177  
Figure 8.6(d) Absolute neutrophil count in portal venous blood   177  
Figure 8.6(e) Absolute monocyte count in arterial blood    177  
Figure 8.6(f) Absolute monocyte count in portal venous blood   177  
Figure 8.7(a)  Portal venous CD43hi monocyte populations    177 
Figure 8.7(b)  Arterial CD43hi monocyte populations    177 
Figure 8.7(c) Portal venous CD43lo monocyte populations    177 
Figure 8.7(d) Arterial CD43lo monocyte populations    177 
Figure 8.8(a) CD68+ gated mesenteric lymph node populations (%)  180 
Figure 8.8(b) Absolute CD68+ gated mesenteric lymph node populations  180 
Figure 8.9(a) CD68+/CD80+ gated mesenteric lymph node populations (%) 181 
Figure 8.9(b) Absolute CD68+/CD80+ gated mesenteric lymph node populations 181 
Figure 8.10(a) CD163+ gated mesenteric lymph node populations (%)  182 
22 
 
Figure 8.10(b)CD163+ gated mesenteric lymph node populations (%)  182 
Figure 8.11 Total reactive oxidant species production in liver non-parenchymal  
  cell fraction        183  
Figure 8.12 Constitutive reactive oxidant species production in CD163+- liver  
  non-parenchymal cell fraction     183  
Figure 8.13 Lipopolysaccharide-induced reactive oxidant species production in 
  CD163+-gated liver non-parenchymal cell fraction   184  
Figure 8.14 Liver neutrophil constitutive reactive oxidant species production 184  
Figure 8.15 Liver neutrophil lipopolysaccharide-induced reactive oxidant  
  species production       185  
Figure 8.16 Constitutive and lipopolysaccharide-induced reactive oxidant  
  species production in portal venous monocytes   186  
Figure 8.17 Constitutive and lipopolysaccharide-induced reactive oxidant  
  species production in portal venous monocyte subpopulations 187  
Figure 8.18 Constitutive and lipopolysaccharide-induced reactive oxidant  
  species production in portal venous neutrophils    188  
Figure 8.19 Phagocytosis of bead particles in CD163+-gated liver non-  
  parenchymal cell fraction      189  
Figure 8.20 Phagocytosis of bead particles (P3-gated) in neutrophil-gated liver 
  non-parenchymal cell fraction     189 
Figure 8.21 Phagocytosis of bead particles in neutrophil-gated liver non- 
  parenchymal cell fraction      190  
Figure 8.22 Plots demonstrating gating strategy for whole blood populations 190  
Figure 8.23 Gating strategy for whole blood populations    193 
Figure 8.24(a) Inflammasome activation with arterial plasma in HEK reporter  
   cells         194 
Figure 8.24(b) TLR4 activation with arterial plasma in HEK reporter cells  194 
Figure 8.25 Relative expression of TNFα in terminal ileal tissue   195  
Figure 8.26 5 hour urinary excretion of lactulose, rhamnose and 6-OMG 195 
Figure 8.27(a) Relative expression of defensin 8     196 
Figure 8.27(b) Relative expression of defensin 5     197 
Figure 8.27(c) Relative expression of lysozyme 2     197 
Figure 8.28 Final body weight       198  
Figure 8.29 Plasma folate concentrations      198  
Figure 8.30 Plasma micronutrient and electrolyte concentrations  199  
Figure 8.31(a) Arterial concentrations of Cholic acid    200  
Figure 8.31(b) Arterial concentrations of Glycocholic acid    200  
Figure 8.31(c) Arterial concentrations of Taurocholic acid    200  
Figure 8.32(a) Arterial concentrations of chenodeoxycholic acid   201  
Figure 8.32(b) Arterial concentrations of Glycochenodeoxycholic acid  201  
Figure 8.32(c) Arterial concentrations of Taurochenodeoxycholic acid  201  
Figure 8.33(a) Arterial concentrations of deoxycholic acid    202  
Figure 8.33(b)Arterial concentrations of Glycodeoxycholic acid   202  
Figure 8.33(c) Arterial concentrations of Taurodeoxycholic acid   202  
Figure 8.34(a) Arterial concentrations of Lithocholic acid    203  
Figure 8.34(b)Arterial concentrations of Glycolithocholic acid   203  
Figure 8.34(c) Arterial concentrations of Taurolithocholic acid   203  
Figure 8.35(a) Arterial concentrations of Ursodeoxycholic acid   204  
Figure 8.35(b)Arterial concentrations of Glycoursodeoxycholic acid  204  
Figure 8.35(c) Arterial concentrations of Tauroursodeoxycholic acid  204  
Figure 8.36 Arterial concentrations of muricholic acid    204  
Figure 8.37 Hydrophobicity index of bile acids     206 
Figure 8.38 Phylogenic profile of stool (phyla level)     207 
Figure 8.38 Phylogenic profile of stool (order level)     208 
Figure 8.39 Phylogenic profile of stool (family level)     209 
23 
 
Figure 8.40 Phylogenic profile of stool (genus level)     210 
Figure 8.41  Principal Component Analysis     212 
Figure 8.42 Relative urinary concentrations of metabolites (BDLvsSham)  213 
Figure 8.43 Relative urinary concentrations of metabolites in (BDL+CvsBDL)  213 
Figure 8.44 Relative urinary concentrations of metabolites (Sham+CvsSham) 214 
Figure 8.45(a) Portal venous endotoxin      215  
Figure 8.45(b)Portal venous plasma bacterial DNA positivity   215  
Figure 8.45(c)Mesenteric lymph node culture positivity    215  
Figure 8.46(a) Alanine transaminase       216  
Figure 8.46(b)Alkaline phosphatase       216 
Figure 8.46(c) Albumin        216  
Figure 8.46(d)Creatinine        216  
Figure 8.47 Portal Pressure       217  
Figure 8.48 Mean Arterial Pressure      217  
Figure 8.49 Liver histology        218 
 
Chapter 9 Oral nanoporous carbons attenuate disease pathogenesis in  
  models of non-alcoholic fatty liver disease 
 
Figure 9.1  Plasma alanine transaminase concentrations   229 
Figure 9.2 Liver histology of leptin-deficient mice    230 
Figure 9.3 F4/80+ cell populations in leptin-deficient    232  
Figure 9.4 F4/80+ cell sub-populations      232 
Figure 9.5  F4/80+ cell ROS production      234 
Figure 9.6 Principal Component Analysis (Urinary 1NMR analysis)   235 
Figure 9.7  Final body weight       235  
Figure 9.8 Plasma alanine transaminase concentrations in methionine  
  choline deficient mice       237 
Figure 9.9 Liver histology of methionine choline deficient mice   238 
Figure 9.10 NAS score of methionine choline deficient mice   239 
 
 
Chapter 10  Conclusions 
 
Figure 10.1  Pathogenesis of bacterial translocation and role in the natural history 
  of cirrhosis        242 
Figure 10.2  Effects of Yaq-001 on pathogenesis of cirrhosis   244 
 
List of Tables 
Table 1.1 Microbiome Composition in Cirrhosis     44 
Table 1.2 Summary of Interventional Clinical studies to manipulate the  
  microbiome in cirrhosis       64 
Table 4.1 Patient Characteristics Pre-TIPSS insertion    104 
Table 4.2  Neutrophil Function (Non-ACLF vs ACLF)     109 
Table 4.3  Univariate analysis of neutrophil function and mortality  109 
Table 4.4  Cytokine profile in patients with and without ACLF   110 
Table 4.5 Univariate analysis of cytokines and mortality   111 
Table 5.1 Physical properties of carbons TE1-9    120 
Table 6.1 Biochemical and Haematological Profile (BDL+LPS Model)  135 
Table 7.1  Absolute Leucocyte Populations in Sham and BDL   161 
Table 9.1 Plasma biochemistry       238 
 
24 
 
List of Abbreviations 
Abbreviation Definition 
A Arterial 
ACE Angiotensin Converting Enzyme  
ACLF Acute-on-Chronic Liver Failure 
AJ Adherens junction 
ALD Alcoholic Liver Disease 
ALP Alkaline Phosphatase 
ALT Alanine Transaminase 
AST Aspartate Aminotransferase 
ATP Adenosine Triphosphate 
B/E Bifidobacteria/Enterobacteriaceae  
BDL Bile Dict Ligation 
BMI Body Mass Index 
BPI Bactericidal permeability increasing protein 
CARS Compensatory anti-inflammatory response syndrome 
CBA Cytometric Bead Array 
CCL4 Carbon Tetrachloride 
cDNA Complementary DNA 
CDR Cirrhosis Dysbiosis Ratio 
DAPI 4',6-Diamidino-2-Phenylindole, Dihydrochloride 
DIH 2-diphenylacetyl-1,3-indandione-1-hydrazone 
DMA Dimethylarginine 
DMEM Dulbecco's modified Eagle's medium 
DNA Deoxyribonucleic acid 
ECL Electrochemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EM Electron Microscopy 
ESI-MS Electrospray Ionisation Mass Spectrometry 
FACS Fluorescence-activated cell sorting 
FE Fractional Extraction 
FITC Fluorescein isothiocyanate 
fMLP N-Formylmethionyl-leucyl-phenylalanine 
FXR Farnesoid X receptor 
GABA Gamma-Aminobutyric acid 
GFR Glomerular Filtration Rate 
H&E Haematoxylin and Eosin 
HBSS Hanks' Balanced Salt Solution 
HE Hepatic Encephalopathy 
HLA-DR Human Leukocyte Antigen - antigen D Related 
HPLC High Performance Liquid Chromatography 
HVP Hepatic venous plasma 
25 
 
HVPG Hepatic Venous Pressure Gradient 
IFN Interferon 
IL Interleukin 
IMV Inferior Mesenteric Vein 
iNOS inducible Nitric Oxide Sythetase 
KC Kupffer cell 
LAL Limulus amebocyte lysate 
LBP Lipopolysaccharide binding protein 
LC-MS Liquid chromatography–mass spectrometry 
LGV Left Gastric Vein 
LPS Lipolysaccharide  
MARS Mixed anti-inflammatory response syndrome 
MARS Molecular Adsorbent Recirculation System 
MCD Methionine Choline Deficient  
MELD Model for End-Stage Liver Disease 
MGS MetaGenomic Species 
MLN Mesenteric Lymph Node 
NAFLD Non-Alcoholic Fatty Liver Disease 
NASH Non-Alcoholic Steatohepatitis 
NFkB 
nuclear factor kappa-light-chain-enhancer of activated B 
cells 
NLRP6 NOD-like receptor family pyrin domain containing 6 
NMR Nuclear Magnetic Resonance 
NO Nitric Oxide 
NOD Nucleotide-binding oligomerization domain 
NPC Non-Parenchymal Cell 
OMD O-Methyl-Dextrose 
PAMP Pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell  
PBS Phosphate Buffered Saline 
PBST Phosphate Buffered Saline with Tween 
PCA Principal Component Analysis 
PCR Polymerase Chain Reaction 
PE Phycoerythrin 
PMA Phorbol myristate acetate 
PP Portal Pressure 
PPI Proton Pump Inhibitor 
PV Portal Vein 
PVP Portal Venous Plasma 
RAS Renin Angiotensin System 
RNA Ribonucleic Acid 
ROS Reactive Oxidant Species 
SBP Spontaneous Bacterial Peritonitis 
SD Standard Deviation 
SEM Standard Error of the Mean 
26 
 
SIF Simulated intestinal Fluid 
SIRS Systemic Inflammatory Response Syndrome 
SMV Superior Mesenteric Vein 
SNS Sympathetic Nervous System 
SV Splenic Vein 
TIPSS Transjugular Intrahepatic PortoSystemic Stent Shunt 
TLR Toll Like Receptor 
TMA Trimethylamine 
TMAO Trimethylamine Oxidase  
TNFα Tumour Necrosis Factorα 
TSB Tryptone soya broth  
TSP Trimethylsilylpropanoic acid 
ZO-1 Zonula occludens-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Chapter 1 
Introduction 
 
1.1 Cirrhosis and Acute-on-Chronic Liver Failure 
Cirrhosis is currently the 3rd most common cause of premature death in the United 
Kingdom with a 400% increase in mortality observed since 1970 (Williams et al, 
2014). Exponential rises in incidence of cirrhosis have been observed over the last 
decade principally due to increasing alcohol consumption and obesity. Mortality 
occurs typically in the context of an acute decompensating event and may be 
precipitated by sepsis, alcoholic hepatitis, variceal haemorrhage or even in the 
absence of a clear precipitating event.  
Historically the natural history of patients hospitalized with a complication of cirrhosis 
has been considered as a single, albeit heterogenous clinical entity following a step-
wise progression from compensated to decompensated disease manifest clinically by 
jaundice, variceal bleeding, ascites, hepatic encephalopathy and infection. Over the 
last few years, large prospective clinical studies have informed understanding of this 
group of patients (Gustot et al, 2015; Moreau et al, 2013).  This has led to the 
understanding that in contrast to patients with chronic end-stage liver failure, patients 
with an acute deterioration in liver function in the context of established cirrhosis 
have a distinct pathophysiology. This clinical entity is termed acute-on-chronic liver 
failure (ACLF) and is characterized by a dysregulated systemic inflammatory 
response with a significantly higher risk of multi-organ failure and mortality. ACLF is 
an exceptionally dynamic disease entity with variable outcomes. Resolution is seen 
to occur in approximately 50% of patients, a steady or fluctuating course observed in 
30% with deterioration in approximately 20% of patients (Gustot et al, 2015). In 
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ACLF, organ function is potentially recoverable and therefore interventional 
strategies to impact on pathogenesis have the potential to reduce mortality. 
 
The pathogenesis of ACLF is incompletely understood. Current data suggests that in 
patients with cirrhosis, there are two underlying factors that render them susceptible 
to the deleterious effect of a superimposed insult (Jalan et al, 2012). The first is the 
underlying cirrhosis and the structural disturbances, portocaval shunting, portal 
hypertension and metabolic disturbance this entails. ACLF may develop at any stage 
of disease. The second is the observation of heightened translocation of bacterial 
and bacterial ligands to the liver and systemic circulation which ‘primes’ the patient’s 
organs and immune response to the effect of a superimposed secondary insult. The 
patient therefore responds abnormally to the superimposed insult and this results in 
multi-organ failure.  
 
 
 
Figure 1.1 Role of bacterial translocation in the natural history of cirrhosis 
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1.2 Systemic Inflammation; cirrhosis and ACLF 
1.2.1 Nature of immunological response in cirrhosis and ACLF 
Advanced cirrhosis is characterized by a dysregulated inflammatory response, a 
central feature of pathogenesis resulting in a heightened propensity to organ injury 
with functional immunoparesis, which may be responsible for its complications 
(Albillos et al, 2004; Jalan et al, 2012; Wasmuth et al., 2005). Exposure to bacterial 
endotoxin may either induce a heightened biological sensitivity to LPS termed 
priming or a diminished endotoxin sensitivity termed endotoxin tolerance. Factors 
such as endotoxin dose, duration of exposure will influence the nature of the 
response. (Morris et al, 2015). There is a growing body of evidence suggestive that 
both states are observed in cirrhosis but in different stages of disease (Albillos et al, 
2004; Wasmuth et al, 2005). The mechanisms of the increased susceptibility to 
infection are unclear but recent studies suggest that even in patients with 
compensated cirrhosis, the innate immune response is defective (Tritto et al, 2011).  
Models of Immunopathology in ACLF 
 
 
Figure 1.2 Immunopathology of ACLF (Macnaughtan J et al, 2011) 
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The immunological response in sepsis is multimodal, characterised by an initial pro-
inflammatory process (SIRS) followed by a mixed anti-inflammatory response 
syndrome (MARS) followed by a compensatory anti-inflammatory response 
syndrome (CARS). The systemic inflammatory response syndrome includes but is 
not limited to, greater than one of the following clinical manifestations: (1) body 
temperature > 38°C or < 36°C; (2) heart rate > 90 beats per minute; (3) respiratory 
rate > 20 breaths per minute, or hyperventilation, as indicated by a PaCO2 of less 
than 32 mm Hg; and (4) an alteration in leucocyte count either >12,000/ cu mm or< 
4,000/cu mm, or the presence of more than 10 per cent immature neutrophils 
(“bands”) (Bone et al, 1992). 
The presence of a dysregulated systemic inflammatory response syndrome is a 
cardinal feature of ACLF and appears to be a key driver promoting the transition from 
stable cirrhosis to ACLF associated with increased mortality. The presence of SIRS 
is associated with more severe encephalopathy, renal failure and an increased 
incidence of bacterial infection (Cordoba et al, 2014; Maiwall et al, 2016; Thabut et 
al, 2007). SIRS is associated with a hyper-dynamic circulation with low systemic 
vascular resistance and a low mean arterial pressure resulting in low organ perfusion 
compounding organ injury. Higher leucocyte counts are associated with more severe 
grades of ACLF and are predictive of poor outcome (Moreauet al, 2013). Early 
mortality has been attributed to cytokine storm-mediated events.  
Experimental strategies targeting this hyper-inflammatory phase have however been 
associated with variable outcomes and mortality largely occurring in septic patients 
who are immune suppressed such as infliximab therapy in alcoholic hepatitis. A case 
series of single low dose infliximab described an improvement in hepatic and renal 
haemodynamic status but randomized, placebo-controlled studies have failed to 
demonstrate an improvement in survival (Mookerjee et al. 2004; Naveau et al, 2004; 
Spahr et al, 2002). Naveau et al (2004) performed the largest placebo-controlled 
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randomized study in a cohort of 36 patients evaluating prednisolone and infliximab 
for the management of severe alcoholic hepatitis. A significant increase in infection 
and upward trend in mortality was observed in the treatment group and the trial was 
terminated early as a result. The study was criticized for the high dose of infliximab 
but highlighted the susceptibility of patients to sepsis and the risks of ablating the 
pro-inflammatory response. Hotchkiss et al (2009) described that most deaths 
secondary to sepsis occurred in the prolonged state of immune suppression as a 
function of immune incompetence at multiple cellular levels. Given the heightened 
susceptibility to infection in cirrhotic patients, the degree of immune incompetence is 
much greater. 
Features of a compensated anti-inflammatory response syndrome (CARS) may 
predominate over SIRS in sub-groups of patients with ACLF in particular during later 
stages of the syndrome. Such patients are immune deficient and prone to 
nosocomial infection. Berres et al (2009) observed that a reduction in monocyte HLA-
DR expression correlated with reductions in interferon gamma concentrations and 
ICU mortality. Xing et al (2007) observed a pre-dominantly pro-inflammatory cytokine 
profile in early stage ACLF with increases in IL1β, TNFα and IL-12p70. In late stage 
ACLF, a predominance of IL10 and reduced surface monocyte HLA-DR expression 
was observed. In practice, a state of immunological dissonance in ACLF is observed 
at the level of both cell-mediated and humoral innate immunity. TNFα and IL-6 are 
both known to be raised in cirrhosis yet elevated levels of IL-10, an anti-inflammatory 
cytokine, have also been found to be elevated and correlate with endotoxin 
concentrations and degree of liver failure (Qi et al 2011; Peter et al, 2013). As with 
sepsis, it is in the state of immune paralysis that many ACLF patients develop organ 
dysfunction and die.  
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1.2.2 Innate immunity 
1.2.2.1 Neutrophil Dysfunction 
Neutrophil function is known to be impaired in cirrhosis both in the context of stable 
disease (Tritto et al. 574-81) or ACLF (Fiuza et al, 2000; Mookerjee et al, 2007). 
Neutrophils exhibit an activated but dysfunctional phenotype with heightened 
spontaneous production of reactive oxidant species but diminished phagocytic 
function, the severity of which predicts mortality in alcoholic cirrhosis patients 
(Mookerjee et al., 2007). Treatment of patient plasma with endotoxin-removal 
columns or with anti-CD14 antibodies prevented neutrophil dysfunction, implicating 
endotoxin in pathogenesis.  
Bacterial DNA is also known to have a marked effect on neutrophil function via TLR9 
and TLR9-independent pathways (El Kebire et al, 2008). This results in a heightened 
neutrophil primed state for ROS production and enhanced chemokine expression. 
Neutrophil TLR9 expression is known to be increased in patients with alcoholic 
cirrhosis (Stadlbauer et al, 2009). 
 
1.2.2.1 Monocyte/Macrophage Dysfunction 
Kupffer cell (KC) and intestinal monocyte/macrophage populations play a key role in 
immune surveillance directing the initial immune response to gut-derived antigens 
towards either an appropriate antimicrobial inflammatory response or the induction of 
tolerance. In liver failure there is diminished reticulo-endothelial activity with reduced 
elimination of endotoxin (Nakao et al, 1994). This is compounded functionally by 
portosystemic shunting resulting in enhanced systemic endotoxin exposure and thus 
diminished immune surveillance. In cirrhosis, portal endotoxin levels are higher due 
to increased bacterial translocation resulting in priming towards a more activated 
state. Activated Kupffer cells produce pro-inflammatory cytokines and result in 
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hepatic stellate cell activation and fibrogenesis. Kupffer cells mediate liver injury by 
TLR4-mediated mechanisms in alcoholic and non-alcoholic fatty liver disease (Gao 
et al, 2011; Rivera et al, 2007). Serum and ascitic bacterial DNA positivity in patients 
with decompensated cirrhosis has been shown to correlate with peritoneal 
macrophage iNOS and NO levels and enhanced cytokine production (Frances et al, 
2004).  
A marked increase in the number and activation state of peripheral monocytes has 
been observed in cirrhotic patients. Albillos et al (2004) demonstrated an increase in 
the number and activation status of peripheral monocytes in ascitic alcoholic cirrhotic 
patients. Increased HLA-DR expression and spontaneous and LPS-induced TNFα 
production was observed. Treatment with norfloxacin normalised monocyte 
populations and activation phenotype implicating bacterial products in pathogenesis. 
Further evidence implicates TLR-mediated pathways in pathogenesis.  
Overexpression of TLR2 but not TLR4 was found on PBMCs of cirrhotic patients 
(Riordan et al, 2003). TLR2 expression was found to correlate with circulating levels 
of the pro-inflammatory cytokines TNFα and sTNFα. Despite these observations, 
constant stimulation of peripheral blood mononuclear cells (PBMC) with endotoxin 
leads to the development of endotoxin tolerance, characterized by reduced capacity 
to produce pro-inflammatory cytokines (Granowitz et al, 1993). Indeed a state on 
monocyte hypo-responsiveness has been demonstrated in more advanced disease 
in the context of ACLF (Wasmuth et al, 2005). This is evidenced by reduced HLA-DR 
expression which correlates with reduced interferon-γ and TNF-α production and 
diminished survival (Berres et al, 2009, Wasmuth et al, 2005).  
Dendritic cells play a key role in orchestrating the innate immune response. In health 
intestinal conditioning of dendritic cell function shapes tolerance and immune 
response. Dendritic cells dictate the homing potential of recently activated T cells and 
promote the development of regulatory T cells in the periphery from naïve T cells 
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(Mann et al, 2013). They also can interact with tight junctions to modulate 
permeability (Rescigno M et al, 2001). The ability of mesenteric lymph node and 
Peyer Patch dendritic cells to imprint T cells with gut-homing potential is dependent 
on retinoic acid (Zeng et al, 2013). In the context of vitamin A-deficiency, the balance 
is shifted in favour of the generation of Th1 cell responses, an immunological profile 
observed in the mesenteric lymph nodes of cirrhotic rats (Munoz et al, 411-19). 
Vitamin A levels are closely linked to the magnitude of IgA responses in the intestine 
(Stephensen et al, 1996), with vitamin A deficiency leading to reduced levels of IgA 
and increased rates of sepsis (Wiedermann et al, 1996). Total hepatic Vitamin A and 
retinol stores are lower in cirrhotic patients than controls and may contribute to the 
immunological profiles observed in chronic liver disease (Ukleja et al, 2002). Limited 
clinical data exists regarding dendritic cell function in cirrhotic patients. Tanoue et al 
(2015) observed enhanced M2 polarisation in monocyte-derived dendritic cells but 
with a similar capacity for activation and antigen presentation in a small study of 15 
patients. Further mechanistic studies are required. 
 
1.2.3 Acquired immunity 
Cirrhotic patients are known to have low numbers of naïve and memory T cells with 
an increased percentage of activated T cells. Cirrhotic patients were shown to have a 
higher percentage of CD4+ T lymphocytes exhibiting an activated state (as 
evidenced by expression of CD25 and CD122) (Marquez et al, 2009). It is thought 
that these activated lymphocytes traffic systemically to result in a systemic 
inflammatory process. The composition of T lymphocyte populations is also known to 
be altered in cirrhosis. Polarisation towards a Th1-predominant profile is known to 
occur within mesenteric lymph nodes (Munoz et al, 2005). Munoz et al (2005) 
demonstrated an expansion in the Th1 lymphocyte population within the mesenteric 
lymph nodes of rats with cirrhosis with a resultant increase in IFNγ production. The 
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hallmark cytokine profile and Th1 polarisation described above was abrogated by the 
use of norfloxacin suggesting an important role of bacterial translocation in the 
immune dysfunction of cirrhosis. 
Cirrhotic patients also have higher proportion of memory CD4 and CD8+ T cells 
expressing apoptotic markers showing a commitment to activation-induced death. 
Most effector memory cells lack the ability to enter the lymph nodes from the blood. 
Instead they traffic towards inflamed tissue, a task naïve lymphocytes cannot 
perform. It has been suggested on the basis of these observations that a state of 
immune exhaustion occurs in cirrhosis which accounts in part for the functional 
impairment of the adaptive response.  
CD4 CD25 high regulatory T cells which play a key role in dampening 
immunopathological responses have been the subject of much interest. Cirrhotic 
patients of alcoholic or viral aetiology had higher levels of regulatory T cells with an 
increase in lipopolysaccharide binding protein indicative of an increased antigenic 
load suggesting that these T cells permit endotoxaemia (Marquez et al, 2009). Data 
suggests that chronic antigenic stimulation may result in modulation of the adaptive 
immune response to induce a state of ‘permissive antigenaemia’. Marquez et al 
(2009) demonstrated an increase in ‘exhausted’ cytotoxic T cell populations 
(CD8+CD45RO+CD57+) in cirrhosis with an increase in expression of apoptotic 
markers (CD95). These immunosenescent cells are known to be unable to proliferate 
in response to a new antigenic load. Together this data suggests an exhausted 
adaptive immune response in cirrhosis resulting in tolerance of endotoxaemia. 
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1.2.4 Other factors modulating immune function 
As a consequence of hepatic synthetic dysfunction, complement and C-reactive 
protein levels are low in cirrhotic patients which further contribute to impaired innate 
immunity. Secretory immunoglobulin A levels are known to be reduced together with 
opsonising proteins.  
Vitamin D deficiency has been shown to be a common finding amongst patients with 
chronic liver disease affecting  over half of cirrhotic patients and is a near universal 
finding in patients with ascites (Chinnaratha et al, 2015, Zhang et al, 2012).  Low 25-
hydroxylated D3 has been shown to be associated with mortality on multivariate 
analysis of a cohort of 251 cirrhotic patients (Finkelmeier et al, 2015). This affects 
macrophage function and dendritic cell differentiation and induces the expression of 
cathelicidin (antimicrobial peptide). Significantly higher expression of vitamin D 
receptor and LL-37 was observed in patient with spontaneous bacterial peritonitis 
compared to sterile ascites (Zhang et al, 2012). Effects on lymphocytes include 
modulation of the T cell receptor, a decrease in Th1/Th17CD4+T cells and cytokines 
(IL-1, 6, 8, TNFα), T cell homing and IgG production (Semba, 1994).  
The concept of neurohumoral regulation of immune function is increasingly 
recognised. Autonomic dysfunction, in particular a heightened sympathetic drive, is 
known to be a feature of advanced cirrhosis. Early data suggests this may play an 
important role in pathogenesis. Non-selective beta-blockade has been shown to be 
associated with an improvement in survival in ACLF patients and this was associated 
with a reduction in white cell count (Mookerjee et al, 2016). In a rodent model of 
cirrhosis chemical sympathectomy prevented translocation of E..coli but not S. 
aureus (Worlicek et al 2010).and was associated with increased influx of peritoneal 
polymorphonuclear cells exhibiting increased phagocytosis. Emerging data in the 
renal and cardiovascular literature suggests a role for renin-angiotensin system 
37 
 
modulation of immune function, most typically towards a pro-inflammatory phenotype 
(Crowley & Rudemiller, 2017). Heightened renin-angiotensin system activation is 
evident in advanced cirrhosis but the mechanistic link with immune pathology is yet 
to be explored.   
 
1.2.5 Role of bacterial ligands in pathogenesis (TLR pathways) 
 
 
Figure 1.3 Inter-relationship of PAMP-sensing pathways in the pathogenesis of ACLF  
The biological effect of bacterial translocation is determined not only by the absolute 
levels of bacterial product but also the magnitude of downstream sensing pathways. 
Toll like receptors 2,4 and 9 are responsible for sensing different bacterial ligands: 
peptidoglycan (TLR2), endotoxin (TLR4), bacterial CpG motifs (TLR9). All three 
receptors have been implicated in innate immune dysfunction in cirrhosis. 
Furthermore there is evidence that TLR expression may determine enhanced organ 
sensitivity to a second pathological ‘hit’ in ACLF and promote multiple organ failure. 
Indeed TLR4 expression is upregulated in rodent models of ACLF in which 
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expression was increased in the kidney, brain and liver. Norfloxacin prevented acute 
kidney injury in this context suggesting that modulation of gut flora can diminish 
‘organ priming’ to a subsequent endotoxin insult sensed by TLR4 (Shah et al, 2012). 
In clinical studies TLR2 polymorphisms have been associated with increased 
susceptibility to SBP infection (Nischalke et al, 2011). Multiple cells types in the liver 
express TLRs; a necessary and appropriate measure given exposure to the antigenic 
load of portal venous blood; Hepatocytes (TLR1); Stellate cells, Kupffer cells (TLR2, 
3,4); Bile duct epithelium (TLR2, 3,4,5) (Testro & Visvanathan, 2009). Not 
unsurprisingly, the magnitude of these pathways are critical determinants in the 
pathogenesis of cirrhosis, in particular with regards to production of cytokines, 
reactive oxidant species and consequent liver injury. TLR 4 stimulation has been 
shown to play an important role in fibrogenesis. This was elegantly demonstrated by 
attenuation of fibrosis in bile duct ligated TLR4-/- mice (Seki et al, 2007). 
 
The nucleotide-binding oligomerization domain (NOD) like receptors also play a role 
in recognition of pathogenic bacteria and stimulation of the innate immune response. 
Variants of NOD2 have been also been identified as predictors of culture-positive 
SBP and survival in cirrhosis (Bruns et al, 2012). Other endotoxin sensing 
mechanisms include lipopolysaccharide-binding protein (LBP) and 
Bactericidal/Permeability-increasing protein (BPI) LBP is an endotoxin binding 
molecule produced by the liver mediating a predominantly pro-inflammatory 
response, levels of which have been shown to increase with more advanced disease. 
BPI is also an endotoxin-binding molecule but derived from the primary azurophilic 
granules of the neutrophil. BPI has a high binding affinity for endotoxin and mediates 
a pre-dominantly anti-inflammatory response (Balakrishnan et al, 2013). Therefore 
availability of all of these sensing molecules will determine the magnitude of 
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biological response to the translocated product. Further work is required to more 
comprehensively understand these mechanisms.  
 
1.3 The role of alterations in the Gut Barrier interface and bacterial 
translocation on pathogenesis of cirrhosis and ACLF 
1.3.1 Background 
The symbiotic relationship that exists between the enteric microflora and human host 
is integral to health. The microbiome plays a key role in shaping immunological 
tolerance and contributing to the metabolic status of the host. In liver disease this 
interaction becomes pathological in nature with evidence of bacterial translocation 
and consequent immunopathology compounded by deleterious metabolic sequelae. 
Bacterial translocation is defined as the migration of bacteria or bacterial products 
from the intestinal lumen to mesenteric lymph nodes or other extra-intestinal organs 
or sites (Berg & Garlington 1979) and has been demonstrated in cirrhotic patients by 
a number of methods including mesenteric lymph node culture and detection of 
bacterial DNA products in serum and ascitic fluid (Gonzalez-Navajas et al, 2007).  
The presence of viable bacteria and metabolic or structural components have been 
shown to be associated with hepatic fibrogenesis (Bilzer M et al 2006), and 
complications of cirrhosis such as spontaneous bacterial peritonitis (Riordan & 
Williams 2006), hepatorenal syndrome (Fernandez et al, 2007; Shah et al, 2012), 
variceal haemorrhage (Thalheimer et al, 2005), hepatic encephalopathy ((Bajaj et al 
2012; Riordan & Williams, 2010) ), hepatopulmonary syndrome (Sztrymf et al, 2005), 
and diminished survival (Gonzalez-Navajas et al, 2007). Endotoxaemia has also 
been implicated in the pathogenesis of both innate and adaptive immune dysfunction 
(Lin et al, 2007) resulting in a dysregulated systemic inflammatory response 
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syndrome so central to the pathogenesis of ACLF. Whether these changes are a 
cause or consequence of advancing liver disease is unclear.  
 In addition to the immunological sequelae of translocated bacteria and 
bacterial products, the resident microflora has a key role in metabolism. In fact 
although the composition of the gut microflora is diverse and subject-specific, its 
functionality is thought to be homogenous between individuals in health. The 
metabolic contribution of the microflora to disease pathogenesis is already 
recognised in chronic liver disease in particular with reference to alcoholic liver 
disease (Salaspuro, 1996), non-alcoholic fatty liver disease (Tilg, 2010), hepatic 
encephalopathy (Riordan & Williams, 2010) and portal hypertension (Chu et al,  
2000). It is the combined metabolic output of the gut and microflora referred to as the 
metabiome which is of functional relevance. It is likely that the mucosa-associated 
bacterial populations have a far greater contribution in this regard than the central 
intraluminal compartment. Given the central role of translocated bacteria/bacterial 
products in the pathogenesis of cirrhosis, strategies which target this process have a 
potential to impact on outcome at all stages of disease.  
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1.3.2 Mechanisms of Bacterial Translocation 
 
Figure 1.4   Factors determining Bacterial Translocation Rates 
 
Bacterial translocation is defined as the migration of bacteria or bacterial products 
from the intestinal lumen to mesenteric lymph nodes or other extra-intestinal organs 
or sites (Berg & Garlington, 1979) and has been demonstrated in cirrhotic patients by 
a number of methods including mesenteric lymph node culture and detection of 
bacterial DNA products in serum and ascitic fluid which have been shown to have 
prognostic significance (González-Navajas et al, 2007). The three principal factors 
promoting bacterial translocation are intestinal bacterial overgrowth, intestinal 
permeability, and diminished immune surveillance. Each of these factors has been 
shown to be more pathologically disturbed with progressive disease.  
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1.3.3 Intestinal Microbiota 
1.3.3.1 How does the microbiota of cirrhosis differ from that of health?  
The understanding of the composition of the microbiota has been significantly 
advanced by the use of newer culture-independent techniques. These have been 
complemented by metagenomic studies to determine the microbial gene pool and 
therefore provide key information regarding the collective functionality of the 
microbiota. Whilst the microbiota plays a key role in the progression to cirrhosis, we 
will not consider the data for microbiota composition in the pre-cirrhotic context. The 
nature of the dysbioses of pre-cirrhotic liver disease is complex and typically 
aetiology-specific.  
Dysbiosis has been described in a broad range of liver diseases and its 
manifestations. In general, clinical studies demonstrate a perturbation in the typical 
composition of enteric flora in cirrhotic patients with an increase in enterobacter and 
enterococcus and a reduction in bifidobacteria most marked with advancing disease 
(Zhao et al, 2004). As with pathological states such as obesity and inflammatory 
bowel disease, a reduction in microbial phylogenic and metagenomic diversity is 
observed in patients with cirrhosis compared to healthy controls.  
 
1.3.3.1.1 Data from Phylogenic Studies 
Scoring systems, which have been clinically validated to differentiate cirrhosis from 
health and predictive of disease stage include the cirrhosis dysbiosis ratio (CDR) 
(Bajaj et al, 2014a) and Bifidobacteria/Enterobacteriaceae (B/E) ratio (Lu et al, 2011). 
Both provide measures of dysbiosis and both have been validated in studies of 
healthy versus cirrhotic patients. The B/E ratio reflects the ability of the bowel to 
counteract pathogen colonization, termed colonization resistance. CDR is 
determined by multitagged pyrosequencing to determine microbiome composition in 
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cirrhotic patients. Whilst inter-individual species variation was found to be 
considerable, quantifying the degree of dysbiosis by determining the ratio of 
autochthonous to non-autochthonous taxa was found to be a consistent and reliable 
predictor of disease severity. CDR was highest in controls followed by compensated, 
decompensated cirrhosis, and in-patient cirrhotics, negatively correlating with 
endotoxin levels (Bajaj JS et al. 2014b). In longitudinal studies, CDR remained 
unchanged in stable outpatient cirrhotics. In contrast, patients who subsequently 
developed hepatic encephalopathy (HE) exhibited a dynamic change in population 
towards dysbiosis. Significant differences in the microbiota of cirrhotic patients who 
went on to develop sepsis compared with uninfected cirrhotics were observed at 
baseline. CDR was found to be predictive of organ failure and 30 day mortality. 
These data indicate a strong association between CDR and disease state but 
whether these are mere associations or whether they are the pathophysiologic basis 
of disease is unclear. 
Chen et al (Chen et al, 2015) observed the phylogenetic profiles of the faecal 
microbiome in cirrhotic patients to be characterized by a relative expansion of 
pathogenic bacteria such as enterobacteriaceae and streptococcaceae with a 
reciprocal reduction in autochthonous bacteria such as lachnospiraceae. Similarly, 
Qin et al (Qin et al, 2014) identified an over-representation of Veillonella and 
Streptococcus at the expense of bacteroidetes and clostridiales populations in a 
cohort of cirrhotic patients. A majority of the patient-enriched species were observed 
to be of buccal origin suggesting that there is distal migration of pathogenic species 
from the oropharynx which influences the composition of the downstream bacterial 
populations.  
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Table 1.1 Microbiome Composition in Cirrhosis 
 
1.3.3.1.2 Data from Metagenomic studies  
Quantitative metagenomic studies by Qin et al (2014) revealed over 75,000 genes 
which differed in abundance between the intestinal microbiome of cirrhotic patients 
and healthy individuals. A group of 15 bacterial species were identified as potential 
biomarkers to define a highly accurate patient discrimination index which could be 
used as a biomarker for cirrhosis. This was subsequently validated in an independent 
cohort (Qin et al, 2014). Metagenomic species (MGS) were identified based on 
abundance profiles of bacterial genes associated with disease. Abundance of MGS 
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enriched in cirrhosis was found to positively correlate with stage of cirrhosis. 
Conversely an inverse correlation with cirrhosis s severity and MGS enriched in 
controls was observed. Thus, the pathological signature of disease in cirrhosis may 
be described at a bacterial genomic level both with regard to gene abundance and 
functional profile. 
 
1.3.3.2 Clinical relevance of bacterial translocation in cirrhosis 
1.3.3.2.1 Hepatic encephalopathy 
Gut bacteria contribute to the development of HE by generation of ammonia and 
promotion of a pro-inflammatory response (Shawcross et al, 2004) and neutrophil 
dysfunction (Shawcross et al, 2010), both of which are driven by endotoxaemia 
(Wright et al, 2007). Culture-independent techniques are beginning to further inform 
understanding of the role of the microbiome in the pathogenesis of hepatic 
encephalopathy. Studies to date have evaluated the stool microbiome (Bajaj et al 
2012a, Bajaj et al, 2014a) in addition to the mucosal adherent populations (Bajaj et 
al, 2012b) and salivary microbiome (Bajaj et al, 2015). Broadly, reductions in 
autochthonous and increases in non-autochthonous microbial populations are 
observed in patients with a current or past history of hepatic encephalopathy. 
Increases in enterobacteriaceae and enterococcaceae have been observed in both 
the stool and salivary microbiome. Indeed, microflora of oral origin were also 
identified in the stool microbiome in other studies of cirrhosis (Qin et al, 2014) as well 
as in a cohort of compensated cirrhotics treated with proton pump inhibitors (PPI) 
(Bajaj et al, 2014c). It may therefore be that disease-specific changes in luminal 
environment compounded by side effects of PPI therapy may serve to promote 
colonization of more distal gut with bacteria from the oral microbiome and predispose 
to an encephalopathic state. 
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On network analysis, improved cognition and decreased inflammation is observed 
with autochthonous genera in both cirrhotics with and without hepatic 
encephalopathy (Bajaj et al, 2012a). Indeed higher prevotella representation is 
associated with prevention of recurrence of hepatic encephalopathy. In contrast, 
worsening cognition was observed in patients with a higher representation of 
alcaligeneceae and porphyromonadaceae, veillonellaceae, enterococcus, 
megasphaera, and burkholderia. 
Inflammation plays a key role in pathogenesis of hepatic encephalopathy, frequently 
driven by gut-derived bacterial ligands (Wright et al, 2007). In the context of hepatic 
encephalopathy, positive correlation with inflammatory indices was observed with 
fusobacteriaceae, veillonellaceae, and enterobacteriaceae, enterococcus, 
megasphaera, and burkholderia (Bajaj et al, 2012a). A negative correlation was 
observed with ruminococcaceae and the relative abundance of lachnospiraceae was 
obviously decreased in ACLF patients with hepatic encephalopathy (Chen et al, 
2011). Interestingly, the stool microbiota of cirrhotic patients was more significantly 
correlated with systemic inflammation as compared to saliva microbiota. This may be 
a reflection of differential immunogenicity of bacterial ligands derived from these two 
sites. 
Gut bacteria contribute to the development of HE by means of ammoniagenesis and 
generation of an endotoxin-driven inflammatory response acting synergistically 
(Butterworth, 2013). The important role of gut bacteria in this process is highlighted 
by the effects of lactulose and oral antibiotics on lowering gut-derived ammonia and 
encephalopathic state (table 1.2). Despite improving encephalopathic state, 
interventions such as rifaximin and lactulose impose only modest changes in 
microbiome composition (Bajaj et al, 2013a). Rifaximin is associated with a shift in 
bacterial metabolic phenotype towards a more physiological state (Bajaj et al, 
2013a). Bajaj et al (2013) demonstrated that eight weeks of rifaximin therapy in 
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twenty cirrhotics with minimal HE was associated with only modest changes in 
microbiome composition (increase in eubacteriaceae and decrease in 
veillonellaceae) despite a significant improvement in cognition. This may be 
explained by an apparent change in linkage of networks centered on 
enterobacteriaceae, porphyromonadaceae and bacteroidaceae towards more 
physiological metabolites. Lactulose withdrawal was found to be associated with a 
reduction in faecalibacterium in two studies. Functionally, Prevotella was found to be 
associated with improved cognition and inflammatory state in patients without HE 
recurrence.  
 
1.3.3.2.2 Spontaneous bacterial peritonitis 
Translocation of enteric bacteria is considered to be the principal underlying 
mechanism responsible for spontaneous bacterial peritonitis (SBP). The three key 
factors responsible for promoting bacterial translocation; bacterial overgrowth, 
increased intestinal permeability and integrity of immune surveillance mechanisms, 
are important in driving SBP. Of these three factors, bacterial overgrowth is of 
particular importance in pathogenesis.  
SBP rates have been shown to be significantly higher in ascitic patients with 
evidence of intestinal bacterial overgrowth than without (Morencos et al, 1995). 
Indeed in experimental models of cirrhosis, bacterial translocation is almost always 
associated with intestinal bacterial overgrowth. Intestinal bacterial overgrowth rates 
increase with progressive disease in cirrhosis (Gunnarsdottir et al, 2003; Morencos 
et al 1995). Delayed intestinal transit time is a key factor driving this process and is 
more prevalent in patients with a history of SBP (Chang et al 1998). Other 
intraluminal factors such as presence of alcohol (Bode et al 1984), bile acid profile, 
nutritional factors and pH will further contribute. Perhaps the most convincing 
evidence for the association and importance of intestinal bacterial overgrowth and 
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SBP is the observation that selective intestinal decontamination with non-absorbable 
antibiotics such as norfloxacin is associated with a significant improval in survival in 
this context (Fernández et al, 2007). 
 
Factors which promote bacterial overgrowth such as proton pump inhibitor (PPI) 
therapy have been associated with increased risk of SBP and mortality (Deshpande 
A et al, 2013; Kwon et al, 2014). The most recent meta-analysis was performed in 
2013 by Deshpande et al who evaluated 8 studies (3815 patients) and identified a 
three-fold increased risk of developing SBP with PPI. A recent prospective study 
have since been published suggesting no significant correlation (Terg et al, 2015). 
The heterogeneity in the literature may be a function of the heterogeneity of the 
patient group and variations in physician practice.  
The emergence of multi-resistant organisms and induction of further dysbiotic states 
such as Clostridium difficile colitis is a particular concern in patients on oral antibiotic 
therapy with SBP. Multiple studies have highlighted the shift in microbial sensitivity 
patterns in SBP charting a concerning rise in resistant strains and also an increase in 
gram-positive infections particularly in context of patients receiving quinolone 
prophylaxis (Alexopoulou et al, 2013). 
Finally, integrity of the innate immune response is another important factor promoting 
SBP. Genome wide association studies have identified polymorphisms in the Toll-like 
receptor (TLR) 2 and Nucleotide-Binding Oligomerization Domain Containing 2 
(NOD2) as risk factors for the development of SBP (Appenrodt B et al 2010; Bruns et 
al, 2012; Nischalke et al, 2011). Increased intestinal permeability associated with 
Child Pugh status is also associated with a history of SBP (Scarpellini et al, 2010). 
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1.3.3.2.3 Portal hypertension and circulatory dysfunction 
Splanchnic vasodilatation is a hallmark of advanced cirrhosis. Selective intestinal 
decontamination is associated with improvement in vascular resistance and 
reduction in portal pressure suggestive of interplay between these hemodynamic 
disturbances and the resident microflora (Albillos et al, 2003). Antibiotic prophylaxis 
in context of variceal bleeding has been shown to be associated with a significant 
reduction in early re-bleeding rates and transfusion requirements (Hou et al, 2004). 
Although this was not associated with a significant improvement in survival, it does 
highlight the important association between gut bacteria and hemodynamic status. 
Splanchnic vasodilation is thought to result in part from activation of the local immune 
system and endothelial dysfunction. Gut bacteria with the propensity to translocate 
(in particular facultative anaerobes such as enterobacteraceae) possess diverse 
nitric oxide handling mechanisms, which may put them at a competitive advantage 
under conditions of nitrosative stress (Tiso & Schechter, 2015). Microbial nitric oxide 
production may further contribute to exacerbating splanchnic vasodilation. Hydrogen 
sulphide (H2S) derived from gut bacteria has also been implicated in mediating 
splanchnic vasodilatation in cirrhosis (Iwakiri, 2007).  
Bacterial translocation has also been implicated in the pathogenesis of 
hepatopulmonary syndrome. Treatment with norfloxacin diminishes the incidence 
and severity of hepatopulmonary syndrome in cirrhotic rats (Rabiller et al, 2002).  
 
1.3.3.2.4 Acute-on-chronic liver failure (ACLF) 
Chen et al demonstrated that gut dysbiosis has been shown to be a prognostic 
determinant in acute-on-chronic liver failure (ACLF) (Chen et al, 2011). Overall 
microbial diversity and richness were significantly lower in ACLF than in controls with 
lower abundance of bacteroidaceae, ruminococcaceae, and lachnospiraceae, and 
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higher abundance of pasteurellaceae, streptococcaceae, and enterecoccaceae. 
Interestingly, the gut microbiota was relatively stable in a short term after the onset of 
ACLF and use of antibiotics only showed moderate impacts on the gut microbiota. 
Network-analysis comparison showed robust correlations between autochthonous 
bacteria and inflammatory cytokines. The relative abundance of pasteurellaceae and 
MELD score were found to be independent factors predicting mortality rate. It must 
be noted however that viral hepatitis was the underlying cause of cirrhosis in the 
majority of patients in this study. Aetiology-specific factors are likely to impact on 
microbiome composition. Further studies are required in which other aetiologies are 
represented. 
 
1.3.3.2.5 Pre-cirrhotic chronic liver disease 
Multiple lines of evidence implicate gut-derived bacterial products in the promotion of 
fibrogenesis in the liver. Endotoxin-induced Kupffer cell activation has been identified 
as an important event in the induction of hepatic stellate cell activation and fibrosis in 
alcoholic, non-alcoholic and cholestatic liver injury. Indeed LPS/TLR4 signalling is 
implicated in disease pathogenesis in alcoholic liver disease, non-alcoholic fatty liver 
disease, primary sclerosing cholangitis, primary biliary cirrhosis, chronic hepatitis B 
and C (Mencin, Kluwe & Schwabe, 2009). Modulation of TGF-signalling by a TLR4-
MyD88-NFKβ axis provides a novel link between pro-inflammatory and pro-fibrotic 
pathways (Seki et al, 2007). Mice deficient in TLR4 exhibit significantly attenuated 
steatohepatitis and fibrosis (Csak et al, 2011). Indeed selective intestinal 
decontamination with antibiotics results in prevention of hepatic fibrosis after bile-
duct ligation, CCL4 treatment or a choline-deficient diet (Zhu et al, 2012). Rifaxamin 
treatment in bile duct ligated (BDL) mice was also associated with a reduction in 
portal pressure. Manipulation of the gut flora with probiotic VSL3 results in 
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attenuation of fibrosis in methionine choline deficient (MCD) mice (Velayudham et al, 
2009).  
 
1.3.3.3 Metabolic sequelae of dysbiosis in cirrhosis 
1.3.3.3.1 Background 
There is a complex, dynamic and pathological metabolic interplay between host and 
microbiota in cirrhosis, which is incompletely understood. Metagenomic studies 
suggest that multiple metabolic pathways are over-represented in the microbiome of 
cirrhotic patients implicating them in either a pathogenic or compensatory role.  
Disordered bile salt metabolism is observed in cirrhosis, a finding which is associated 
with a shift in microbiota composition Ridlon et al, 2014). Cirrhotic patients with 
hepatitis B were found to have a metagenomic profile characterized by an 
enrichment in the metabolism of glutathione, gluconeogenesis, branched-chain 
amino acid, nitrogen, and lipids, with a decrease in the level of aromatic amino acid, 
bile acid and cell cycle related metabolism (Wei et al, 2013). Qin et al (2014) 
observed that the microbiome of cirrhotic patients had an over-representation of 
products of nitrate and ammonia metabolism, de-nitrification, GABA (gamma-
aminobutyric acid) synthesis, phosphotransferase systems and amino acid 
membrane transports. 
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Figure 1.5 Metabolic contributions of the gut microbiome in the pathogenesis of liver 
disease 
 
1.3.3.3.2 Bile acid metabolism and the microbiome in cirrhosis 
Reduced colonic bile salt availability is observed in cirrhosis, with a marked effect on 
secondary bile salts resulting in a reduction in secondary/primary bile acid ratio 
(Kakiyama et al, 2013). Low intraluminal bile salt levels are a composite function of 
progressive cholestasis compounded by a reduction in bile acid production due to 
hepatic inflammation and an observed increase in expression of ileal bile salt 
transporters (Ridlon et al, 2013). This metabolic shift is associated with a change in 
microbiome composition with progressive disease associated with a lower 7α-
dehydroxylating bacteria representation and a reciprocal expansion of potentially 
pathogenic enterobacteriaceae (Kakiyama et al, 2013).  
Bile acids exert a bacteriostatic effect, in particular in relation to anaerobic bacteria. 
Administration of conjugated bile acids to cirrhotic rats is associated with a reduction 
in bacterial overgrowth and translocation (Lorenzo-Zúñiga et al, 2003). 7α-
dehydroxylating bacteria have a selection advantage in context of intraluminal bile 
acids due to their metabolic pathways and bile-tolerance. Without such selection 
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Figure 2. Pathological metabolic contribution of the gut microbiome in liver disease
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pressures, the 7α-dehydroxylating bacterial populations collapse, associated 
functionally with an increase in primary/secondary bile acid ratio due to a reduction in 
secondary bile acid synthesis (Ridlon et al, 2013). Interestingly, this observed shift in 
microbiota composition in the context of cirrhosis may be protective to the host in the 
context of cirrhosis.  A reduction in secondary bile acids, which are responsible for 
membrane instability, may have a beneficial effect on epithelial integrity (Stenman et 
al, 2013). Furthermore, primary bile acids are more potent FXR (Farnesoid X 
receptor) agonists with beneficial effect on portal pressure and haemodynamic status 
and promotion of antimicrobial peptide production (Ridlon et al, 2013).  
 
1.3.3.4 Aetiology-specific changes in microflora 
1.3.3.4.1 Alcohol 
Small bowel bacterial overgrowth is well documented in patients with chronic alcohol 
use. Jejunal aspirate culture yielded significant bacterial counts of >105 colony 
forming units/ml in 48% of patients with chronic alcohol use compared with 7.6% in a 
control group (Bode et al, 1984). Coliform organisms were cultured more frequently 
in the jejunal fluid of alcoholics (55.6%) compared to control (15.4%). Morencos et al 
established that 30.3% of patients with alcoholic cirrhosis had evidence of bacterial 
overgrowth (Morencos et al, 1995). The prevalence of small bowel overgrowth 
increased with Child Pugh score affecting 48.3% of patients with Child Pugh C 
cirrhosis.  
Intraluminal bacteria play an important role in bacterial translocation in chronic 
alcohol consumption (Ferrier et al, 2006). They are the principal source of alcohol 
dehydrogenase responsible for the generation of acetaldehyde from ethanol and 
bacterial overgrowth is a key factor in determining bacterial translocation rates. 
Acetaldehyde results in mucosal injury thus facilitating translocation.  
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1.3.3.4.2 Non-alcoholic fatty liver disease 
Small intestinal bacterial overgrowth occurs in patients with NAFLD and correlates 
with the severity of steatosis (Miele et al, 2009; Sabate et al, 2008). Over-
representation of firmicutes at the expense of bacteroides has been demonstrated 
both in clinical studies and in genetically obese mice (Ley et al, 2005). The increase 
in small intestinal bacterial overgrowth is associated with enhanced TLR-4 
expression and production of IL-8 (Shanab et al, 2011). In murine models, a high fat 
diet has been associated with modulation of the dominant bacterial populations 
within the commensal bacteria and resulted in a continuous increase in plasma 
endotoxin (Serino et al, 2012).  Endotoxin then contributes to the development of a 
subclinical inflammatory state and insulin resistance associated with metabolic 
syndrome by stimulating the release of pro-inflammatory cytokines from the adipose 
tissue. Endotoxin is thought to be an important co-factor in the development of 
steatohepatitis in the setting of established steatosis. Animal studies have 
demonstrated that systemic endotoxaemia results in TNFα-mediated steatohepatitis 
in genetically obese mice. These mice have an increase in intestinal permeability and 
portal endotoxaemia which renders hepatic stellate cells more susceptible to 
endotoxin (Yang et al, 1997). Mice deficient in TLR4 (endotoxin receptor) have 
significantly attenuated steatohepatitis and fibrosis when fed a methionine choline 
deficient diet compared to wild type MCD fed controls (Rivera et al, 2007). Recent 
evidence has also highlighted the importance of the inflammasomes NLRP3 and 
NLRP6 in negative regulation of disease progression in NAFLD in parallel to TLR-
mediated mechanisms (Henao-Mejiaet al, 2012).  
Gut bacteria are thought to contribute to the pathogenesis of NASH by increasing gut 
luminal alcohol production derived from carbohydrate metabolism and subsequently 
metabolising this to acetaldehyde. Nair et al (2001) identified an association of 
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obesity with high breath ethanol levels, particularly significant in patients with a BMI 
over 36. Genetically obese mice have also been shown to have higher breath 
ethanol concentrations than lean mice, an effect significantly attenuated by oral 
antibiotics implicating gut flora in pathogenesis (Cope, Risby & Diehl 2000). 
Subsequent metabolism of alcohol by gut bacteria to acetaldehyde with resultant 
mucosal injury is well documented.  
In addition to endogenous generation of ethanol and acetaldehyde, gut bacteria 
further contribute to liver injury by promoting disordered carbohydrate and lipid 
metabolism within the gut lumen. The microflora of genetically obese leptin deficient 
mice have been shown to contain genes encoding enzymes to digest otherwise 
indigestible polysaccharides, more end products of fermentation such as acetate and 
butyrate and fewer calories in the faeces of microflora. Transfaunation of the faecal 
microflora of genetically obese mice to lean mice conferred a significant increase in 
body fat associated with an increase in calorific extraction from food (Turnbaugh et 
al,  2006). Germ-free mice have been shown to be resistant to obesity when 
consuming a Western-style high fat high sugar diet (Rabot et al, 2010). This occurs 
by two mechanisms both resulting in an increase in fatty acid metabolism. An 
increase in the activity of adenosine monophosphate-activated protein kinase which 
determines cellular energy status was observed together with an increase in Fiaf-
induced PPAR co-activator expression which results in an upregulation of regulators 
of mitochondrial fatty acid oxidation. In addition to this action, Fiaf acting as a 
lipoprotein lipase inhibitor promotes fatty acid uptake. 
 
1.3.3.4.3 Cholestatic Liver disease  
Luminal bile salt availability in cholestatic disorders plays a role in bacterial 
translocation. Bile acids have a bacteriostatic effect, in particular in relation to 
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anaerobic bacteria. The increased intestinal permeability and morphological 
disturbance of terminal ileum observed in bile-duct ligated rats was prevented with 
duodenal administration of bile (Ogata et al, 2003). Supplementation of 
ursodeoxycholic acid has been shown to be associated with a reduction in bacterial 
translocation rates in rats after seven days of bile duct ligation (Aldemir et al, 2003). 
Further studies in bile duct ligated rats have demonstrated that endotoxin levels and 
rate of positive mesenteric lymph node cultures were reduced following 
administration of cholic acid, deoxycholic acid or whole bile (Ding et al, 1993).  
 
1.3.4 Intestinal Permeability 
1.3.4.1 Evidence for alterations in intestinal permeability in cirrhosis 
Increased intestinal permeability has been well documented in chronic liver disease 
and shown to increase with severity of disease. Increased intestinal permeability has 
been described using sugar probe-based assays (Zuckerman et al, 2004) and also 
(51)Cr-EDTA in up to 45% cirrhotic patients compared with 4% controls (Scarpellini 
et al,  2010). Independent determinants of altered intestinal permeability included 
alcohol, diabetes, portal hypertension and age. Increased intestinal permeability was 
significantly associated with severity of liver disease (Child-Pugh Score A-22%, B-
39%, C-75%), presence of ascites (60%) and history of spontaneous bacterial 
peritonitis (100%) (Cariello R et al. 2010). Keshavarzian et al (1999) demonstrated 
that increased intestinal permeability and endotoxaemia preceded steatohepatitis 
suggesting that gut-barrier injury and resultant endotoxaemia are necessary for the 
development of liver injury. In principle bacteria can traverse the mucosal epithelium 
via either paracellular or transcellular routes. Paracellular permeability is determined 
by alterations in the tight junction proteins and transcellular permeability by 
enterocyte channels and membrane pumps. It is the latter which is thought to be 
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primarily responsible for bacterial translocation in cirrhosis although data on the 
integrity of the gut barrier in cirrhosis is conflicting.  
The ability of tight junctions to discriminate between and restrict solute based on size 
varies with location in the intestine as permeability to larger solutes decreases from 
the crypt to the villus. In addition to the fixed differences, mucosal permeability of 
many tissues is adaptable and may be regulated in response to extracellular stimuli, 
such as nutrients, cytokines, bacteria and nitric oxide. The tight junction is the rate 
limiting step in trans-epithelial transport and therefore the principle determinant of 
mucosal permeability. At least two routes exist which allows transport across the tight 
junction. One route termed the leak pathway, allows paracellular transport of large 
molecules including limited flux of proteins and bacterial endotoxin. The leak pathway 
does not exhibit charge selectivity. Flux across the leak pathway may be increased 
by cytokines IFNγ and TNFα. A second pathway characterised by small pores that 
are thought to be defined by tight junction-associated claudin proteins, which are also 
the primary determinants of charge selectivity. Active transcellular transport depends 
on the presence of intact tight junctions. Transcellular transport can activate 
intracellular signalling events which then regulate the tight junction barrier such as 
apical Na-nutrient co-transport. This allows passive paracellular absorption of 
nutrients and water to amplify transcellular nutrient absorption particularly when high 
luminal concentrations exceed the capacity of apical Na-nutrient co-transporters. The 
best data are from studies of the effects of alcohol, cirrhosis and role of nutrition and 
portal hypertension. 
 
Structural abnormalities in intestinal mucosa have been shown to occur in cirrhosis. 
Bile duct ligated cirrhotic rats were shown to have increased gut permeability with 
loss of occludin expression and increased endotoxemia in one study whereas the 
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zona-occludens-1 expression was shown to be normal in another. Morphological 
abnormalities included a reduction in villus height, mucosal thinning, inflammatory 
infiltrate with oedema and focal separation and vacuolation of enterocytes (Parks et 
al 2000). The terminal ileum was most markedly affected. The mechanisms these 
abnormalities are thought to result from oxidative damage of the intestinal mucosa as 
evidenced by increased xanthine oxidase activity, altered antioxidant status, 
increased lipid peroxidation of brush border membranes and abnormal intestinal 
transport (Schimpl et al, 1996). Inhibition of xanthine oxidase by allopurinol resulted 
in a reduction in bacterial translocation in bile duct ligated rats (Schimpl et al, 1996). 
It is unclear however whether increased intestinal permeability is a primary 
mechanism of bacterial translocation or the result of endotoxin-driven inflammation 
and/or high NO production which secondarily compromises gut barrier function.  
 
1.3.4.2 Alcohol 
Metabolites of alcohol in particular acetaldehyde can directly influence the function of 
epithelial tight junction and adherens junction proteins leading to an increase in 
paracellular permeability. Acetaldehyde dose-dependently increases colonic 
paracellular permeability and has been shown to affect bioavailability of low-
molecular weight hydrophilic probes in chronic alcohol fed rodent models. 
Acetaldehyde is known to disrupt adherens junctions (AJ) within 10 minutes of 
exposure as evidenced by a redistribution of E-cadherin and β-catenin from the 
intercellular junctions (Atkinson & Rao 2001). This then results in a redistribution of 
the tight junction (TJ) proteins occludin and zonula occludens-1 (ZO-1). Disruption of 
TJ and AJ has been observed in human colonic tissue (Basuroy et al,  2005).  
Histologically, alcoholic liver disease is associated with architectural disturbance of 
the small intestine and abnormal activities of brush border, cellular and membrane 
enzymes (Bhonchal et al, 2008). These abnormalities are most pronounced within 
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cirrhotic patients. Acute alcohol intake is associated with increased gastro-duodenal 
permeability and chronic intake with increased distal small bowel permeability which 
occurs prior to the development of endotoxaemia and liver injury (Keshavarzian et al, 
1999). Alcohol-induced nitric oxide production can influence tubulin function and 
cytoskeletal dysfunction (Banan et al, 2000) resulting in altered gut barrier function. 
Data from rodent models of ALD suggests that NO production is responsible for the 
development of increased intestinal permeability, oxidative stress, endotoxaemia and 
liver injury (Tang et al, 2009). iNOS inhibitors attenuated these features in this 
context. Acute administration of alcohol inhibits active intestinal absorption of L-
amino acids and reduces the activity of the Na+/K+ ATPase brush border enzymes 
(necessary for sodium-dependent amino acid uptake) which is further decreased with 
more advanced liver disease (Beesley 1986). Bala et al (2014) demonstrated that 
acute alcohol consumption in healthy volunteers was associated with bacterial 
translocation as evidenced by increased serum endotoxin and bacterial DNA. These 
abnormalities are most pronounced in cirrhotic patients. 
 
1.3.4.3 Nutritional factors and obesity 
Intestinal permeability is increased in patients with NAFLD and its severity correlates 
with the severity of steatosis (Miele et al, 2009). Genetically obese obob-/- mice 
display enhanced intestinal permeability leading to increased portal endotoxaemia 
(Yang et al, 1997).   
Glutamine is an important fuel for the enterocytes and its deficiency results in 
compromised gut barrier integrity due to reduced expression and localisation of tight 
junction proteins. Supplementation of glutamine in BDL rats at ten days does result in 
a reduction in BT rates and an improvement in ileal histology (Margaritis et al, 2005). 
Zinc deficiency is also frequently observed in patients with cirrhosis, and its 
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supplementation has been shown to result in preservation of intestinal integrity, 
prevention of endotoxaemia and resultant TNFα production (Mohammad et al, 2012).  
 
1.3.4.4 Portal Hypertension 
The interplay between portal hypertension, intestinal permeability and bacterial 
translocation is complex and incompletely understood. In a large cohort of cirrhotic 
patients the presence of portal hypertension and ascites was an independent 
determinant of intestinal permeability in addition to age, alcohol intake and diabetes 
(Cariello et al, 2010). Gastric permeability was shown to be increased in patients with 
portal hypertensive gastropathy (Giofre et al, 2000) and TIPS insertion and treatment 
with propanolol was found to improve intestinal permeability (Senzolo et al, 2009; Xu, 
Wu & Li, 2002). Importantly, a reduction in hepatic venous pressure gradient by non-
selective beta blockers reduced the incidence of spontaneous bacterial peritonitis 
(Senzolo et al, 2009). It is unclear at present as to whether this is merely a function 
of portal pressure reduction or an effect on gut transit with associated reduction in 
bacterial overgrowth.  
These observations suggest a causal association with portal hypertension and 
associated vascular congestion and increased intestinal permeability. Importantly, a 
reduction in portal pressure by non-selective beta-blockers reduced the incidence of 
spontaneous bacterial peritonitis (Senzolo et al 2009). It is unclear at present as to 
whether this is merely a function of portal hypertension or an effect on gut transit with 
associated reduction in bacterial overgrowth.  
1.4 Manipulation of the microbiota as a therapeutic manoeuvre in liver disease 
1.4.1 Reducing gut bacterial populations: Antibiotics 
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Clinically, the strategy of selective intestinal decontamination to diminish gut-derived 
endotoxemia has been shown to be associated with a reduction in multiple 
complications of cirrhosis: spontaneous bacterial peritonitis, variceal hemorrhage, 
hepatic encephalopathy and hepatorenal syndrome (see table 1.2). Selective 
intestinal decontamination with oral antibiotics remains the primary therapeutic 
strategy to manipulate the microbiota and thus the natural history of advanced 
cirrhosis. This highlights the central role of the gut microbiota in determining risk of 
development of complications of cirrhosis, in particular, organ failure and thus 
mortality.  
Modulation of commensal enteric flora with norfloxacin and rifaximin have been 
shown to partially reverse the hyperdynamic circulatory state in cirrhotic patients 
(Miele et al,  2009) and improvement in systemic hemodynamics and HVPG 
respectively (Giofre et al, 2000), which was associated with improvement in 
glomerular filtration rate (GFR) and natriuresis. Furthermore, reduction in bacterial 
translocation with empirical broad-spectrum antibiotic therapy in the context of 
variceal bleeding has been shown to result in a reduction in re-bleeding and mortality 
rates (Bernard et al, 1999).  
Translocation of enteric bacteria is considered to be the principal underlying 
mechanism responsible for SBP. Administration of norfloxacin as secondary 
prophylaxis for SBP has been shown to result in a reduction in the probability of 
developing SBP significantly (Gines et al 1990) and a reduction in hepatic 
encephalopathy (Dawson et al 1957; Morgan, Read & Speller, 1982). RIfaximin has 
been shown to significantly reduce recurrence of hepatic encephalopathy (Bass et al 
2010).  
Shah et al demonstrated that selective intestinal decontamination with a 10 day 
course of norfloxacin in BDL and LPS-treated BDL rats resulted in a significant 
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improvement in ALT and creatinine (2012). This improvement in organ injury was 
associated with a significant attenuation in neutrophil ROS production and systemic 
TNFα concentrations. Marked reductions in immunostaining for TLR4 and caspase3 
were observed in norfloxacin-treated BDL and BDL+LPS rats compared to untreated 
controls (Shah et al, 2012).   
Taken together, these observations demonstrate that manipulation of the microflora 
with quinolone therapy in a model of cirrhosis and ACLF is associated with significant 
improvements in organ injury and improvement in innate immune phenotype. 
Growing concern regarding resistance, super-infection and emergence of greater 
numbers of gram positive organisms limits the role of oral antibiotics.  
 
1.4.2 Altering Bacterial composition: Probiotics 
Probiotic therapy provides an attractive alternative strategy with a preferable safety 
profile. In vitro and animal studies indicate a strong role of probiotics in 
immunomodulation via modulating dendritic cell function and epithelial barrier 
function. Available clinical trials of probiotics are summarized in table1.2. The marked 
heterogeneity of studies particularly in regards to microbial composition and 
concentration of probiotic, duration of therapy, aetiology and stage of disease limits 
interpretation of the established literature in particularly with regards to 
decompensated disease. Given the important contribution of the gut microbiota in the 
pathogenesis of other complications of cirrhosis, probiotic therapy is likely to have a 
broader application in the future treatment algorithms of cirrhosis. Further trials are 
required to established optimal probiotic doses and compositions.  
 
1.4.3 Other potential and emerging approaches 
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1.4.3.1 Beta-blockers 
Use of beta-blockers in cirrhosis have been found to be protective against infection 
and associated with a lower morbidity and mortality. A meta-analysis by Senzolo et al 
(2009) described a significant protective effect of beta-blockade against SBP. It has 
been suggested that this effect may be mediated by modulating intestinal motility, 
small bowel overgrowth and therefore bacterial translocation rates. The use of these 
agents is controversial in patients with decompensated cirrhosis and refractory 
ascites (Ng et al, 2009).  
1.4.3.2 Targeting toll-like receptor pathway 
TLR pathways have been shown to play a key role in complications of cirrhosis 
(Bosoi et al, 1995; Shah et al, 2012). Inhibition of the endotoxin receptor TLR4 with 
antagonist STM-28 has been shown to significantly improve dendritic cell populations 
in models of cirrhosis (de Oca et al, 2010). Zhu et al (2012) demonstrated the central 
importance of the TLR4 pathway as a mediator of rifaximin-induced reduction in 
portal pressure, fibrosis, and angiogenesis in a murine model of cirrhosis. Given the 
central role of TLR pathways in priming organ injury in acute on chronic liver failure, 
TLR antagonists represent attractive future therapies to improve survival in advanced 
cirrhosis.  
1.4.3.3 Faecal Transplantation 
Faecal transplantation is an emerging therapeutic strategy to correct dysbiotic states 
such as Clostridium difficile colitis (Youngster et al, 2014). Transfaunation of stool 
from animal models of NAFLD and obesity to germ free animals has been shown to 
confer disease phenotype highlighting the potential of stool transplantation in 
modulating liver disease (Le Roy et al, 2013). Currently, no data are available but 
different approaches may be needed for different aetiologies. 
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HE = hepatic encephalopathy; SBP = spontaneous bacterial peritonitis; HVPG = hepatic 
venous pressure gradient; VB = variceal bleeding; HRS = hepatorenal syndrome; CP = Child 
Pugh score; FOS = fructo-oligosaccharides 
 
Table 1.2  Summary of Interventional Clinical studies to manipulate the microbiome in  
cirrhosis 
 
 
Intervention Endpoint evaluated (n) Outcome Authorship 
Selective Intestinal Decontamination    
Norfloxacin vs placebo SBP recurrence 80 Superiority Ginés P et al 1990 
Norfloxacin vs placebo SBP, HRS, mortality 68 Positive Fernández J et al 
2007 
Norfloxacin vs ceftriaxone Bacterial infection post- VB 111 Inferiority Fernández J et al 
2006 
Norfloxacin vs placebo Bacterial infection post- VB 119 Positive Soriano G et al 
1992 
Norfloxacin  HVPG 16 Negative Kemp W et al 2009 
Rifaximin vs placebo HE  299 Positive Bass N et al 2010 
Rifaximin VB/HE/SBP/HRS/Survival 69 Positive Vlachogiannakos J 
et al 2013 
Rifaximin vs lactulose Overt HE 58 Yes Bucci L et al 1993 
Rifaximin+lactulose vs 
lactulose 
Overt HE/mortality 120 Superiority Sharma BC et al 
2013 
Rifaximin vs lactitol Acute HE (grade 1-3) 103 Superiority Mas A et al 2003 
Neomycin vs lactulose Minimal HE 173 Equivalent Orlandi F et al 
1981 
Neomycin-sorbitol vs 
lactulose  
Acute PSE 45 Equivalent Atterbury CE et al 
1978 
     
Probiotics     
VSL#3 vs placebo HVPG 94 Negative Gupta N et al 2013 
Probiotics Minimal HE 43 Negative Saji S et al 2011 
SF-68 vs lactulose Minimal HE 40 Superiority Loguercio C et al 
1995 
Probiotic HE 155 Positive Agrawal A et al 
2012 
Probiotic Minimal HE 25 Positive Bajaj J et al 
Probiotic Overt HE 160 Positive Lunia MK et al 
2014 
Probiotic HE 80 Positive Mittal VV et al 2011 
Probiotic vs placebo HE 36 Negative Pereg D et al 2011 
E.coli Nissle vs placebo CP score 39 Negative Lata J et al 2006 
     
Synbiotic vs FFvs placebo HE 55 Positive Liu Q et al 1995 
Synbiotic vs placebo Minimal HE 60 Positive Malaguarnera M et 
al 2007 
     
Lactulose     
Lactulose Minimal HE 40 Yes Dhiman RK et al 
2000 
Lactulose Minimal HE 75 Yes Watanabe A et al 
1997 
Lactulose HE 80 Positive Mittal VV et al 2011 
Lactulose HE 158 Positive Agrawal A et al 
2012 
Lactulose vs lactose Minimal HE 14 Yes Horsmans Y et al 
1997 
Lactulose vs sorbitol Chronic HE 7 Yes Elkington SG et al 
1969 
Lactulose vs lactitol Acute PSE 40 Equivalent Heredia D et al 
1987 
Lactulose vs lactitol Chronic HE 9 Equivalent Morgan MY et al 
1987 
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1.5 Nanoporous carbons  
Selective intestinal decontamination with oral antibiotic therapy is currently the only 
intervention in clinical practice with proven efficacy to modulate bacterial 
translocation rates in cirrhosis. Whilst associated with improvements in complications 
of cirrhosis such as hepatic encephalopathy, hepatorenal syndrome and 
spontaneous bacterial peritonitis, concerns regarding resistance and superfection 
limits their role. Novel oral therapeutic strategies to adsorb immunogenic and 
metabolic bacterial products in the gut therefore remain an unmet clinical need.  
Activated carbons have a high adsorptive capacity and surface area. They have 
been used historically to adsorb a range of drugs and toxic compounds both orally 
and latterly in context of extracorporeal devices such as the Prismaflex Adsorba 
haemoperfusion system for severe poisoning (Juurlink et al, 2015) and as part of the 
MARS liver assist device (Bañares et al, 2013). Developments in synthetic carbon 
production have facilitated the manufacture of activated carbons of highly tailored 
porosity. Conventionally manufactured activated carbon is typically microporous 
(pore diameter <2 nm) with few pores in the mesoporous (2-50 nm) or macroporous 
(>50 nm) range. AST 120, currently licensed in Japan for oral administration in renal 
failure, is a typical example of a microporous carbon but remains limited in it’s 
capacity to adsorb larger biologically relevant molecules (Niwa, 2016).  
Yaq-001 is a highly adsorbent, pyrolysed spherical carbon synthetically derived from 
phenolic resin. It has a highly tailored bimodal pore size distribution extending into 
the larger nanoporous range to allow removal of larger biotoxins in addition to the 
microporous range with adsorption of smaller targets (Howell et al, 2013). The Yaq-
001 carbons have a powerful, non-selective adsorptive capacity with a large surface 
area. 
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Given that Yaq-001 had the physical properties appropriate to the adsorption of 
bacterial toxins and metabolites, we sought to determine the effects of oral carbon 
therapy in models of cirrhosis, ACLF and non-alcoholic fatty liver disease.  
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Chapter 2 
Hypothesis and Aims 
 
2.1 Hypotheses 
2.1.1 Hypothesis 1 
The nature of the portal derived innate immune response in cirrhosis is pathologically 
disturbed and associated with heightened bacterial translocation 
2.1.2 Hypothesis 2 
The gut barrier interface is pathologically disturbed in bile duct ligated rats and is 
associated with disturbance of the gut microbiota and innate immune response 
2.1.3 Hypothesis 3 
Oral administration of Yaq-001 will attenuate organ injury, improve portal pressure 
and normalise innate immune profile in bile duct ligated rats 
2.1.4 Hypothesis 4 
Oral administration of Yaq-001 will attenuate organ injury and improve Kupffer cell 
function in models of non-alcoholic steatohepatitis 
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2.2 Aims 
 
2.2.1  Characterisation of the portal-derived neutrophil and cytokine profile 
and association with markers of bacterial translocation  
The nature of the portal-derived innate immune response remains poorly described. 
The aim of this study was to characterize the portal-derived neutrophil, cytokine 
profile together with markers of bacterial translocation. In so doing, the relative 
contribution of the gut and liver to the nature of the innate immune response will be 
described and the degree to which this is associated with markers of bacterial 
translocation. This data will provide a quantatitive measure of the magnitude of 
bacterial translocation and the integrity of endotoxin clearance mechanisms in the 
liver. 
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2.2.2  Assessment of the integrity of the gut barrier interface and correlation 
with clinical, immune and pathological characteristics of bile duct 
ligated rats 
Alterations in microbiome, gut barrier integrity and innate immune function have been 
shown to contribute to bacterial translocation and disease progression in cirrhosis 
(see figure 2.1). The first aim of this study was to describe each of these three 
factors in context of the 4 week bile duct ligated rat model. Whilst data does exist 
describing each of these factors in isolation, concomitant characterization of all three 
factors in this model system has not been previously described and thus the relative 
contribution to pathogenesis is incompletely understood.  
 
 
Figure 2.1  Role of bacterial translocation in disease progression in chronic liver disease 
 
Alcohol 
NAFLD 
Cholestasis 
Cirrhosis 
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2.2.3  Characterisation of functional, immunological and microbiological 
changes in the gut-liver axis with oral administration of Yaq-001 in bile 
duct ligated rats 
Bacterial products, in particular endotoxin, accelerate disease progression to 
cirrhosis and play a key role in pathogenesis of decompensated disease and acute-
on-chronic liver failure. Yaq-001 activated carbons have been shown in in vitro 
studies to exhibit a high adsorptive capacity for biologically relevant intra-luminal 
factors such as endotoxin and other bacterial metabolites without exerting an effect 
on bacterial growth kinetics (unpublished data). The primary hypothesis of this study 
was that oral administration of Yaq-001 carbons would abrogate disease progression 
of cirrhosis clinically manifest by a significant improvement in liver biochemistry and 
improvements in haemodynamic status. A key objective was therefore 
characterisation of the effects of oral Yaq-001 carbon therapy on each of the three 
factors which promote bacterial translocation in a 4 week bile duct-ligated rat model 
of cirrhosis. As the carbons should be retained in the gut due to the bead size, they 
exert their effect at a local level. In order to determine how this results in a distant 
biological effect, elements of the gut-liver axis were described.  
 
Figure 2.2  Potential role of oral Yaq-001 therapy in prevention of complications of cirrhosis 
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2.2.4 Characterisation of effects of oral administration Yaq-001 in models of 
non-alcoholic fatty liver disease 
Multiple lines of evidence implicate the gut microbiota in disease pathogenesis of 
non-alcoholic steatohepatitis. The final aim of the study was to evaluate oral Yaq-001 
in models of non-alcoholic fatty liver disease to ascertain whether a similar biological 
effect was observed in pre-cirrhotic liver disease. The final hypothesis was that oral 
administration of Yaq-001 results in significant attenuation of liver injury in models of 
steatohepatitis as evidenced biochemically by alanine transaminase.  
 
 
Figure 2.3  Potential role of oral Yaq-001 therapy in prevention of complications of non-
alcoholic fatty liver disease 
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Chapter 3 
Methods 
 
3.1 Clinical study 
 
The study was undertaken with the approval of the local research ethics committee 
and in accordance with the Declaration of Helsinki (1951) of the World Medical 
Association. The TIPSS procedure was performed by the interventional radiology 
teams at the University of Edinburgh and University College London and laboratory 
analysis performed by Dr. Ter Steege and Dr. Vanessa Stadlbauer. Statistical 
analysis was performed by myself.  
 
3.1.1 Patients 
 
26 patients with alcoholic cirrhosis were studied prior to and 1-hour after TIPSS 
insertion. Patients were included into the study if they had clinical, biochemical or 
histological evidence of cirrhosis and were undergoing TIPSS placement indicated 
for variceal haemorrhage. All patients were haemodynamically stable at the time of 
TIPSS insertion and informed consent (from the patient) or assent (from next of kin) 
was obtained. Other exclusion criteria included pregnancy, a diagnosis of diabetes, 
cardiovascular disease or malignancy.  
 
3.1.2 Patient Management 
 
The patients were managed according to a standardized protocol, and in accordance 
with the UK guidelines for variceal haemorrhage (Jalan & Hayes, 2000). TIPSS 
insertion was indicated either because the patient had variceal bleeding refractory to 
endoscopic therapy or due to recurrent bleeding despite endoscopic therapy. At the 
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time of TIPSS insertion, the patients were mechanically ventilated following sedation 
with propofol and paralysed with atracurium besylate (300-600g/Kg/hr). Routine 
invasive and electrocardiographic monitoring was performed. Fluid resuscitation and 
red cell concentrate were administered in guidance with the central venous pressure, 
mean arterial pressure and the haematocrit. All the patients received broad spectrum 
prophylactic antibiotics. Blood glucose levels were maintained between 5-7 mmol/l.  
 
3.1.3 Transjugular Intrahepatic Portosystemic Stent Shunt procedure and 
catheter insertion 
 
A single interventional radiologist on each site performed all the TIPSS procedures 
using standard techniques. Pre-TIPSS procedure, a femoral artery was cannulated 
using an 18 gauge needle (Vygon leader company, Ecoven, France).  The right 
internal jugular vein was then punctured and a 10 F sheath (William-Cook, 
Bjaeverskov, Denmark) introduced. The right or middle hepatic vein was selected 
using a stiff hydrophilic guide wire (Terumo, Hatagaya, Tokyo, Japan) and a fine 
stylet was used to puncture a branch of the portal vein.  
 
3.1.4 Blood sampling and Measurements 
 
Blood from the femoral artery (A), hepatic vein (HV) and portal vein (PV) sampled 
before insertion of the TIPSS. A sub-group of patients underwent further blood 
sampling of the left gastric vein, splenic vein, superior mesenteric vein and inferior 
mesenteric vein. An angioplasty balloon catheter was then used to dilate the 
parenchymal tract prior to stent insertion (10 mm Wallstent, Schneider, Bulach, 
Switzerland). Portal venous and inferior vena caval pressures were recorded pre- 
and post-TIPSS insertion and the portal pressure gradient determined (portal venous 
pressure minus inferior vena caval pressure). One hour after TIPSS insertion blood 
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was sampled from the following: femoral artery, hepatic vein (not involving TIPSS-
shunt) and portal vein.  
 
3.1.5 Calculations 
Intestinal and hepatic fractional extraction rates of endotoxin, BPI, LBP, IL-6, IL-10, 
were calculated according to the following equation using pre-TIPSS plasma levels. 
The calculation of hepatic fractional extraction assumes a 70% contribution from the 
hepatic artery and 30% contribution from the portal vein in this patient cohort. 
Previous data supports this assumption (Bloeman et al, 2010). 
 
Hepatic Fractional Extraction Rate= [Hepatic vein-(0.7xarterial +0.3xportal 
vein)]/[0.7arterial+ 0.3 portal vein] 
Intestinal Fractional Extraction Rate = [Portal vein-arterial]/Arterial 
 
3.1.6 Patient Follow-up 
 
Patients were followed up until death or 240 days post-TIPSS insertion. 
 
3.2 Animal Models 
 
All animal experiments were conducted according to Home Office guidelines under 
the UK Animals in Scientific Procedures Act 1986.  Male Sprague-Dawley rats (body 
weight 280-300g) and C57B mice (body weight 25g) were used (Charles River 
Laboratories UK Ltd.). All rats/mice were housed in the unit and given access to 
standard powdered rodent chow and water, with a light/dark cycle of 12 hours, at a 
temperature of 19°C to 23°C and humidity of approximately 50%. All animal studies 
were performed by myself under supervision from Dr. Nathan Davies. 
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3.2.1 Bile Duct Ligated Rat Model 
 
 
Figure 3.1  Experimental Schedule for Bile Duct Ligated Rat Model 
 
Under halothane anaesthesia male Sprague-Dawley rats underwent bile duct-ligation 
or sham biliary surgery. Rats were pair-fed powered chow until completion of the 
experiment at 4-5 weeks from initial surgery. Rats were randomised to receive 
standard powdered chow or powdered chow supplemented with Yaq-001 carbon 
therapy (4g/kg body weight/day) two weeks following surgery until the completion of 
the experiment. Previous studies with AST-120 in bile duct ligated rats had 
demonstrated tolerability and efficacy with regards to ammonia reduction with a dose 
of 4g/kg/day. This was therefore the dose selected for this study. The following 
groups were studied: Sham (n=23), Sham + carbon (n=18), Sham + LPS (n=8), 
Sham+LPS+carbon (n=10), BDL (n=25), BDL + carbon (n=26), BDL+LPS (n=12), 
BDL+LPS+carbon (n=10).  
Under halothane anaesthesia (5ml/min induction 2ml/min maintenance) an internal 
carotid catheter (0.96 outer diameter Portex fine-bore polythene tubing, Scientific 
Laboratory Supplies Ltd., Nottingham, UK) was inserted. The catheter was held in 
place for the duration of the study by both proximal and distal holding sutures. The 
catheter was transduced and mean arterial pressure determined. A laparotomy was 
then performed under sterile conditions and a catheter placed in the portal vein. 
Arterial and portal venous catheters were transduced. Concomitant arterial and portal 
Bile Duct  
Ligation/ 
Sham Biliary 
Surgery 
Week         0 2 
+/-	YAQ-001	Treatment	
4 
Haemodynamic Assessment 
Sample Collection 
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venous plasma was collected aseptically into lithium heparin and EDTA tubes until a 
state of exsanguination was achieved. 5ml of ice-cold PBS was then perfused into 
the liver to achieve organ blanching. The liver was extracted and placed in 10ml of 
ice cold PBS. Plasma was centrifuged at 3,500rpm for 10 minutes at 4°C. The 
supernatant was transferred immediately to cryotubes and stored at -70°C. 
Duodenum, mid-jejunum, terminal ileum and ascending colon was collected and 
stored in formaline and electron microscopy preservation solution (200mM sodium 
cacodylate, 4% gluteraldehyde, pH=7.2-4). Histological specimens were collected 
with no attempt to irrigate or decontaminate the lumen. Samples were also collected 
from all four sites following decontamination of the lumen and irrigation with saline 
solution. These samples were transferred immediately to cryotubes and stored at -
70°C. Liver, kidney and brain tissue was also collected and stored in formaline and 
cryotubes and stored at -70°C.  
3.2.2 Murine models of Non-Alcoholic Fatty Liver Disease 
 
Samples were collected as previously described for rat studies with the exception of 
no invasive arterial pressure monitoring. 
 
3.2.2.1 Leptin deficient mice (ob/ob) 
 
Male genetically leptin deficient (ob/ob) mice were randomized to receive standard 
powdered chow with or without carbon supplementation for four weeks. Heterozygote 
mice were used as the control population and also randomized to receive standard 
powdered chow with or without carbon supplementation for four weeks. Carbon 
supplementation was administered at a dose of 4g/kg body weight per day for four 
weeks.  
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Figure 3.2 Experimental Schedule for Yaq-001 treatment in ob/ob mouse model 
 
3.2.2.2 Methionine Choline Deficient Mice 
 
Male C57/B mice were randomized to receive a diet of control powdered chow or 
powdered chow deficient in methionine choline (IPS Irradiated Baker Amino Acid Diet 
without Choline or Methionine (578B – 1811438) for 4 weeks. These feeds were 
randomized to be supplemented with carbon or not. The carbon was administered at 
a dose of 0.4g/100g body weight per day. The diet and treatment was continued for 4 
weeks.  
 
Figure 3.3 Experimental Schedule for Yaq-001 treatment in MCD model 
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3.3 Cell Culture Experiments 
Cell culture experiments were performed by Dr, Isi Ranchal and analysed by myself. 
 
3.3.1 HEK-Blue hTLR4 cells 
 
HEK-Blue hTLR4 cells (HEK-Blue LPS Detection Kit, InvivoGen) were cultured 
according to the manufacturer's instructions. Cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM) high-glucose medium supplemented with foetal 
bovine serum (FBS, 10 %), glutamine (2 mM), 1× Normocin (InvivoGen), and 1× 
HEK-Blue Selection (InvivoGen). Cell concentration was determined with a cell 
counter, cells were then diluted in DMEM medium supplemented with FBS (10 %), 
glutamine (2 mM), 1× Normocin (InvivoGen) and 200 μL of cell suspension (105 cells) 
was added to each well on a 96-well plate. Following 72 hours of incubation (37 °C, 
5 % CO2, 95 % humidity), the cells reached 80 % confluency. The supernatant was 
removed and cell monolayers washed with warm PBS without Ca2+ and Mg2+, and 
incubated for 24 hours in 180 μL DMEM and 20 μL of rat or human plasma. Rat 
plasma concentrations up to 1:200 rat plasma were evaluated. Lipopolysaccharide 
(LPS) derived from Klebsiella pneumoniae (Sigma-Aldrich; L4268) and LPS from 
Salmonella ssp  (Sigma-Aldrich; L6143) at final concentrations of 0.001, 0.01, 0.1, 1, 
10, 100 or 1000 ng /mL were then added as a stimulus (10 μL per well), and the cells 
incubated for 24 hours under the same conditions as above. Following the 
incubation, the supernatants were collected and 20 μL added to a Quanti-blue 
reagent assay (200 μL). The plates were incubated in the dark at room temperature 
and then analyzed using a spectrophotometer (absorbance at 615 nm).  
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3.3.2 HEK-Blue IL-1β/IL-18 cells 
 
HEK-Blue IL-1β/IL-18 cells containing an IL-1β-sensitive reporter and IL-18-sensitive 
reporter (InvivoGen, San Diego, CA, USA) were grown at 37°C with 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (vol/vol) 
foetal bovine serum (FBS), 4.5 g/L glucose, 2 mM GlutaMAX medium, 100 U/ml 
penicillin, 100 μg/ml streptomycin (all obtained from Gibco BRL/Life Technologies, 
London, UK), 100 μg/ml zeocin, 200 μg/ml hygromycin and 100 μg/ml Normocin 
(InvivoGen). The cells were seeded onto a 96-well plate (200 μL, 5 x 105 cells). After 
24 hours of incubation at 37°C, supernatant was removed, and cell monolayers were 
washed with warm PBS without Ca2+ and Mg2+ and incubated for 24 hours in 180 μL 
DMEM with 20 μL of rat or human plasma. 40 μl of the cell supernatants were added 
to each well of a 96-well plate together with 160 μl of QUANTI-Blue (InvivoGen), 
incubated at 37°C for 60 minutes and measured in an enzyme-linked immunosorbent 
assay (ELISA) reader at 615 nm to determine the expression levels of reporter genes 
activated by NF-κB. 
Quanti-Blue SEAP (secreted embryonic alkaline phosphatase) Reporter Assay: 20 µl 
aliquots of cell culture medium were removed and added to plates containing 180 µl 
of pre-warmed Quanti-Blue detection reagent per well as per manufacturer’s 
instructions. Colour was allowed to develop for 1 h, and absorbance was read at 615 
nm in Bio-Tek® microplate reader (Burlington, VT). 
Cell Viability and toxicity Assays: Cells were labeled with (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazoliumbromide (MTT) for 2 hours followed by dissolution of the 
violet crystals. Cell viability was determined by measuring the absorbance at 570 nm 
in a Bio-Tek® microplate reader (Burlington, VT). Cell morphology was assessed at 
24 hours under phase-contrast inverted microscopy. 
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3.4 Immunology Methods 
All rodent immunology studies were performed by myself. 
 
3.4.1 Clinical study 
 
3.4.1.1 Neutrophil isolation 
4ml of whole blood was layered over 5 ml of Polymorphprep (Axis-Shield), 
centrifuged for 30 minutes at 400 g at 21°C. Neutrophils were aspirated from the 
second buffy coat and washed with phosphate buffered saline (PBS, Sigma Aldrich). 
Total neutrophil cell yield was determined and re-suspended in PBS to produce a cell 
suspension of 1x107/ml. 50 µL of cell suspension and 50 µL of plasma were used per 
assay. Viability was tested by Trypan blue exclusion and was over 98%.  
3.4.1.2 Neutrophil function 
3.4.1.2.1 Phagoburst Assay 
 
The Phagoburst kit (Orpegen Pharma, Heidelberg, Germany) was used to determine 
the percentage of neutrophils that produce reactive oxidants as previously described 
(FACS Canto II, BD Bioscience) (Mookerjee RP et al, 2007). 20μl of each of the 
following was added to FACS tubes containing 5x105 neutrophil cell suspension: 
PBS, pre-cooled unlabelled E.coli, fMLP (low control), PMA (high control). The 
samples were then incubate for 20 minutes at 37°C. 20ul of substrate solution was 
then added and the samples were incubated at 37°C for 20 minutes. 3ml of lysing 
solution (reagent F, Phagoburst, Orpegen Pharma) was then added to each sample. 
The samples were then centrifuged at 1800rpm for 5 minutes at 4°C. The 
supernatant was then decanted, the samples washed with 3ml of PBS and 
centrifuged for 5 minutes at 400g at 4°C. The supernatant was then decanted and 
incubated with anti-CD16-(PE) (Immunotools) for 30 minutes at 4C in the dark. The 
samples were immediately analysed using a Beckton Dickinson FACS Canto II flow 
cytometry machine. 
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3.4.1.2.2 Phagotest 
 
The Phagotest (Orpegen Pharma) was used to measure phagocytosis by using 
FITC-labeled opsonized E. coli bacteria. 20μl of FITC-labeled E.coli (Phagotest 
reagent B) was added to FACS tubes containing 5x105 neutrophil cell suspension. 
The samples were then incubated for 20 minutes at 37°C. Control samples were 
incubated at 4C. Samples were then transferred to ice to stop phagocytosis and 
100ul of brilliant blue solution (stored on ice) was added to quench the bacteria 
bound to the surface. 3ml of PBS was then added and samples centrifuged at 400g 
for 5 minutes at 4C. The supernatant was then decanted and 3 ml of lysing solution 
was added to each sample. The samples were then incubated at 21C for 20 
minutes. The samples were centrifuged 1800rpm for 5 minutes at 4C and 
supernatant decanted followed by washing with 3ml of PBS and a repeat 
centrifugation step at 1800rpm for 5 minutes at 4C. The samples were then 
incubated for 30 minutes at 4C in the dark with anti-CD16-(PE) (Immunotools). 
Following this, samples were washed with PBS, centrifuged at 400g at 4C, 
supernatant decanted and cells re-suspended in PBS and immediately analysed 
using a Beckton Dickinson FACS Canto II flow cytometry machine. 
 
3.4.2 Rodent Studies 
 
3.4.2.1 Sample Preparation 
 
3.4.2.1.1 Isolation of Non-Parenchymal Cell Fraction from Rodent Liver Tissue 
 
Perfused liver tissue was dissected with a scalpel and homogenized in Hanks 
balanced salt solution (with calcium and magnesium + collagenase 0.01% and 
DNAse I (0.01%). The homogenate was transferred to a 50ml Falcon tube and 
incubated at 37°C prior to filtration through a cell strainer (100m for rat tissue; 70m 
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for murine tissue). This was then centrifuged at 30g for 5 minutes at 4°C and the 
supernatant subsequently centrifuged at 500g for 10 minutes at 4°C. The 
supernatant was discarded and the pellet re-suspended in PF4 (HBSS with no 
calcium or magnesium, DNAse I 0.01%, bovine serum albumin (0.25%)) and 
centrifuged at 500g for 10 minutes at 4°C. The pellet was then re-suspended in 3.9ml 
of RPMI 1640 and mixed gently with 2.1ml (RPMI and Optiprep 22%). RPMI was 
then layered on top followed by a 25 minute centrifugation step at 900g without brake 
at 4°C. The non-parenchymal cells were isolated from the interface, re-suspended in 
an equivalent volume of PF4 and centrifuged at 2000rpm at 4°C for 10 minutes.  
The pellet was re-suspended in 5ml of Red Cell Lysis Buffer (BioLegend) and 
incubated for 5 minutes at 4°C with occasional shaking. The reaction was then 
stopped by addition of 10 ml of PBS. This was then centrifuged at 500g for 10 
minutes at 4ºC, the supernatant discarded and the cells re-suspended in 3ml of 
culture media. The cells were counted and adjusted to a concentration of 107 cells/ml. 
1x106 cells were used in all subsequent assays.  
3.4.2.1.2 Whole Blood Preparation (Arterial and portal venous) 
 
2ml of blood was collected from portal vein and arterial blood. 40ml of RBC lysis 
buffer was added to each 2ml sample, vortexed and incubated for 15 minutes at 
room temperature. Following centrifugation at 450g for 5 minutes the supernatant 
was discarded and the pellet re-suspended with 1ml of complete culture media 
(RPMI (Gibco), 10% FBS, 200mM L-Glutamine) .The cell number using the 
nucleoCounter method and adjusted to 1x107cell/ml. 
 
3.4.2.1.3 Mesenteric Lymph Node Cell Isolation 
 
The resected mesentery was placed on a sterile petri dish filled with ice cold HBSS. 
All mesenteric lymph nodes were dissected. One lymph node was stored 
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immediately in RNA later and one in 10% formalin. The remaining mesenteric lymph 
nodes were placed on a cell strainer (100m pores) on a 50ml Falcon tube, 
homogenised and re-suspended in 10ml of ice cold HBSS. The homogenate was 
then centrifuged at 450xg for 5 minutes at 4ºC, supernatant discarded and the pellet 
re-suspended in 10ml of FACS buffer. One further passage through the cell strainer 
was performed and the cell number determined and standardised to a cell 
concentration of 1x107 cells/ml. 
 
3.4.2.2 Population Studies 
 
3.4.2.2.1 Kupffer Cell Population studies 
 
2ul of Fc blocker (anti-CD32 antibody) was added to 106 cells (non-parenchymal cell 
fraction) and incubated for 5 minutes at 4°C. The cells were then co-incubated with 
anti-CD163 antibody for 30 minutes at 4°C in the dark. The cells were washed with 
1ml of FACS buffer, centrifuged and re-suspended in 100l FACS buffer solution and 
analysed immediately on a Becton Dickinson LSR II flow cytometer. 
 
3.4.2.2.2 Cell population assay (Portal Venous and Arterial Blood) 
 
2ul of Fc blocker (anti-CD32 antibody) was added to 106 cells and incubated for 10 
minutes at 4°C. The cells were then co-incubated with the following primary 
antibodies for 20 minutes at 4°C: PE-CD11b (0.2mg/ml), Alexa647-CD43 (0.5mg/ml), 
FITC-HIS48 (200ug/ml). After incubation, 2 ml of FACS buffer was added to each 
tube, centrifuged at 450xg for 5 minutes at 4°C and supernatant discarded. This last 
step was then repeated with 1ml FACS solution and the pellet re-suspended the 
pellet in 100ul of FACS buffer. 5ul of DAPI solution was added into the each tube 
prior to analysis. 
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3.4.2.2.3 Mesenteric Lymph Node Cell Population Assay  
 
2ul of Fc blocker (anti-CD32 antibody) was added to 106 cells and incubated for 5 
minutes at 4°C. The cells were then co-incubated with the following primary 
antibodies and incubated for 30 minutes at 21°C: 0.2ug PE-CD80, 1ug FITC-HIS48, 
5ul Alexa647-CD163 (ED2). 1ml of FACS buffer was then added per tube and 
centrifuged at 450g for 5 minutes at 4ºC. After discarding the supernatant, 100ul of 
Leucoperm Reagent A was added per tube and incubated for 30 minutes at 21°C. 
Each tube was then washed with 3ml of FACS buffer, centrifuged and supernatant 
discarded. The pellet was then re-suspended with 100ul of Reagent B followed by 
addition of 5ul of biotin conjugated CD68. Following a 30 minute incubation at 4°C, 
the tubes were washed with 1ml of FACS buffer and then centrifuged at 450g for 5 
minutes at 4°C. The pellet was then re-suspended in 100ul of FACS buffer containing 
1ul BV650- streptavidin and incubated for 20 minutes at 4°C. Finally 2ml of FACS 
buffer was added per tube, samples centrifuged at 450g for 5 minutes at 4°C. After 
discarding the supernatant, each sample was re-suspended with 100ul of FACS 
buffer. 
 
3.4.2.3 Functional Assays  
 
3.4.2.3.1 Rat Kupffer Cell and Portal Venous ROS studies 
 
20ug/ml of E.coli endotoxin was added to 1x 106 non-parenchymal cells sample and 
incubated for 30 minutes at 37°C. ROS inducer at a final concentration of 200-500uM 
was used as a positive control. The samples were then centrifuged at 500g for 5 
minutes and the supernatant discarded. The cells were re-suspended in 5ml of wash 
buffer, centrifuged at 500g for 5minutes and the supernatant removed. The cells 
were re-suspended in 500ul of ROS detection solution and incubated for 30 minutes 
at 37°C in the dark. Following centrifugation, the cells were re-suspended in 100ul of 
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FACS buffer, Fc blocker added (1:25) and incubated for 10minutes at 4°C.  Anti-
CD163 antibody was added and the cells incubated for 30 minutes at 4°C in the dark 
(Kupffer cells). The cells were then washed with 1ml of FACS buffer, centrifuged and 
re-suspended in 100l FACS buffer solution.  
 
3.4.2.3.2 Murine Kupffer cell ROS studies 
 
ROS inhibitor (N-acetyl-L-cysteine) was added to the negative control samples to 
achieve a final concentration of 5mM and incubated for 30 minutes. 20ug/ml of LPS 
was added to the pre-aliquoted cell suspension samples and incubated for 30 
minutes at 37°C. For the positive control sample, ROS inducer (pyocyanin) was 
added to achieve a final concentration of 500uM and incubated for 30 minutes. 
During the incubation step, the tube was agitated occasionally. The cells were then 
centrifuged at 500g for 5 minutes and the supernatant discarded. The cells were then 
re-suspended in 5ml of FACS wash buffer, centrifuged at 500g for 5 minutes and the 
supernatant removed. The cells were then re-suspended n 500ul ROS detection 
solution (ENZO life sciences (ENZO cat ENZ-51011)) and incubated for 30 minutes 
at 37°C in the dark. The cells were then centrifuged the cells, media removed and 
cells re-suspended in 100ul of FACS buffer. 2μl of anti-mouse CD16/32 (Biolegend 
101301:0.5mg/ml) was added and incubated for 10 minutes at 4°C. F4/80 antibody 
PerCP/Cy5.5 anti-mouse F4/80 clone BM8  (Biolegend 123127; 0.2mg/ml) was then 
added and incubated for 30 minutes at 4°C in the dark.  (Isotype control: 
PerCP/Cy5.5 Rat IgG2a k Isotype  (Biolegend 400531; 0.2mg/ml)). 1ml of FACS 
wash buffer was then added and the samples centrifuged at 2000rpm. Following one 
further wash step, the samples were analysed on a BD LSR II Flow Cytometer. 
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3.4.2.3.3 Kupffer cell phagocytic function 
 
The cells were centrifuged at 500g for 5 minutes at 4ºC and the supernatant 
discarded. 200ul of latex beads containing media were added to the pellet and 
incubated at 37°C in the dark for 20 minutes. 5ml of ice cold phosphate buffered 
saline (PBS) was then added and centrifuged at 2000rpm for 5 minutes at 4ºC. The 
pellet was then washed with 5ml of cold PBS and centrifuged. Anti-CD32 antibody 
(Fc blocker) was then added and incubated for 10 minutes at 4°C. Anti-CD163 
antibody was then added and incubated for 30 minutes at 4°C in the dark.  
 
3.4.2.3.4 Flow Cytometer Analysis 
 
All samples were kept at 4°C and analysed immediately using a FACS LSR II 
machine. Data was analysed using FlowJo software. 
 
3.5 Microbiological Methods 
 
Stool 16S sequencing was performed outside the institution. Otherwise all 
microbiological studies were performed by myself.   
3.5.1 Bacterial PCR 
 
3.5.1.1 Bacterial DNA Isolation from Plasma 
 
100μl of fresh or thawed plasma was added to 600μl of chilled Nuclei Lysis Solution 
and homogenized for 10 seconds. This was followed by a 15-30 minute incubation 
step at 65°C. 3μl of RNase solution was added to the lysate, mixed and incubated for 
15-30 minutes at 37°C. The solution was then cooled to room temperature, 200μl of 
Protein Precipitation Solution added and subsequently chilled on ice for 5 minutes. 
This was then centrifuged at 13000-16000g for 4 minutes. The supernatant was 
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transferred to a fresh tube containing 600μl of room temperature isopropanol and 
mixed gently by inversion. The samples were then centrifuged at 13000-16000g for 1 
minute, supernatant removed and 600μl of room temperature 70% ethanol added. 
Following mixing and a further centrifugation step, the ethanol was aspirated and 
pellet allowed to air dry for 15 minutes. The DNA was then re-suspended in 100μl of 
DNA Rehydration Solution overnight at 4°C.  
 
3.5.1.2 DNA Amplification and Sequencing (Plasma samples) 
 
2μl of DNA template was added to a reaction mix containing: 10mmol/L Tris buffer 
(pH 8.3), 50 mmol/L KCl, 1.5mmol/L MgCl2, 200 mol/L of each deoxynucleoside 
triphosphate, 50 pmol of primers 5_-AGAGTTTGATCATGGCTCAG-3_ and 
5_ACCGCGACTGCTGCTGGCAC-3_, 1.25 U BioTaq (Bioline, London, England) to 
complete a final volume of 50μl. A 35-cycle PCR was then run in GeneAmp 9700 
(Applied Biosystems, Foster City, CA) using the following profile: 94°C for 30 
seconds, 55°C for 30 seconds, 72°C for 60 seconds. The total PCR reaction volume 
was then filtered with QIAquick Spin Columns (QIAquick PCR Purification Kit; 
QIAGEN) to remove rests of primers. 5mcl of purified products were then analysed 
by 2% agarose gel electrophoresis and UV visualization. A band of about 540 base 
pairs was obtained from different bacterial cultures corresponding to the specific 
amplification of the prokaryotic 16S ribosomal RNA gene. 
 
3.5.1.3 Isolation of DNA from Stool for Pathogen Detection 
 
180–220 mg stool was placed into a 2 ml microcentrifuge tube at 4°C and1.4 ml 
Buffer ASL (Qiagen) added to each sample. The samples were then vortexed for 60 
seconds and the suspension heated to 95°C for 5 minutes. The samples were then 
vortexed for 15 sseconds, centrifuged at 13000g for 1 minute and 1.2 ml of the 
supernatant was then pipetted into new 2 ml microcentrifuge tubes. 
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One InhibitEX Tablet was then added to each sample and vortexed for 60 and the 
suspension incubated for 1 minute at 21°C following which the samples were 
centrifuged at full speed for 3 minutes. All of the supernatant was then transferred 
into a new 1.5 ml microcentrifuge tube and the pellet discarded. These samples were 
then centrifuged at full speed for 3 minutes. 15 μl proteinase K and subsequently 200 
μl Buffer AL (Qiagen) was added to 200 μl of the supernatant, vortexed for 15 
seconds and incubated at 70°C for 10 minutes. 200 μl of ethanol (96–100%) was 
added to the lysate, vortexed and passed through a new QIAamp spin column by 
means of centrifugation at full speed for 1 minute. 500 μl Buffer AW1 (Qiagen) was 
added to the lysate and centrifuged at full speed for 1 minute. 500 μl Buffer AW2 
(Qiagen) was subsequently added to the lysate and centrifuged at full speed for 3 
minutes. 200 μl Buffer AE (Qiagen) was then added directly onto the QIAamp 
membrane, incubated for 1 min at room temperature, then centrifuged at full speed 
for 1 minute. The samples were then stored at –20°C prior to determination of DNA 
concentration by spectrophotometry (Nanodrop). 
 
3.5.1.4 Sequence-based microbiota composition determination 
 
DNA was extracted from 200 mg of faecal material /animal. Total DNA was extracted 
initially with bead-beating step and the QIAamp DNA stool mini kit (Qiagen, West 
Sussex, UK). Universal 16SrRNA primers, forward primer F1 (5′-
AYTGGGYDTAAAGNG) and four reverse primers R1 (5′-
TACCRGGGTHTCTAATCC), R2 (5′-TACCAGAGTATCTAATTC), R3 (5′-
CTACDSRGGTMTCTAATC) and R4 (5′-TACNVGGGTATCTAATC) were used for 
Taq-based PCR amplification. Sequencing was performed on a Roche 454 GS-FLX 
using Titanium chemistry by the Teagasc 454 Sequencing Platform (Teagasc, 
Fermoy, Ireland). The reads were quality trimmed, clustered, aligned and checked for 
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chimeras (Qiime). The reads for the major phyla were averaged for each group and 
expressed as a percentage of the total number of reads for that particular group. 
 
3.5.2 Endotoxin measurement 
 
The chromogenic limulus amoebocyte lysate (LAL) kinetic assay (Charles River 
Laboratories) was used for the detection of endotoxin. Portal venous plasma 
(100mcl) was diluted 1:10 with endotoxin-free water and incubated at 75°C for 30 
minutes. 100mcl of sample and 100mcl of LAL reagent were mixed in a 96-well plate 
and analysed at 405nm with spectrophotometer using the Endoscan V software. 
Results are expressed as EU/ml. 
 
3.5.3 Mesenteric Lymph Node Culture 
 
Mesenteric Lymph nodes were isolated and prepared as previously described. Blood 
agar plates were inoculated with mesenteric lymph node homogenate and incubated 
at 37°C for 48 hours following which the culture positivity was determined.  
 
3.6 Histological analysis 
All histological analysis was performed by myself. Mr. Ray Moss supervised 
acquisition of electron microscopy images. 
 
3.6.1 Light microscopy 
 
Liver tissue was processed in accordance with standard protocol and Haematoxylin 
and Eosin together with Sirius Red staining was performed.  
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3.6.1.1 Haematoxylin and Eosin Staining 
 
Sections were deparaffinised and rehydrated as follows: 3 x 5 minutes Xylene (blot 
excess xylene before going into ethanol) 3 x 5 minutes 100% ethanol; 1 x 5 minutes 
95% ethanol; 1 x 5 minutes 80% ethanol; 1 x 5 minutes deionized H2O. 
Haematoxalin staining was performed as follows: 1 x 5 minutes Haematoxalin. Rinse 
deionized water, 1 x 5minutes Tap water (to allow stain to develop), Dip 8‐ 12x (fast) 
Acid ethanol (1 ml concentrated HCl + 400 ml 70% ethanol), Rinse 2 x 1minute Tap 
water, Rinse 1 x 2 minutes Deionized water. Eosin staining and dehydration:1 x 30 
seconds Eosin, 3 x 5  minutes 95% ethanol, 3 x 5  minutes 100% ethanol, 3 x 15  
minutes Xylene. Slides were dried overnight in the hood. 
3.6.1.2 Sirius Red staining 
 
Picro-Sirius Red mixture is prepared as follows (10ml 1% aqueous Sirius Red F3B, 
90ml Saturated aqueous picric acid). Mix together and add excess picric acid crystals 
to ensure saturation.  Stand solution for 24 hours before use. Take the sections to 
water (Xylene x 3: 3 mins, IMS x 3: 1 min). Treat sections with freshly filtered picro-
sirius mixture for 8 minutes. Rinse directly in 100% IMS (74 OP). Dehydrate, clear 
and mount. (IMS x 3: 1 min, Xylene x 3: 1 min) 
Sirius red staining was quantified using computer assisted digital image analysis. 
Collagen proportionate area was determined using Zeiss KS300 image analysis 
software.  
3.6.2 Electron microscopy 
 
The tissue was drop-fixed in sodium cacodylate buffer at room temperature and 
dehydrated through increasing concentrations of alcohol (50-100%) prior to 
embedding in Spurr’s resin (Agar Scientific). 80-100nm sections were cut, stained 
with 2 % aqueous uranyl acetate and subsequently Sato’s lead stain for 20 minutes 
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each prior to viewing with a Hitachi 7100 transmission electron microscope at 75 kV. 
Images were captured using a column-mounted CCD camera (Gatan) (1024x1024 
pixels).  
 
3.6 Biochemical Analysis 
Bile acid analysis was conducted at King’s College tertiary biochemistry unit and 
mass spectroscopy analysis performed by colleagues at the Institute of Child Health. 
All other biochemical analysis was perfomed by myself.  
3.6.1 COBAS 
250mcl of lithium heparin anti-coagulated plasma was analysed using an automated 
biochemical analyser (COBAS, Roche Diagnostics, UK) for the following: bilirubin, 
ALT, AST, alkaline phosphatase, albumin, urea, creatinine, calcium, phosphate, 
glucose. 
3.6.2 Bile acid Analysis 
 
250 µl of plasma was added to 800 µl of protein precipitation reagent containing 
acetonitrile and internal standards, vortexed for 30 seconds and centrifuged for 10 
minutes at 13000rpm. 900 µl of the supernatant was then dried with compressed air 
in a 60ºC heated block. The samples were then reconstituted in 250 µl of 50:50 
mixture of mobile phases A and B and transferred to a glass HPLC injection vial and 
10 µl injected into the LC-MS/MS system. Samples were resolved using a Supelco 
Analytical, Ascentis Express C18 fused core column (15 cm x 4.6 mm, 2.7 μm, 
SigmaAldrich) on a Jasco high pressure liquid chromatography (HPLC) system by 
reverse phase HPLC using mobile phases A: methanol and B: water each with 5nM 
ammonium acetate and 0.012% (v/v) formic acid. The Jasco HPLC system is 
coupled to an Applied Biosystems API 3200 triple stage quadrupole mass 
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spectrometer operated with electrospray ionisation source in negative ionisation 
mode followed by detection by multiple reaction monitoring. 
3.6.3 Lactulose/Rhamnose Test 
 
3.6.3.1 General 
 
Intestinal permeability assays were conducted 1 day prior to completion of the 
experiment. Animals were placed in metabolic cages for overnight acclimatisation. 
Baseline urine samples were collected in cryotubes and stored at -70°C. 0.6ml of a 
solution of lactulose (277mM), L(+)-Rhamnose (10mM) and 3-methyl-o- pyranose 
(2.0mM) was then administered by gavage and urine collected for the subsequent 5 
hours. Urine samples were analysed using mass spectroscopy to determine urinary 
excretion of lactulose, rhamnose and 6-0-methy-glucose. Animals were returned 
back to their group cages for re-acclimatisation and fasted prior to termination. 
 
3.6.3.2 Electro-Spray Ionization Mass Spectrometry (ESI-MS) 
 
ESI-MS was performed using a LTQ Orbitrap XL mass spectrometer (Thermo Fischer 
Scientific, USA). A 1:10 serial dilution was prepared for 3-OMD, lactulose and rhamnose in 
70:30 acetonitrile and water (LC-MS grade) (Sigma Aldrich, UK). 0.2µl of formic acid was 
added to each sample. Samples of µM concentration were then analysed by direct injection to 
check for detection limits. Urine samples were prepared in a 1:50 dilution with acetonitrile 
following a centrifuged for 5 minutes centrifugation step at 4000g prior to analysis. Samples 
and standards were transferred to appropriated labeled glass vials and placed in the 
autosampler to be analysed.  
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3.7 Protein Expression 
 
Western blot analysis and cytokine bead array was performed by myself. 
 
3.7.1 Protein Extraction Methods 
 
300micg duodenal tissue was homogenized in TRIS buffer 50 mM, pH 7.4. 20 uL of 
protease inhibitor cocktail (Sigma) was added. The samples were then centrifuged 
for 59 min at 12000 rpm supernatant collected. 1 l of DM buffer was added per 100 
ul of solution. Protein content was then determined using the Biuret method. Serial 
dilutions of Human Serum Albumin were prepared as follows:  50 mg/mL, 25 mg/mL, 
12.5 mg/mL, 6.25 mg/mL, 3.125 mg/mL, 1.5625 mg/mL, 0.781 mg/mL. 15 ul of 
standard was added to 1 mL of Biuret solution (0.75g g Cu SO4, 3 g Na K tartrate, 25 
g NaOH in 500 mL of distilled water) and incubated for 1 hour at room temperature. 
Protein concentrations were then determined using Agilant 8453.  
Stock Sample Solution was prepared to achieve a protein concentration of 80ug/80ul 
with NuPAGE sample buffer (20mcl) and reducing agent. Samples were heated for 
10 min at 70oC. 15mcl of samples was then loaded into 4-12 % Bis Tris Gel with 
10mcl of standard used. The gel was then run for 40-60 minutes at 120V. The 
samples were then transferred to a membrane for 1 hour at 30V at room 
temperature. Transfer efficiency was then determined using Ponceau Red stain. The 
membrane was then washed 3 times in PBST and blocked for 1 hour with 30 ml 5% 
milk in PBST. The membrane was then co-incubated with 2% milk in TPBS with 
primary antibody at a concentration of x overnight at 4ºC. The membrane was then 
washed 4 times with PBST for 5 minutes and co-incubated with secondary antibody 
for 1 hour. The membrane was then washed a further 4 times with PBST for 5 
minutes and developed using a standard ECL kit. Protein expression was determined 
by optical densitometry and quantified.  
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3.7.2 Tight junction protein expression  
 
3.7.2.1 Western Analysis of Connexin-43/iNOS/eNOS/ZO-1/Claudin 3 
Sample Solution (80ug/80ul) was added to 20 ul of NuPAGE Sample Buffer and 
reducing agent with water added up to 80 ul. Samples were heated for 10 minutes at 
70 oC. 15 uL of sample was loaded per well into a 4-12% Bis Tris running gel 
(NuPAGE Novex Bis/Tris Mini Gel) and running buffer added. The gel was then run 
at V for 40 minutes. The proteins were then transferred to the membrane (Transfer 
buffer: 25ml Transfer Buffer Invitrogen Nu PAGE x20; 375 mL distilled water; 100ml 
methanol 20%). The transfer stage is for 1 hour at 30V at room temperature. Protein 
transfer efficiency was determined with staining with Ponceau Red (1-2ml). The 
membrane was subsequently washed 3 times for 15 minutes with PBST. The 
membrane was then co-incubated for one hour at room temperature with 30 ml 5% 
milk in TPBS. The membrane was then incubated overnight with the primary 
antibody at 4ºC (20ml of 2% milk with TPBS and 1:500 of 1st antibody). The 
membrane was then washed 4 times for 5 minutes with TPBS. The membrane was 
then co-incubated with 20ml of secondary antibody 1:1000 in TPBS for 1 hour and 
washed another 4 times for 5 minutes with TPBS. The enhanced chemiluminescence 
(ECL) Western Blotting System (Amersham ECL Prime GE Healthcare Life 
Sciences) was used to develop the images. The membranes were exposed to the 
film for 2-5 minutes and subsequently emersed in developing solution (30-45 
seconds), fixer solution ( 1minute with agitation) and finally washed with water. The 
films were then scanned and optical density determined with digital image analysis 
software.  
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3.7.3 Cytokine Studies 
 
3.7.3.1 Clinical studies 
 
Plasma levels of IL-10 and IL-6 were determined using commercially available ELISA 
assays in accordance with manufacturers instructions (R and D Biosystems). 
 
3.7.3.2 Rodent Studies 
 
Portal venous TNFα, IL-4, IL-10 levels were determined using the BD™ Cytometric 
Bead Array (CBA) kit. 50μL of the mixed capture beads were added to each assay 
well of a pre-wetted plate. 50 μL of standard or sample was then added to the assay 
wells. The plate was agitated for 5 minutes using a digital shaker at 500 RPM and 
the plate incubated for 1 hour at room temperature. 50 μL of mixed PE detection 
reagent was then added to each assay well. The plate was then agitated for 5 
minutes using a digital shaker at 500 RPM and incubated at room temperature for 2 
hours. The plate was vacuum aspirated until the wells were drained. 150μL of wash 
buffer was added to each assay well. The plate was then agitated on a digital shaker 
at 500 RPM for 5 minutes to resuspend the beads. The samples were then analysed 
by flow cytometry and data analysed using FACS Diva software. 
 
3.8 Gene Expression 
Gene expression studies were performed by Esther Putzjens. 
 
3.8.1 RNA extraction from terminal ileal tissue 
 
2 ml microcentrifuge tubes containing one 5mm stainless steel bead and one 7mm 
stainless steel bead were kept on dry ice for at least 15 minutes. 50 mg of frozen 
tissue was then transferred to the precooled tubes and incubated for another 15 
minutes on dry ice. The tubes were then placed into the insert of the TissueLyser LT 
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Adapter, and incubate at room temperature for 2 minutes. 700 μl QIAzol Lysis 
Reagent was then added to each tube. The tubes were then transferred to the 
TissueLyser LT Adapter and homogenised at 50Hz for 8 minutes. The tube 
containing the homogenate was then placed at room temperature (15–25°C) for 5 
minutes.140 μl chloroform was then added to each tube containing the homogenate 
and capped securely and agitated vigorously for 15 seconds. The homogenate was 
then placed on the bench top at room temperature for 2–3 minutes. The tubes were 
then centrifuged for 15 minutes at 12,000 g at 4°C. The upper aqueous phase was 
then transferred to a new collection tube and 1.5 volumes of 100% ethanol added 
and mixed. 700 μl of the sample was then pipetted into a spin column in a 2 ml 
collection tube. The tubes were then centrifuged at 10,000 rpm for 15 seconds at 
room temperature and the flow-through discarded. This last step was repeated with 
remaining sample. 700 μl Buffer RWT (RNeasy mini kit) was added to the spin 
column and centrifuged for 15 seconds at 10,000 rpm and the flow-through 
discarded. 500 μl of Buffer RPE (RNeasy Mini kit) was then added to the spin column 
and centrifuged for 15 seconds at 10,000 rpm and the flow-through discarded. A 
further 500 μl of Buffer RPE was added to the spin column and centrifuged for 2 
minutes at 10,000 rpm. 50 μl of RNase-free water was the pipetted directly onto the 
RNeasy Mini spin column membrane and the tube centrifuged for 1 minute at 10,000 
rpm. The RNA quality and yield was then determined using Nanodrop technology. 
 
3.8.2 Quantitative PCR 
 
cDNA synthesis (iScript cDNA Synthesis Kit, BioRad). QPCR was conducted on 
MyIQ real time PCR system (BioRad) with primer pairs as per manufacturers 
protocol.  
Gene Forward   Reverse   
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Gapdh 5’-TGCACCACCAACTGCTTAGC-3’ 5’-GGCATGGACTGTGGTCATGAG-3’ 
Actb 5’-AGAGGGAAATCGTGCGTGAC-3’ 5’-CGATAGTGATGACCTGACCGT-3’ 
Lyz2   5´-CTGTCCATACATCTCTGCTG-3´   5´-ACAGTGAGAAAGAGACAGAGTG-3´  
Rd5 5´-GAAGACACTTGTCCTCCTTTCTG-3´ 5´-TGTTGCAGATCCCCATAATGCCT-3´ 
Defa8 5´-GAAGACTCTTGTCCTCCTCTCTG-3´ 5´-AATAGACCTGGACGACAGGACC-3´ 
Tnfa 5’-CTCACACTCAGATCATCTTCTC-3’ 5’-TGGTATGAAATGGCAAATCGG-3’ 
 
3.9 1Nuclear Magnetic Resonance Spectroscopy 
1NMR spectroscopy and analysis was performed by myself under the supervision of 
Dr. Jane Cox. 
 
400μl of urine were mixed with 200μl of 0.2 M phosphate/TSP buffer, pH 7.4 and 
centrifuged at 13000 rpm for 10 minutes. 550μl of supernatant was then transferred 
into a 5 mm tube and maintained at 4°C until analysis. Analysis was performed using 
a JEOL ECP 500 nuclear magnetic resonance spectrometer at MRC Harwell. Data 
was acquired at 25°C using a pulse-collect sequence with water pre-saturation.  
Urinary NMR spectra were acquired at 298K from using a JEOL ECP 500 MHz NMR 
spectrometer (JEOL Ltd, Tokyo, Japan). A standard pulse-collect sequence with 
water presaturation was used to acquire the NMR data. The spectral width was 15 
ppm, pulse angle 90°, acquisition time 4.36 s and relaxation delay 3 s. 32K data 
points were acquired per collect and 64 transients were summated. The receiver gain 
was constant for all samples. The resulting free induction decay was zero filled and 
multiplied by an exponential function corresponding to 0.3 Hz line broadening prior to 
Fourier Transformation. The NMR spectra were manually phased using the JEOL 
Delta.  
 
 
 
98 
 
3.10 Carbon Adsorption studies 
 
Carbon adsorption studies were performed by Dr. Susi Sandeman. 
 
3.10.1 Cytokine adsorption by carbon beads from plasma 
 
Human recombinant IL-6 and TNFα (BD Biosciences, Oxford, UK) was added to 
defrosted fresh frozen plasma (National Blood Service, London, UK) at a final 
concentration of 1000 pg/ml and 300 pg/ml respectively. 1ml of phosphate buffered 
saline (PBS) was added to 0.02g of carbon beads and incubated at 37°C for 2 hours. 
The samples were then centrifuged at 2000 g, supernatant removed and 800 μl of 
spiked plasma was added to each carbon and incubated at 37°C. Negative controls 
of non-spiked plasma and positive control with no carbon beads were also included. 
At timed intervals (5, 45, and 90 minutes) the samples were centrifuged at 2000 g 
and 150 μL aliquots removed. They were then stored at -20 ̊C prior to ELISA analysis 
to determine cytokine concentration (BD Biosciences, Oxford, UK) according to 
manufacturer’s instructions.  
3.10.2 Carbon Adsorption of TNFα from simulated intestinal fluid 
 
Different weights of carbon bead (0.001-0.005 g) were incubated with 1 ml of SIF 
(Sigma 53757) for 2 hours. Following centrifugation at 8000 rpm for 3 minutes, the 
supernatant was removed and SIF spiked with 10 ng/ml of recombinant TNFα added. 
Following 24 hour incubation at 37° C at 90 rpm, samples were centrifuged at 8000 
rpm for 3 minutes and supernatant collected and stored at −20° C. The samples were 
diluted in assay diluent prior to measurement of TNFα concentration by ELISA in 
accordance with the manufacturer's instructions (BD Biosciences). 
3.11.3 Carbon Endotoxin Adsorption Kinetics 
 
TE8 test carbon beads underwent dry heat sterilisation at 250° C for three hours. 
Carbons were pre-wetted with simulated intestinal fluid (Sigma-Aldrich) (22mM 
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Sodium hydroxide, 50mM Potassium phosphate) . SIF was prepared to the United 
States Pharmacopoeia 26 recipe without pancreatin and using endotoxin-free 
reagent water. E coli 055:B5 endotoxin standard solution was prepared at a 
concentration of 200 EU ml−1 in SIF. SIF was then aspirated from the carbons and 
endotoxin spiked SIF added to each test carbon (10 ml/gram of carbon). Test 
samples and positive controls without carbon were incubated at 37° C. 450 μl of 
sample was removed at time points 0, 15, 30, 45 and 60 minutes and the endotoxin 
concentration of each sample was calculated using the limulus amebocyte lysate 
(LAL) endosafe endochrome-K test (Charles River Laboratories UK) and Tecan 
Sunrise incubating plate reader with endoscan-V software as described.  
3.10.4 Carbon Acetaldehyde Adsorption Kinetics 
 
Different weights of carbon bead (0.001-0.005 g) were incubated with 1 ml of 
simulated intestinal fluid (Sigma-Aldrich) (22mM Sodium hydroxide, 50mM 
Potassium phosphate) at 37°C for 2 hours. A 7.2 mM spike (0.1 g/ml) of 
acetaldehyde was added at 4° C. Eppendorfs were then centrifuged (8000 rpm for 3 
minutes) at a range of time intervals up to 30 minutes following addition of 
acetaldehyde spike. Acetaldehyde adsorption was measured using a derivatisation 
method with 2-diphenylacetyl-1,3-indandione-1-hydrazone (DIH) and HPLC analysis.  
3.10.5 Determination of the Effect of Direct Contact Incubation of Test Carbon 
on Bacterial Metabolism 
 
Yaq-001 carbon beads were dry heat sterilised in glass universal bottles for 2 hours 
at 80° C. 1 ml of phosphate buffered saline (PBS) was added to 0.1 g of Yaq-001 
and incubated at 37° C for 1 hour at 120 rpm. Tryptone soya broth (TSB) was 
inoculated with Staphylococcus aureus (NCTC 6571) or Escherichia coli (NCTC 
10418) and incubated overnight at 37° C at 120 rpm. Following centrifugation, the 
pellet was re-suspended in 1 ml PBS and the absorbance of the suspension 
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measured at 540 nm. The suspension concentration was adjusted to give a value of 
0.5 and this dilution factor was then used to prepare a bacterial suspension in TSB.  
Serial dilutions of E coli suspension were prepared and inoculated onto agar plates. 
1 ml of inoculum was added to each material and incubated at 37° C at 120 rpm. At 
timed intervals of 30 minutes, 2 and 6 hours, 100 μl of bacterial suspension was 
removed from each sample and placed into the wells of a 96 well plate. Samples 
were lysed and analysed for ATP content as a measure of cell metabolism using the 
BacTiter-Glo microbial cell viability assay (Promega). 
3.10.6 Determination of the Effect of Carbon Leachate on Bacterial Metabolism 
 
Yaq-001 carbon beads were dry heat sterilised in glass universal bottles for 2 hours 
at 120° C. 2 ml of phosphate buffered saline (PBS) was added to each 0.2 g of 
material and samples were incubated for 24 hours at 37° C at 120 rpm. TSB was 
inoculated with Bacillus subtilis or Escherichia coli (NCTC 10418) and incubated 
overnight at 37° C at 120 rpm. Following centrifugation, the pellet was re-suspended 
in TSB to achieve a final approximate concentration of 1×109 bacteria/ml. 100 μl of 
TSB, 100 μl of inoculum and 100 μl of extract were added in a 100 well Bioscreen 
plate. Bacterial growth was determined with a Bioscreen turbidometric analyser at 
540 nm for 72 hours. 
3.11 Statistical Analysis 
 
One-way ANOVA and MANOVA tests were performed using SPSS version 24 with 
post-hoc analysis (Tukey test). Descriptive variables analysed were as follows: 
Arterial neutrophil ROS pre-TIPSS, Arterial neutrophil ROS post-TIPSS portal 
pressure, hepatic venous neutrophil ROS, portal venous neutrophil ROS, arterial 
LPS pre-TIPSS, arterial LPS post-TIPSS, hepatic venous LPS, portal venous LPS, 
arterial IL-10, hepatic venous IL-10, portal venous IL-10, arterial IL-6, hepatic venous 
IL-6, portal venous IL-6, creatinine, albumin, bilirubin, prothrombin time, INR, portal 
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pressure gradient pre-TIPSS insertion, portal pressure gradient post-TIPSS insertion, 
mortality, MELD score, encephalopathy. 
Prior to statistical analysis, all NMR spectra were baseline corrected to a 4th degree 
polynomial, zero filled by a factor of 2 and referenced with the TSP peak set to 0.00 
ppm using KIA version 9.0 (Bio-Rad, Philadelphia, USA). NMR spectral resonances 
were assigned according to previously described methods. 
The resonances attributable to residual water and urea (δ 4.6– 6.4 ppm) were 
excluded from further analysis. NMR spectra were normalised to the total spectral 
integral in the range δ =0.2–10 ppm (excluding 4.6– 6.4 ppm). NMR spectra were 
bucketed (total buckets 603) using the Intelligent Bucketing algorithm and mean 
centred. Principal Components Analysis (PCA) was used as an unsupervised 
method for data visualisation and outlier identification and performed using BioRad 
KnowItAll software. 
All other statistical analysis was performed using Graph Prism Version 7.0. 
Parametric (paired t-test, Pearson) and non-parametric (Mann Whitney, Spearman) 
analyses were performed as appropriate. Significance was considered present at 
p<0.05. 
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Chapter 4  
TIPSS Study 
 
4.1 Introduction 
A substantial body of evidence exists to implicate gut-derived bacterial ligands, in 
particular endotoxin, in the promotion of a dysregulated inflammatory response 
central to the pathogenesis of many complications of cirrhosis, in particular, ACLF. 
Manipulation of gut bacterial flora with oral norfloxacin has been associated with an 
improvement in neutrophil function, improvement in vascular resistance and 
reduction in portal pressure. Higher systemic endotoxin levels have been observed in 
cirrhotic patients with decompensated disease compared to compensated controls.  
Several questions remain however regarding the underlying mechanisms of bacterial 
translocation. These include the relative contribution of compromised gut barrier 
integrity and defective hepatic immune surveillance to the development of systemic 
endotoxaemia. In order to answer this question, arterial, portal and hepatic venous 
blood was sampled in patients undergoing TIPSS (transjugular intrahepatic 
portosystemic shunt) insertion indicated for refractory variceal haemorrhage and 
neutrophil function, cytokine concentrations and markers of bacterial translocation 
determined. 
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4.2 Aims 
The first aim of this study was to determine relative endotoxin concentrations within 
different splanchnic territories and characterise the associated neutrophil response 
and cytokine concentrations. The second aim was to determine whether the early 
effects of artificial portosystemic shunting with TIPSS insertion on systemic endotoxin 
concentrations and neutrophil function. The final aim was to ascertain whether these 
parameters were associated with clinically relevant end-points, in particular, ACLF, 
mortality and portal pressure.  
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4.3 Results 
4.3.1 Patient Characteristics 
 
Table 4.1 Patient Characteristics Pre-TIPSS insertion 
 
Twenty-nine patients underwent TIPSS insertion indicated for variceal haemorrhage 
refractory to standard endoscopic therapy. The mean age was 51.66+2.50 years with 
a male:female ratio of 16:13. The mean MELD score was MELD score 21.48+1.29 
and ascites was found to be present in 66% patients. Mean encephalopathic grade 
was 1.55+0.17. The predominant aetiology of underlying cirrhosis was alcohol in 26 
patients. Two patients had a diagnosis of autoimmune hepatitis and one Primary 
Sclerosing Cholangitis. Mean laboratory values were as follows: albumin 27.48+0.78 
g/dL, bilirubin 107.90+14.85 μmol/L, INR 1.80+0.09, Creatinine 118.40+ 2.92 μmol/L.  
Mean portal pressure gradient pre-TIPSS was 21.07+1.04 mm Hg. Mean portal 
pressure gradient post-TIPSS insertion was 9.52+0.32 mm Hg.  
Patient Characteristics Mean + SEM
n 29
Age (yrs) 51.66 + 2.50
M:F 16:13
Weight (kg) 56.93 + 3.00
Aetiology
Alcohol 26
Autoimmune Hepatitis 2
Primary Sclerosing Cholangitis 1
MELD score 21.48 + 1.29
Ascites present (%) 66
Encephalopathic grade 1.55 + 0.17
Albumin (g/dL) 27.48 + 0.78
Bilirubin (µmol/L) 107.90 + 14.85
INR 1.80 + 0.09
Creatinine (µmol/L) 118.40 + 12.92
PPG pre-TIPSS (mm Hg) 21.07 + 1.04
PPG post-TIPSS (mm Hg) 9.52 + 0.32
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4.3.2 Endotoxin studies 
Mean endotoxin concentrations in the portal vein and hepatic vein pre-TIPSS 
insertion were 0.22±0.02 and 0.04±0.02 EU/ml respectively (p<0.0001). The pre-
TIPSS trans-intestinal (TI) fractional extraction (FE) rate was 2.7±0.7 indicative of net 
intestinal endotoxin generation. Conversely, negative fraction extraction rates of -
0.79 were observed across the liver consistent with endotoxin clearance. TIPSS 
insertion resulted in a significant increase in arterial endotoxin levels from 0.08 ±0.02 
to 0.19±0.02 EU/ml (p=0.0001). 
 
(a)     (b) 
 
(c) 
Figure 4.1(a) Endotoxin concentrations in portal and hepatic venous blood 
Figure 4.1(b) Endotoxin Fractional extraction rates across liver and intestine 
Figure 4.1(c) Arterial endotoxin levels pre- and 1 hour post-TIPSS insertion 
 
***  denotes p<0.001 
 
Pre-TIPSS intestinal fractional extraction of BPI (Bactericidal Permeability Increasing 
Protein) were found to be strongly positive at 12.40. Intestinal fractional extraction of 
LBP (Lipopolysaccharide binding protein) were also positive at 0.28. Negative 
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hepatic fractional extraction of BPI but positive hepatic fractional extraction of LBP 
were observed.  
 
 Hepatic fractional 
extraction 
 
Intestinal fractional 
extraction 
 
BPI -0.573 (0.07) 12.404 (6.7) 
LBP 0.308 (0.21) 0.278 (0.15) 
 
Figure 4.1 (d)  Hepatic and Intestinal Fractional Extraction Rates of endotoxin-binding 
molecules 
 
 
 Paired Differences T df Sig.(2-
tailed) 
Mean SD SEM 95% Confidence Interval 
of the Difference 
Lower Upper 
 PV endotoxin -.057 .065 .018 -.097 -.017 -3.134 12 .009 
 
Figure 4.1 (e) Univariate analysis of portal venous endotoxin concentrations and mortality 
 
Portal venous endotoxin concentrations were found to be predictive of survival in 
patients with variceal haemorrhage. No significant correlation was found with portal 
pressure gradient. Neither arterial nor hepatic venous endotoxin concentrations were 
found to be predictive of survival or portal pressure gradient. 
 
 
4.3.3 Neutrophil Function 
 
 
An intra-splanchnic difference in neutrophil function was observed in patients 
undergoing TIPSS insertion for variceal haemorrhage. A statistical significance in 
hepatic and portal venous neutrophil resting burst at 52.45+5.3% and 84.64+3.5% 
respectively (p<0.0001) was observed. Hepatic venous neutrophil resting burst was 
significantly increased from 52±5.3 to 78±4.5% after incubation with portal venous 
plasma (p<0.0001). Conversely, portal venous neutrophil resting burst was 
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significantly reduced from 85±3.5 to 60±5.3% (p<0.0001) after incubation with 
hepatic venous plasma.  
 
Paralleling the observed increase in systemic endotoxaemia, peripheral neutrophil 
function was found to be significantly impaired following the insertion of TIPSS. 
Neutrophil phagocytic function was significantly reduced from 66±7.5% to 42±6.5% 
(p=0.0004) and resting burst increased from 62±5.6 to 87±2.8% (p=0.0001).  
Arterial neutrophil phagocytosis was found to be significantly lower 1 hour post-
TIPSS insertion in patients with ACLF compared to those without ACLF in the 
context of refractory variceal haemorrhage (49.24+4.93 vs 31.00+2.71 % 
respectively p<0.05). Survival during follow-up was 67% in patients without ACLF 
and 27% in the ACLF group.  
 
Portal venous neutrophil ROS production was found to significantly correlate with 
portal pressure gradient. No significant association with survival and neutrophil ROS 
(portal or hepatic venous) or arterial neutrophil phagocytosis was identified.  
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(a) 
  
(b)      (c) 
  
(d)      (e) 
 
* denotes p<0.05 
***  denotes p<0.001 
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Figure 4.2(a) Neutrophil ROS production in hepatic venous (HV) and portal venous 
(PV) blood 
Figure 4.2(b) Neutrophil ROS production in hepatic venous blood pre- and post-
incubation with portal venous plasma (PVP) 
Figure 4.2(c) Neutrophil ROS production in portal venous blood pre- and post-
incubation with hepatic venous plasma (HVP) 
Figure 4.2 (d)  Arterial neutrophil phagocytosis pre- and post-TIPSS insertion 
Figure 4.2 (e) Correlation between portal pressure gradient and portal venous 
neutrophil ROS production pre-TIPSS insertion (Pearson Coefficient 
R2 = 0.3058, Spearman Coefficient = 0.522) 
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Table 4.2 Neutrophil Function (Non-ACLF vs ACLF) 
 
 Non-
ACLF 
 ACLF   
 Mean SEM  SEM p value 
    Arterial pre-TIPSS neutrophil phagocytosis  65.65 4.87 53.82 5.33 0.1 
    Arterial post-TIPSS neutrophil phagocytosis  49.24 4.93 31 2.71 0.01 
    HV neutrophil respiratory burst  45.94 4.19 34 5.09 0.06 
    PV neutrophil respiratory burst  86.29 2.67 87.73 2.45 0.92 
 
Table 4.3  Univariate analysis of neutrophil function and mortality 
 
 Paired Differences t df Sig.(2-
tailed) 
Mean SD SEM 95% Confidence 
Interval of the 
Difference 
Lower Upper 
 PV neutrophil ROS -3.231 13.211 3.664 -11.214 4.752 -.882 12 .395 
 HV neutrophil 
ROS 
-11.692 21.708 6.021 -24.810 1.426 -1.942 12 .076 
 Arterial neutrophil 
phagocytosis 
5.538 26.082 7.234 -10.223 21.300 .766 12 .459 
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4.3.4 Cytokine levels in splanchnic circulation pre-TIPSS insertion 
  
(a)     (b) 
  
(c)           (d) 
Figure 4.3(a) Interleukin 6 concentrations in hepatic and portal venous blood 
Figure 4.3(b) Interleukin 10 concentrations in hepatic and portal venous blood 
Figure 4.3(c) Fractional extraction of IL6 across liver and intestine 
Figure 4.3(d) Fractional extraction of IL10 across liver and intestine 
 
***  denotes p<0.001 
 
 
 Non-
ACLF 
 ACLF   
 Mean SEM  SEM p value 
    Arterial IL10  0.50 0.09 0.77 0.08 0.03 
    Hepatic venous IL10 0.52 0.06 0.55 0.06 0.9 
    Portal venous IL10 0.74 0.11 0.85 0.08 0.7 
    Arterial IL6 0.52 0.09 0.67 0.10 0.3 
    Hepatic venous IL6 0.78 0.13 0.88 0.12 0.49 
    Portal venous IL6 0.39 0.07 0.51 0.09 0.24 
 
Table 4.4  Cytokine profile in patients with and without ACLF 
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 Paired Differences t df Sig.(
2-
taile
d) 
Mean SD SEM 95% Confidence 
Interval of the 
Difference 
Lower Upper 
 Arterial IL10 .036 .541 .163 -.327 .400 .223 10 .828 
 HV IL10 .084 .306 .092 -.122 .289 .908 10 .385 
 PV IL10 .110 .515 .155 -.235 .456 .711 10 .493 
 Arterial IL6 .283 .317 .100 .057 .509 2.827 9 .020 
 HV IL6 .215 .460 .145 -.114 .544 1.478 9 .174 
 PV IL6 .257 .273 .086 .062 .452 2.977 9 .016 
  
Table 4.5 Univariate analysis of cytokines and mortality 
 
   
 
Figure 4.3 (e) Differential cytokine levels within splanchnic bed 
 
     
Portal venous IL6 concentrations were found to be significantly lower than 
concentrations within the hepatic vein (0.44+0.28 vs 0.83+0.09 ng/ml) (p<0.0001). 
Conversely, portal venous IL10 levels were significantly higher in the portal vein 
compared to hepatic vein (0.78 + 0.07 vs 0.53 + 0.04 ng/ml) (p=0.004). IL6/IL10 
ratios were significantly higher in the hepatic vein compared to portal vein. 
Positive IL10 fractional extraction (FE) rates were observed across the intestine, 
however trans-hepatic IL10 FE rates were negligible. Positive IL6 FE rates were 
observed across the liver and intestine.  No significant difference in IL-6 or IL-10 
production was observed within the following portal vein tributaries: left gastric vein, 
splenic vein, superior mesenteric vein and inferior mesenteric vein. 
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Figure 4.4  Kaplan-Meier Survival Curve post-TIPSS insertion 
Arterial and portal venous IL6 was found to be predictive of survival. No significant 
association of IL10 with survival was identified. No significant association was 
identified with IL6 or IL10 and portal pressure gradient pre-TIPSS insertion in 
patients with variceal haemorrhage.  
Neither MELD nor portal pressure gradient pre-TIPSS insertion in patients with 
variceal haemorrhage was found to be predictive of survival. Of conventional indices 
of liver function and outcome, only prothrombin time was identified as a predictor of 
survival in a univariate analysis.  
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4.4 Discussion 
4.4.1 Differential intra-splanchnic endotoxin levels 
Pre-TIPSS insertion, positive intestinal fractional extraction rates of endotoxin were 
observed, confirming a gut-derived origin for endotoxaemia consistent with bacterial 
translocation. Negative hepatic endotoxin fractional extraction was observed 
consistent with hepatic clearance of endotoxin.  This is reflected in the significant 
difference between portal and hepatic venous endotoxin concentrations observed 
prior to TIPSS insertion demonstrating the integrity of hepatic endotoxin clearance 
mechanisms and portal compartmentalization of endotoxin despite advanced 
disease. Previous studies evaluating markers of bacterial translocation pre-TIPSS 
are conflicting possibly due to the heterogeneity of the patient cohort studied. Benten 
et al described a trans-hepatic endotoxin gradient in a cohort of 8 patients whereas 
Mortensen et al demonstrated no trans-hepatic bacterial DNA or cytokine gradient in 
patients undergoing TIPSS. In both instances however, the indications for TIPSS 
insertion were mixed with a majority of refractory ascites over refractory variceal 
haemorrhage. Previous studies have suggested that the immunopathology of acutely 
unwell cirrhotics is different from stable decompensated disease. 
Portal venous endotoxin concentration was found to be a predictor of survival in 
variceal haemorrhage. In other studies, markers of bacterial translocation such as 
bacterial DNA and systemic endotoxin have been found to be predictors of survival. 
This may be of particular importance in TIPSS insertion as the portal venous 
endotoxin load is rendered systemic with the attendant risk of a SIRS response. 
Markers of bacterial translocation and associated dysregulatory response may be 
important additional biomarkers to predict survival. Strategies to diminish portal 
venous endotoxin load and SIRS response are important adjunctive measures to 
predict outcome in the context of refractory variceal haemorrhage.  
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Significant differences in endotoxin-binding molecules were also observed in variceal 
haemorrhage. Lipopolysaccharide binding protein (LBP) and 
Bactericidal/permeability-increasing protein (BPI) are endotoxin-binding molecules 
produced by hepatocytes and polymorphonuclear cells, mediating pro- and anti-
inflammatory responses respectively. In this study, we observed high intestinal 
fractional extraction rates for BPI in concert with high portal endotoxaemia. LBP 
intestinal fraction extraction rates whilst positive were considerably lower. The 
mechanism of this increase in BPI is not clear but suggests that that endotoxin-
induced neutrophil degranulation, that has been shown in this study as evidenced by 
an elevated neutrophil burst is also accompanied by release of BPI.  
 
4.4.2 Differential intra-splanchnic neutrophil function 
In parallel to the finding of a trans-hepatic endotoxin gradient, we observed a 
‘compartmentalization’ of neutrophil dysfunction. Portal venous neutrophils were 
found to exhibit pathologically heightened respiratory burst, which was significantly 
elevated compared to hepatic venous neutrophils within a range known to be 
associated with excess mortality. This neutrophil defect could be conferred or 
abrogated by co-incubation of portal venous or hepatic venous plasma respectively. 
Previous studies in patients with alcoholic cirrhosis demonstrated that a humoral 
factor, endotoxin, is responsible for mediating neutrophil dysfunction.   
Portal venous neutrophil ROS production was found to significantly correlate with 
portal pressure gradient in this patient cohort. This observation is consistent with the 
current understanding that there is an additional dynamic component of portal 
hypertension driven by inflammation which may precipitate variceal haemorrhage. It 
reinforces the importance of strategies such as antibiotics to reduce bacterial 
translocation to diminish clinically relevant end-points such as portal pressure and 
goes some way to explaining the observation of reduced re-bleeding rates in patients 
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receiving empirical antibiotic therapy. Mechanistically, reactive oxidant species are 
known to scavenge nitric oxide, contribute to endothelial dysfunction and thus raise 
portal pressures. This study reinforces the importance of the trafficking portal-derived 
innate immune cells in determining haemodynamic status.  
 
4.4.3 Differential intra-splanchnic cytokine levels 
Significant positive intestinal IL10 fractional extraction rates were observed pre-
TIPSS insertion in patients with variceal haemorrhage consistent with intestinal 
generation of IL10. The most likely origin of portal-derived IL10 is from local innate 
immune populations and enterocytes. Production of IL-10 is a key strategy the 
lamina propria macrophages employ to induce an inhibitory, tolerising immunological 
phenotype in the gut in response to enterocyte stress. Trafficking neutrophils may 
further contribute and indeed have been also shown to be significant IL10 producers 
in the context of advanced cirrhosis. Metabolic stress is evident in intestinal mucosa 
even in the context of stable cirrhosis. Portal hypertension with splanchnic venous 
stasis and associated hypoxia is a likely driver of this. Dysbiosis, bacterial 
metabolites such as acetaldehyde and nutritional factors may further contribute.  
In contrast to the intestine, the liver has a negligible role in IL10 production but is a 
significant source of IL6. IL6 is generated by many different cell types within the liver 
including stimulated monocytes, fibroblasts and endothelial cells. Hepatocytes may 
also be directly stimulated to produce IL6 by factors such as bacterial endotoxin. In 
addition to regulation of the acute phase response, IL6 results in activation of 
hepatoprotective pathways, promoting hepatocellular proliferation in response to high 
portal venous endotoxin levels such as in the context of variceal haemorrhage.  
IL6/IL10 ratio has been described in the sepsis literature as a measure of the 
predominant phenotype of the inflammatory response. In this study, whilst hepatic 
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venous and arterial IL6/IL10 ratios are similar, ratios in portal venous blood are more 
skewed towards an anti-inflammatory response.  
 
4.4.4. The effect of TIPSS insertion 
Systemic neutrophil function was found to be impaired following the insertion of 
TIPSS. This was manifest as a significant reduction in neutrophil phagocytosis and 
increase in resting burst and mirrors the rise in systemic endotoxaemia post-TIPSS. 
These observations are consistent with previous studies demonstrating significant 
increases in arterial endotoxin levels following TIPSS insertion associated with a 
significant increase in induced neutrophil oxidative burst (Jalan et al). 
Early TIPSS therapy has been proposed after the study by García-Pagán et al. Our 
data highlights the potential risks of early TIPSS intervention which must be 
considered when deciding on an optimal treatment strategy for the patient. In light of 
the data from this study, it may be appropriate to consider adjunctive therapy with 
endotoxin-binding strategies to diminish systemic endotoxin levels following TIPSS 
placement.  
 
This study demonstrates that in the context of variceal haemorrhage, a trans-hepatic 
gradient of endotoxin and associated neutrophil function is observed. TIPSS insertion 
disturbs this compartmentalisation and is associated with a significant deterioration in 
neutrophil function. Markers of bacterial translocation and pro-inflammatory response 
were found to be predictive of mortality post-TIPSS insertion highlighting the clinical 
importance of bacterial translocation. The data from this study demonstrates that it is 
compromised gut barrier integrity rather than defective hepatic immune surveillance 
mechanisms which are responsible for systemic endotoxaemia in cirrhosis even in 
the context of advanced disease. The subject of subsequent studies was therefore 
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characterisation of the gut liver axis in a model of cirrhosis and evaluation of a novel 
strategy to modulate this process. 
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Chapter 5 
 
In Vitro Adsorption of Biological Targets in Liver Disease 
 
5.1 Introduction 
 
Yaq-001 (TE7/8) is an a synthetic activated carbon produced from phenolic resin with 
a high surface area and tailored bimodal porosity conferring adsorptive properties 
appropriate for a range of biologically-relevant mediators. Yaq-001 has a high 
adsorptive capacity for both larger biologically relevant mediators such as bacterial 
toxins and cytokines, which bind to meso/small macropores (2-50nm) in addition to 
smaller molecules such as bacterial metabolites which bind in the smaller micropores 
(<2nm). The controlled production of these carbons by phase separation during resin 
curing, pyrolysis followed by secondary phase separation, allows for tight control of 
pore size and consistency of product. This is in contrast to many other activated 
carbons which have a more heterogenous pore distribution, typically within the more 
microporous range. Figure 5.1 (a) demonstrates the internal porous structure of a 
Yaq-001 bead comprising both microporous and larger meso/macroporous domains. 
Figure 5.1 (b) demonstrates the cut surface of the Yaq-001 bead. 
(a)      (b) 
      
Figure 5.1 Electron micrograph images of Yaq-001 carbon beads (S Sandeman et al 
  2008) 
Micropore 
Meso/macropore 
20nm 
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Figure 5.2   Pore size distribution of activated carbons TE3, TE5 and TE7 (Yaq-001) 
 
5.2 Aims  
The first objective of this study was to ascertain the optimal carbon porosity for in 
vitro adsorption of larger biologically relevant mediators for translation to in vivo 
studies. The second aim was to describe the adsorption kinetics of the selected 
carbon with endotoxin, cytokines and acetaldehyde. The third aim of this study was 
to ascertain whether Yaq-001 influenced the growth kinetics of gram positive and 
negative bacteria and thus exhibited an antibiotic-type effect. 
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5.3 Results 
5.3.1 Studies to determine optimal carbon porosity for in vivo studies 
Carbons of a range of pore sizes (TE1-9) were studied to determine their differential 
adsorptive properties for pro-inflammatory cytokines. The carbons ranged from the 
smallest pore sizes (microporous carbon TE1), through the medium sized or 
mesoporous carbons such as TE5 to the largest pore size, meso/macroporous 
carbon TE9. TE7/8 (Yaq-001) was found to have the best combination of high 
surface area and pore volume contributing to high adsorptive properties. 
Functionally, this translated to superior binding of TNFα and IL-6 removal by TE7 
(Yaq-001) compared to beads of both larger and smaller pore sizes (figure 5.4 and 
5.5). Figure 5.6 expresses the data as an adsorption isotherm demonstrating 
excellent TNFα adsorption by Yaq-001 from simulated intestinal fluid.  
 
 
Table 5.1 Physical properties of carbons TE1-9 
 
       
Figure 5.3  TNFα adsorption kinetics   Figure 5.4 IL-6 adsorption kinetics  
(n=3, Mean + SEM)    (n=3, Mean + SEM)          
 
Sample Bead 
Diameter 
(µm) 
Surface 
Area SBET
 
 
(m
2
g
-1
) 
Pore 
Volume 
(cm
3
g
-1
) 
Bulk 
Density (g 
cm
3-1
) 
Mean 
mesopore 
diameter 
(nm) 
TE1 250-500 1204 0.69 0.56 microporous 
TE3 250-500 1465 1.30 0.38 30 
TE5 250-500 1493 1.75 0.27 70 
TE7 250-500 1483 2.11 0.21 80 
TE9 250-500 1236 1.61 0.18 120 
 
 
Figure 3.5  TNFα adsorption kinetics of carbons TE3-9  
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Figure 5.5  Adsorption isotherm showing carbon adsorption of TNFα from simulated 
intestinal fluid (n=4, Mean + SEM) (S Sandeman et al, 2008) 
 
5.3.2 Studies to determine adsorption kinetics of Endotoxin 
 
Figure 5.6  Adsorption kinetics of carbon for E. coli endotoxin (n=3, Mean + SEM) 
The concentration of endotoxin detected in the simulated intestinal fluid  (SIF) 
solution initially spiked with 10 EU ml-1 declined from a detected value of 4.5 EU ml-
1 at time 0 to 0.4 EU ml-1 following 60 minutes incubation with the TE7/8. The 
control solution maintained a steady 4.5 EU ml-1 concentration over time. These 
findings demonstrate rapid endotoxin adsorption kinetics. 
 
 
122 
 
5.3.3 Studies to determine adsorption kinetics of Acetaldehyde  
 
Figure 5.7 Acetaldehyde removal over time by TE8 carbon compared to no carbon 
control (n=3, Mean + SEM) 
 
 
Figure 5.8 Carbon acetaldehyde adsorption kinetics expressed as quantity of 
acetaldehyde adsorbed (mg g
-1
) with time (n=3, Mean + SEM)         
 
Rapid acetaldehyde adsorption kinetics were observed with TE8 (Yaq-001) carbon. 
The majority of the acetaldehyde was removed after an incubation time of 1 minute 
at room temperature following a spike of acetaldehyde in simulated intestinal fluid. By 
3 minutes, incubation of carbon with acetaldehyde solution an equilibrium adsorptive 
spike. 
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5.3.4 Studies to determine effects of carbon on bacterial growth kinetics 
5.3.4.1 Investigating the effect of direct contact incubation of carbons on 
bacterial metabolism 
 
Figure 5.9   Effect of TE8 carbon on E. coli growth kinetics (BacTitre-Glo microbial cell 
viability assay) expressed as luminescence signal following direct contact 
with E. coli over time (innoculum 3.9x10
9
 bacteria ml
-1
) (n=3 per group, Mean 
+ SEM)       
 
 
Figure  5.10 The effect of TE7 test carbon on Staphylococcus aureus bacterial growth 
kinetics (BacTiter-Glo microbial cell viability assay) expressed as 
luminescence signal following direct contact with S. aureus over time 
(Inoculum 7.5 x10
7
 bacteria ml
-1
) (n=3, Mean + SEM). 
 
The luminescence measurement is an indirect measure of cell viability and cell 
number via the determination of bacterial ATP. Levels of luminescence, reflective of 
bacterial metabolism on sample contact, were comparable to the no adsorbent 
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control for both species over the time course of the experiment. Therefore the direct 
incubation of TE7/8 carbons with bacterial suspensions of either E. coli or 
Staphylococcus aureus in culture medium had no significant effect on bacterial 
growth kinetics following direct contact for 4 to 6 hours. In contrast, the control 
commercial oral carbon significantly reduced the luminescence signal following only 
30 minutes incubation of bacteria with carbon.  
 
5.3.4.2 Studies to determine the effect of carbon leachate on bacterial 
metabolism  
 
Figure 5.11  The effect of TE7 test carbon leachate on growth kinetics of E. coli over time 
as measured by Bioscreen turbidometric analyser (540nm) (n=4).  
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Figure 5.12  The effect of TE7 test carbon leachate on growth kinetics of Bacillus subtilis 
over time as measured by Bioscreen turbidometric analyser (540nm) (n=4).  
 
The optical density (OD) measurement is an indirect measure of bacterial number. 
OD values for the TE7 sample were comparable to the no adsorbent control for both 
species over the time course of the experiment. The direct incubation of TE7 carbon 
leachate with bacterial suspensions of either E. coli or Bacillus subtilis in culture 
media for 72 hours therefore did not result in a significant difference in bacterial 
growth kinetics for either species.  
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5.4 Discussion 
In summary, in vitro studies demonstrate that activated Yaq-001 carbons exhibit 
rapid adsorption kinetics for endotoxin, pro-inflammatory cytokines and acetaldehyde 
with no significant impact on bacterial growth kinetics. They therefore exhibit optimal 
properties of an oral strategy in liver disease ie binding of important intraluminal 
factors which drive pathogenesis without exerting an antibiotic effect on the resident 
bacterial flora with the attendant risks of dysbiosis. Furthermore, these carbon 
particles are non-absorbable and therefore mediate their effect locally at the gut-
barrier interface.  
These studies identified that TE7/8 carbons (hereafter termed Yaq-001) exhibit 
optimal adsorptive properties for binding both larger biologically relevant molecules 
such as endotoxin and cytokines together with other bacterial metabolites such as 
acetaldehyde. These carbons were therefore selected for further evaluation as an 
oral intervention in in vivo models of liver disease.  
 
 
  
 
 
 
 
 
 
127 
 
Chapter 6 
Validation of the Bile Duct Ligated Rat model 
 
6.1 Introduction 
The bile duct ligated (BDL) rat model is an established surgical model of secondary 
biliary cirrhosis. It has been used widely in animal studies of cirrhosis and has 
features of portal hypertension at 4 weeks. Low dose intra-peritoneal administration 
of lipopolysaccharide (LPS) to 4 week BDL rats (BDL+LPS) has been considered as 
a model of acute-on-chronic liver failure (ACLF).  
6.2 Aims 
The aims of this study were to validate the 4 week bile duct ligated rat model as a 
model of cirrhosis, portal hypertension and bacterial translocation. A secondary 
objective was to characterise the 4 week bile duct ligated rat model with 
intraperitoneal lipolysaccharide as a model of acute on chronic liver failure. 
6.3 Results 
A significant increase in alanine transaminase was observed in bile duct ligated rats 
after 4 weeks (73.95 +4.10 IU/ml) compared to sham controls (48.45 +2.45 IU/ml) 
(p<0.0001). This was found to be associated with a significant decrease in albumin 
(BDL 24.63 +1.10 vs Sham 32.73 + 1.20 g/dL) (p<0.0001) and a significant increase 
in alkaline phosphatase and bilirubin (BDL 230.60 + 13.16 vs Sham 108.10 + 17.65 
IU/L) and (BDL 142.20 + 6.00 vs Sham 1.3 + 0.15 μmol/L) (p<0.0001) consistent with 
a surgical cholestatic model. A significant increase in plasma creatinine was 
observed in BDL rats compared to sham controls (BDL 32.01 + 1.00 vs 28.33 μmol/L 
(p=0.01) although no significant increase in urea was observed.  
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6.3.1 Biochemical Profile 
 
 
 
 
 
Figure 6.1 Biochemical evidence of liver injury in Sham vs BDL rats as evidenced by 
plasma alanine transaminase levels (Sham n=23, BDL n=25)  
***  denotes p<0.001 
 
 
(a) 
 
(b) 
 
 
 
Figure 6.2 Biochemical evidence of cholestasis in Sham vs BDL rats as evidenced by 
(a) plasma bilirubin (Sham n=23, BDL n=25) 
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(b) alkaline phosphatase levels (Sham n=21, BDL n=25) 
***  denotes p<0.001 
 
 
Figure 6.3 Biochemical evidence of liver synthetic function in Sham and BDL rats as 
evidenced by plasma albumin levels (Sham n= 22, BDL n=24) 
***  denotes p<0.001 
 
 
Figure 6.4 Biochemical evidence of renal function as evidenced by plasma creatinine in 
sham and BDL rats (Sham n=23, BDL n=22) 
* denotes p<0.05 
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6.3.2 Histological Profile 
Bile duct ligation was associated with a significant increase in collagen proportionate 
area quantified on digital image analysis (14.44 + 4.38 vs 1.59 + 0.00%). The 
increase in collagen deposition in bile duct ligated rats was associated with 
architectural disturbance evidenced by cholestasis, cholangiocyte proliferation and 
nodule formation. Such features were not evident on liver histology of sham-operated 
rats.  
  
Figure 6.5 Collagen staining of liver tissue with Sirius Red stain in (a) sham and (b) BDL 
rats 
 
Figure 6.6  Quantification of collagen staining by digital image analysis of Sirius red 
stained liver histology in sham and BDL rats as a marker of liver fibrosis 
 (Sham n=6, BDL n=8) 
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6.3.3 Haemodynamic Profile 
Bile duct ligation was observed to be associated with a significant increase in portal 
pressure (BDL 11.86 + 0.56 vs Sham 5.70 + 0.38 mm Hg) (p<0.0001). A significant 
reduction in mean arterial pressure was also observed in BDL rats compared to 
sham controls (BDL 84.17 + 5.76 vs Sham 112.70 + 3.53 mm Hg) (p=0.0006).  
 
Portal Pressure 
 
 
Figure 6.7  Portal haemodynamics in Sham and BDL rats at 4 weeks 
  (Sham n=21, BDL n=15) 
***  denotes p<0.001 
 
Mean Arterial Pressure 
 
Figure 6.8 Systemic haemodynamics in Sham and BDL at 4 weeks (Sham n=13, BDL 
n=12) ***  denotes p<0.001 
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6.3.4 Body weight  
 
 
4 weeks post-surgery 
 
Figure 6.9  Final body weight (g) (Sham n=27, BDL n=27) 
***  denotes p<0.001 
 
 
Percentage body weight increase in 4 weeks post-surgery 
 
 
Figure 6.10  Percentage body weight increase in 4 weeks post-surgery  
(Sham n=27, BDL n=26) 
***  denotes p<0.001 
 
Bile duct ligation was associated with a significantly lower final body weight (BDL 
435.6 + 7.70 vs Sham 474.00 + 5.46 g) (p=0.0003) and percentage body weight 
increase compared to sham controls (BDL 24.70 + 2.30% vs Sham 35.56 + 2.44) 
(p=0.0008). Of note, the rats were pair fed and of equivalent body weight (240-280g) 
at the time of surgery. 
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6.3.5 Markers of Bacterial Translocation 
 
Endotoxin Levels (PVP)      Presence of Bacterial DNA (PVP) 
  
Figure 6.11 Quantification of portal venous endotoxin in sham vs BDL rats as determined 
by the chromogenic limulus amoebocyte lysate kinetic assay (Sham n=6, 
BDL n=4) 
 
Figure 6.12 Bacterial DNA positivity in portal venous plasma in sham and BDL rats 
(Sham n=6, BDL n=5) 
* denotes p<0.05 
PVP = Portal venous plasma 
 
 
Mesenteric Lymph Node Positivity 
     
Figure 6.13 Mesenteric Lymph Node Culture Positivity in sham and BDL rats (n=4/group) 
 
The four week bile duct ligation rat model was found to be associated with a 
significant increase in portal venous endotoxin (BDL 0.50 + 0.32 vs Sham 0.01 + 
0.01 IU/ml) (p=0.01) and bacterial DNA positivity compared to sham controls (BDL 
40% vs Sham 17.5%). Translocation of viable bacteria as determined by mesenteric 
lymph node culture was found to be 25% in BDL rats compared to 0% in sham 
controls. 
Sham BDL
0
10
20
30
M
L
N
 c
u
lt
u
re
 p
o
s
it
iv
it
y
 (
%
)
134 
 
6.3.6 Other metabolic parameters 
 
 
Arterial Ammonia levels    Glucose 
 
 
 
Figure 6.14 Arterial ammonia concentrations in BDL vs sham rats (Sham n=6, BDL n=15) 
* denotes p<0.05 
 
Figure 6.15  Plasma glucose concentrations in BDL vs sham rats (Sham n=11, BDL n=13) 
***  denotes p<0.001 
 
 
Lactate 
 
 
 
Figure 6.16  Plasma lactate concentrations in BDL vs sham rats (Sham n=8, BDL n=4) 
** denotes p<0.005 
 
 
Significantly higher arterial ammonia levels were observed in BDL rats compared to 
sham controls (BDL 170.10 + 14.64 vs Sham 98.63 + 28.73) (p=0.03). Plasma 
glucose concentrations were significantly lower in BDL rats compared to sham 
controls (BDL 5.70 + 0.53 vs Sham 19.02 + 1.15) (p<0.0001). Plasma lactate was 
significantly higher in BDL rats compared to sham controls (BDL 6.60 + 1.26 vs 
Sham 2.12 + 0.17 mmol/L) (p=0.004).  
 
 
135 
 
6.3.7 BDL + LPS Model 
 
 
The BDL LPS model has been used as a model of acute on chronic liver failure. 4-5 
week bile duct ligated rats undergo intra-peritoneal Klebsiella pneumoniae 
lipopolysaccharide injection 3.5 hours prior to sample collection. As evidenced by the 
results in figure 6.18, the BDL model is associated with a significant increase in 
organ injury as evidenced by a significant increase in ALT and creatinine. This is 
associated with a significant increase in portal pressure.  
 
 
 
 
 
Table 6.1 Biochemical and Haematological Profile (BDL+LPS Model) 
 
 
 
 
	
	 Sham	
(Mean+SEM)	
Sham+LPS	
(Mean+SEM)	
BDL	
(Mean+SEM)	
BDL+LPS	
(Mean+SEM)	
ALT		
(IU/ml)	
48.45+2.45	 69.94+11.09	 73.95+4.10	 99.93+6.66	
Creatinine		
(micmol/L)	
28.33+0.96	 24.29+1.44	 32.01+1.00	 40.77+3.88	
Albumin	
	(g/dL)	
32.17+1.42	 34.08+0.72	 25.84+1.07	 24.39+1.60	
Alkaline	phosphatase	
(IU/ml)	
113.4+21.55	 116.9+18.53	 229.9+15.31	 322.5+69.46	
Portal	pressure		
(mm	Hg)	
5.70+0.38	 8.48+0.96	 11.86+0.56	 15.86+1.05	
Mean	Arterial	Pressure	
(mm	Hg)	
112.70+3.53	 102.70+5.11	 84.17+5.76	 102.4+5.73	
	
	 Sham	vs	BDL	 BDL	vs	BDLLPS	 ShamLPS	vs	
BDLLPS	
Sham	vs	ShamLPS	
ALT		
(IU/ml)	
p<0.0001	 p=0.004	 p=0.03	 ns	
Creatinine		
(micmol/L)	
p=0.01	 p=0.0495	 p=0.004	 p=0.03	
Albumin	
	(g/dL)	
P<0.0001	 ns	 p=0.01	 ns	
Alkaline	phosphatase	
(IU/ml)	
p<0.0001	 ns	 p=0.01	 ns	
Portal	pressure		
(mm	Hg)	
p<0.0001	 p=0.005	 p=0.002	 p=0.001	
Mean	Arterial	Pressure	
(mm	Hg)	
p=0.0006	 p=0.07	 ns	 ns	
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Liver Histology  
 
 
Figure 6.17  Liver histology (Haemaoxylin and Eosin)  
(a) Sham (b) sham+LPS  (c) BDL  (d) BDL+LPS 
 
Bile duct ligation is associated with cholangiocyte proliferation, nodule formation and 
inflammatory infiltrate. A marked increase in inflammatory infiltrate is observed in the 
BDL+LPS rats at 4 weeks compared to BDL alone.  
These observations demonstrate that cirrhotic rats are exquisitely sensitive to 
endotoxin challenge and this is manifest by exacerbation of organ injury and portal 
pressure, clinically relevant biological determinants of outcome in cirrhotic patients.  
 
 
(a)           (b) 
(c)             (d) 
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6.4 Discussion 
The 4 week bile duct ligated (BDL) rat model was associated with a significant 
increase in alanine transaminase (ALT) and bilirubin compared to sham controls 
indicative of cholestatic liver injury. A significant reduction in albumin was observed 
consistent with a reduction in liver synthetic function. A significant increase in plasma 
creatinine was observed in bile duct ligated rats compared to sham controls 
indicative of renal injury in the disease group. 
BDL was also found to be associated with significant differences in both splanchnic 
and systemic haemodynamic status as compared to sham controls. A significant 
increase in portal pressure was observed in BDL rats associated with a significant 
reduction in mean arterial pressure. Degree of fibrosis was found to be significantly 
increased in BDL rats as quantified by digital image analysis of Sirius red stained 
liver tissue. A significant difference in nutritional status as evidenced by final body 
weight and percentage body weight increase was also observed. As the animals 
were pair fed, this discrepancy may be attributed to a heightened catabolic state in 
bile duct ligated rats.  
BDL rats were found to have significantly higher markers of bacterial translocation. 
Phenotypically, Bile duct ligation was associated with heightened endotoxin-
sensitivity in vivo with regards to organ injury and portal haemodynamic status. 
Taken together, the BDL model is one of bacterial translocation and a primed state to 
endotoxin challenge. The BDL+LPS model is associated with further increased 
inflammation, organ injury and portal pressure.  
The features of this model which are of particular clinical relevance include portal 
hypertension, liver injury (both inflammatory and fibrotic) and gut barrier dysfunction. 
Subsequent studies were directed towards characterising the relative contribution of 
the three key factors promoting bacterial translocation, namely integrity of gut barrier, 
innate immune response and gut dysbiosis. 
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Chapter 7 
Characterisation of the Gut-Liver axis in Bile Duct Ligated 
Rats 
 
7.1 Introduction 
Bacterial translocation rates are principally determined by three key factors: gut 
barrier integrity, bacterial overgrowth and immune status. The relative contribution of 
these factors is not clearly understood. A key early objective of this study was to 
determine the functional and structural integrity of the intestinal barrier in a model of 
cirrhosis and portal hypertension, the BDL rat and to complement these studies by 
characterisation of the microbiome and innate immune response along the gut-liver 
axis. The exact site of bacterial translocation remained unknown and so therefore all 
four regions of the small and large intestine were studied: duodenum, jejunum, 
terminal ileum and colon by light microscopy and duodenum and colon by electron 
microscopy. These studies were complemented by functional assessments. 
 
7.2 Aims 
The aims of this study were to characterize elements of the gut-liver axis which may 
contribute to bacterial translocation and disease progression. The three broad areas 
studied were integrity of the gut-barrier interface, innate immune phenotype and gut 
microbiota composition and function. 
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7.3 Results 
7.3.1 Light microscopy 
7.3.1.1 Duodenum 
1 (a)       1 (b) 
  
2 (a)     2 (b)  
  
Figure 7.1  Light microscopy images of duodenum (H&E) 
 
1 (a) Sham mucosa (b) Sham sub-mucosa and mesentery  
2 (a) BDL mucosa (b) BDL sub-mucosa and mesentery 
 
Normal appearances of duodenal villi, submucosa and mesentery with associated 
vasculature were observed on light microscopy in BDL rats compared to sham 
controls. 
 
 
 
	
100µm 
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7.3.1.2 Jejunum 
 
1 (a)      1 (b) 
  
2 (a)      (b) 
  
 
 
Figure 7.2  
 
Light microscopy images of jejunum (H&E& Alcian blue) 
 
1  (a) Sham mucosa (b) Sham sub-mucosa and mesentery  
2  (a) BDL mucosa (b) BDL sub-mucosa and mesentery 
 
 
Normal appearances of jejunal villi, submucosa and mesentery with associated 
vasculature were observed on light microscopy in BDL rats compared to sham 
controls. 
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7.3.1.3 Ileum 
 
1 (a)      1 (b) 
  
2 (a)      2 (b)     
  
 
Figure 7.3  Light microscopy images of ileum (H&E) 
 
1 (a) Sham mucosa (b) Sham sub-mucosa and mesentery  
2 (a) BDL mucosa (b) BDL sub-mucosa and mesentery  
 
 
Normal appearances of ileal villi, submucosa and mesentery with associated 
vasculature were observed on light microscopy in BDL rats compared to sham 
controls. 
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7.3.1.4 Colon 
1(a)      1 (b)      
  
1(c)       2(a) 
  
2(b)      2(c)   
   
Figure 7.4  Light microscopy images of colon (H&E&Alcian blue) 
 
1 (a) Sham mucosa (b) Sham sub-mucosa and mesentery (c) Sham mesentery 
2 (a) BDL mucosa (b) BDL sub-mucosa and mesentery  (c) BDL mesentery 
 
Normal appearances of colonic villi was observed in BDL rats compared to sham 
controls. Slight tortuosity of the sub-mucosal vessels with perivascular inflammation 
in the smaller mesenteric vessels close to the peritoneal surface was observed in 
colonic tissue in BDL rats. 
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Light microscopy was performed on full thickness intestinal tissue at multiple sites 
along the gastrointestinal tract: duodenum, mid-jejunum, terminal ileum and colon. 
No significant mucosal abnormality was identified at any of these sites. With no clear 
breach in the mucosal surface, studies were conducted to evaluate ultra-structural 
features of the duodenal and colonic mucosa. 
 
7.3.2 Electron microscopy 
Qualitative analysis of electron microscopy images was performed by an 
independent expert histopathologist. No gross ultra-structural abnormalities were 
observed in the duodenum of cirrhotic compared to control rats although subtle 
changes were observed. These changes included widening of the inter-villus space 
was observed in the duodenum of BDL rats compared to sham controls (figures 7.6 
and 7.5 respectively) and blunting of the microvilli (figures 7.8 vs 7.7). The sub-
mucosa of duodenal tissue was more ragged in BDL rats (figure 7.10) compared to 
sham controls (figure 7.9). No ultra-structural abnormalities were observed in the 
colonic tissue of BDL or sham rats. Of note, microvilli and tight junctions remained 
intact suggestive that architectural disturbance is not a feature of this model.  
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7.3.2.1 Electron Microscopy of the Duodenum   
  
 
Figure 7.5 Electron micrograph of duodenal tissue in sham operated rats.  
 
 
 
 
Figure 7.6 Electron micrograph of duodenal tissue in bile duct ligated rats.  
 
IVS – Inter-villus space 
IVS 
IVS 
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Figure 7.7 Electron micrograph of duodenal microvilli in sham-operated rats  
 
 
 
Figure 7.8 Electron micrograph of duodenal microvilli in BDL rats 
 
MV - Microvilli 
MV 
MV 
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Figure 7.9 Electron micrograph of duodenal tissue in sham operated rats.  
 
  
 
Figure 7.10 Electron micrograph of duodenal microvilli in BDL rats  
SM - submucosa 
S
M
SM 
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7.3.2.2 Electron microscopy of the Colon 
  
 
Figure 7.11 Electron micrograph of colonic tissue in sham operated rats 
 
 
 
 
Figure 7.12 Electron micrograph of colonic tissue in bile duct ligated rats.  
MV - microvilli 
MV 
MV 
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Figure 7.13 Electron micrograph of colonic tissue in sham operated rats. 
 
 
 
 
Figure 7.14 Electron micrograph of colonic tissue in bile duct ligated rats 
 
TJ – Tight junction 
 
TJ 
TJ 
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7.3.3 Paneth Cell Function 
Paneth cells play an important role in antimicrobial defence at the gut-barrier 
interface. Data exists to implicate them in rodent models of portal hypertension 
(CCL4 treated rats and portal vein ligated rats). No data exists as yet in a cholestatic 
model of cirrhosis. Gene expression studies were therefore conducted in terminal 
ileal tissue in sham operated and bile duct ligated rats to identify expression levels of 
Paneth cell antimicrobial factors. 
 
a. b.   
c.     
Figure 7.15  Relative gene expression in the terminal ileum of sham and BDL rats with 
regards to: a. defensin 8 , b. defensin 5, c. lysozyme (n=4 per group) 
* denotes p<0.05 
**  denotes p<0.005 
 
 
A significant increase in the relative expression of alpha defensins 5 and 8 and 
lysozyme (standardised to expression of housekeeping genes gapdh and actb) was 
observed in the terminal ileal tissue of BDL rats as compared to sham. Previous 
studies in carbon tetrachloride-treated rats have demonstrated an opposite effect 
with a decrease in gene expression of alpha-defensins 5 and 7, most markedly in 
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animals with evidence of bacterial translocation. This was not observed in portal 
hypertensive rats without cirrhosis (portal vein ligation model) implicating liver 
cirrhosis rather than portal hypertension in pathogenesis. Why there is a discordance 
in alpha-defensin gene expression profile between BDL compared to CCl4 rats is 
unclear. It is known that alpha-defensin production is induced by microbial products 
such as endotoxin (Palazzo M et al 2007), therefore difference in microbiome 
composition between the two models may exert a differential effect on alpha-
defensin gene expression. It may represent reactive change to a different microbial 
composition occurring as a consequence of chronic cholestasis in BDL rats with an 
increased representation of gram negative organisms with the propensity to stimulate 
defensin expression via TLR4-dependent mechanisms compared to CCl4 models. 
This however is speculative and warrants further studies. 
 
7.3.4 Intestinal Permeability 
a.      b. 
  
Figure  7.16 Urinary Lactulose/creatinine ratio (ESI-MS). 
Figure  7.17 Urinary 3OMD/creatinine ratio (ESI-MS) 
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A significant increase in 5 hour urinary lactulose/creatinine was observed in BDL rats 
compared to sham controls suggesting an increase in intestinal paracellular 
permeability. Of note, intraperitoneal injection of lipopolysaccharide resulted in a 
significant increase in lactulose/creatinine ration in both sham and BDL models 
(Ruan Z et al 2014). Intraperitoneal LPS has been previously demonstrated to result 
in an increase in intestinal permeability as evidenced by increased lactulose/mannitol 
ratio consistent with our observations. This thought to be due to an effect on tight 
junction protein expression and function. 
In contrast, the 3OMD/creatinine ratio was not significantly different between BDL 
and sham and BDL and BDL=LPS. 3OMD/creatinine is a measure of active 
transport. Taken together, this data suggests more of a pathological defect in 
paracellular permeability rather than active transport, potentially implicating tight 
junctions, the key regulators of paracellular permeability in pathogenesis.  
 
7.3.5 Tight Junction Protein expression 
Tight junctions are key regulators of paracellular permeability in the intestine. They 
are highly complex and comprise over 50 different subcomponent proteins. Claudin 3 
is a sealant tight junction protein which has been shown to be downregulated in the 
duodenal biopsies of compensated cirrhotic patients (Piils KE et al 2014). Urinary 
claudin 3 concentrations have been found to be reciprocally elevated in rodent 
models of haemorrhage shock and also patients with active inflammatory bowel 
disease (Thuiils G et al 2010). This was the rationale for evaluating claudin 3 
expression along the small and large intestine of BDL rats. 
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Claudin 3 
(a) Duodenum     (b) Jejunum 
 
(c) Ileum     (d) Colon  
 
Figure 7.18  Relative protein expression of claudin-3 in mucosa of sham and BDL rats 
(Sham n=4, BDL n=6) 
(a) Duodenum  (b) Jejunum  (c) Ileum  (d) Colon 
ns denotes non-significant 
 
Zonula Occludens-1 
Zonula Occludens proteins provide ZO-1 is the most widely studied zonula occludens 
and has been shown to be reduced in the ileum of carbon tetrachloride treated rats 
(Yang DH et al 2012). TLR-mediated pathways have been implicated in redistribution 
of ZO-1, an effect functionally associated with an increase in permeability as 
evidenced by transepithelial electrical resistance (Ulluwishewa D et al 2011). 
Sham BDL
0.0
0.2
0.4
0.6 ns
C
la
u
d
in
3
 p
ro
te
in
 e
x
p
re
s
s
io
n
	 Sham BDL
0.0
0.5
1.0
1.5
ns
C
la
u
d
in
3
 p
ro
te
in
 e
x
p
re
s
s
io
n
Sham BDL
0
1
2
3
4
ns
C
la
u
d
in
3
 p
ro
te
in
 e
x
p
re
s
s
io
n
Sham BDL
0.0
0.2
0.4
0.6
0.8
ns
C
la
u
d
in
3
 p
ro
te
in
 e
x
p
re
s
s
io
n
153 
 
 
Figure 7.19  ZO-1 expression in full thickness colon (Sham n=4, BDL n=6) 
  * denotes p<0.05 
 
Connexin-43 
Connexin 43 is a gap junction protein which plays a key role in restitution of the 
intestinal epithelial layer by allowing inter-enterocyte communication of migrating 
epithelial cells (Leaphart CL et al 2007). Expression of Connexin-43 is therefore 
indicative of degree of restitution.  
 
Figure 7.20  Connexin-43 protein expression in full thickness duodenum (Sham n=4, BDL 
n=6) 
  * denotes p<0.05 
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iNOS 
 
Figure 7.21 Duodenal iNOS expression in full thickness duodenum (Sham n=4, BDL n=6) 
  * denotes p<0.05 
 
eNOS 
 
Figure 7.22 Duodenal eNOS expression in full thickness duodenum (Sham n=4, BDL 
n=6) 
  * denotes p<0.05 
 
No significant difference in claudin-3 expression was observed along the length of 
the small and large bowel although a significant decrease in ZO-1 expression was 
observed in the colon of BDL rats. A significant reduction in gap junction connexion-
43 was observed in full thickness duodenum in BDL rats compared to sham controls. 
A significant increase in full thickness duodenal iNOS protein expression was 
observed in BDL rats compared to sham controls. No significant difference in eNOS 
protein expression was observed.  
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7.3.6 Stool Microbiome Composition 
 
7.3.6.1 Phyla Level 
a           b  
 
 
Figure 7.23 Microbiome composition of stool (phyla level) (n=6 both groups) 
 
a) Sham rats  b) Bile duct ligated rats  
 
At a phyla level, bacteroides and firmicutes are the dominant phylae, comprising over 
95% of stool microbiome. Bile duct ligation was associated with an expansion in the 
relative population of the Firmicutes phyla compared to sham rats (Sham 38.0+9.2% 
vs BDL 59.0+7.2%, p>0.05). A reciprocal reduction in the Bacteroides phyla was 
observed (Sham 59.0+9.6% vs BDL 39.0+7.3%, p>0.05).  
 
 
 
 
 
 
Bacteroides Firmicutes Proteobacteria Other 
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7.3.6.2 Order level 
a                 b 
  
 
Figure 7.24 Microbiome composition of stool (order level) (n=6 both groups) 
a) Sham rats untreated 
b) Bile duct ligated rats untreated 
 
Bacteroidia and clostridia were the dominant orders, comprising over 90% of stool 
microbiome. The expansion in the Firmicutes phyla was principally due to an 
expansion in the clostridia order (Sham 36.3+9.6% vs BDL 58.0+7.3%, p>0.05). A 
non-significant reduction in Bacteroidia was observed (Sham 57.5+9.7% vs BDL 
36.3+7.1%, p>0.05). 
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7.3.6.3 Family level 
 
a.                b.      
 
 
Figure 7.25  Microbiome composition of stool (family level) (n=6 both groups) 
a) Sham rats   b) Bile duct ligated rats  
 
Bile duct ligation was associated with significant reductions in 
Peptostreptococcaceae (Sham 8.2+1.7% vs BDL 0+0%, p=0.005) and significant 
increases in Porphyromonadaceae (Sham 24.7+3.9% vs BDL 42.1+4.5%, p=0.004) 
compared to sham controls. Prevotellaceae was the dominant family in sham rats. A 
near significant reduction in Prevotellaceae and increase in Ruminococcaceae was 
observed in BDL rats compared to sham (Sham 42.6+12.9% vs BDL 6.3+1.8%, 
p=0.07 and Sham 28.5+9.8% vs BDL 49.3+6.6%, p=0.09 respectively).  
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7.3.6.4 Genus Level 
a.     b. 
 
c.      
 
Figure 7.26 Geni in which significant differences between groups of sham and bile duct 
ligated rats were observed (n=6 both groups): 
a) Clostridium XI 
b) Clostridium XIVb 
c) Peptostreptococcaceae 
* denotes p<0.05 
***  denotes p<0.001 
 
 
BDL rats were found to have a collapse in clostridium XI and peptostreptococcaceae 
geni and expansion in Clostridium XIVb. 
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7.3.7 Metabolomic Profiling (urinary 1NMR analysis) 
 
Figure 7.27 Relative urinary concentrations of metabolites in BDL compared to sham 
(n=6 both groups) 
 
Bile duct ligation is associated with a distinct metabolomic profile as compared to 
sham controls. Significant increases in urinary bile acids, Trimethylamine oxidase 
(TMAO), betaine and lactate were and reductions in citrate, dimethylarginine (DMA) 
and creatinine were observed between BDL rats compared to sham controls.  
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7.3.8 Immunological Profiling 
7.3.8.1 Population Studies 
7.3.8.1.1 Liver 
(a) Kupffer cell Populations 
 
(b) Liver neutrophil Population 
 
 
Figure 7.28 Hepatic neutrophil population was observed in bile duct ligated rats 
compared to sham controls (expressed as a percentage of non-parenchymal 
cell fraction). (n=4/group)  * denotes p<0.05 
  (a) Kupffer cell populations 
  (b) Liver neutrophil populations 
 
Bile duct ligation was is associated with an expansion in hepatic innate immune cell 
populations. In this study, a significant increase in hepatic neutrophil populations was 
observed in 4 week BDL rats associated with a trend towards an increase Kupffer 
cell populations.  
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7.3.8.1.2 Portal Venous/Arterial Blood 
 
 Total 
WCC¥ 
(A) 
Total 
WCC¥ 
(PV) 
Neutrophil 
count¥ (A) 
Neutrophil 
count¥ 
(PV) 
Monocyte 
count¥ 
(A) 
Monocyte 
count¥(PV) 
Sham 1.2+0.1 1.5+0.04 0.3+0.1 0.3+0.5 0.1+0.03 0.1+0.02 
BDL 8.9+1.5# 11.1+1.4# 2.6+0.4#  3.3+0.5# 2.9+0.9# 3.6+1.3# 
¥(x107cells/ml); # P<0.05 (BDLvs sham) 
Table 7.1  Absolute Leucocyte Populations in Sham and BDL rats (n=4/group) 
 
A significant increase in both portal venous and arterial total leucocyte count, 
monocyte and neutrophil populations were observed in BDL rats compared to sham. 
Subpopulations of monocytes defined by relative CD43 expression were determined 
in both portal venous and arterial blood to ascertain whether phenotypic changes 
were associated with monocyte subpopulations. A significant reduction in CD43lo 
monocytes was observed in both portal venous and arterial blood. No difference was 
observed between these two compartments.  
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7.3.8.1.3 Mesenteric lymph node populations 
(a) Absolute CD68+population      (b) Percentage CD68+ population  
 
 
(c) Absolute CD68+/CD80+ population (d) Percentage CD68+/CD80+ population 
 
 
(e) Absolute CD163+ population (f) Percentage CD163+ population  
    
Figure 7.29 Mesenteric Lymph Node populations (n=4/group) 
 
(a) Absolute CD68+ population 
(b) PercentageCD68+ population  
(c) Absolute CD68+/CD80+ population 
(d) Percentage CD68+/CD80+ population 
(e) Absolute CD163+ population 
(f) Percentage CD163+ population 
 
MLN population studies were performed using CD68, CD80 and CD163 staining. 
CD68 and CD80 are both more highly expressed in activated macrophages with a 
more pro-inflammatory, M1 phenotype. In contrast, CD163 is expressed on M2 
macrophages with a more anti-inflammatory phenotype. 
	 	
	 	
	 	
163 
 
No significant differences in CD68+, CD163+ or CD80/68+ cells were observed 
between BDL and sham. A non-significant decrease in percentage population of 
CD68+ and CD163+ cells was observed in the mesenteric lymph nodes of bile duct 
ligated rat with an upward trend in CD80+CD68+ cells. When MLN populations were 
expressed as absolute counts, trends towards increases within the CD68+, 
CD68/80+, CD163+ populations were observed. This may represent expansion in 
macrophage populations but without a marked polarisation of macrophage 
phenotype. The studies are however small and warrant further validation. 
7.3.8.2 Reactive Oxidant Species (ROS) Production  
7.3.8.2.1 Liver 
 (a) Total Liver ROS    (b) Total Liver LPS ROS 
 
   
 
(c) Kupffer Cell ROS    (d) Kupffer Cell LPS ROS 
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(e) Liver neutrophil ROS   (f) Liver neutrophil LPS ROS 
 
   
 
 
Figure 7.30  Hepatic ROS production (Sham n=4, BDL n=4) 
(a) Total liver ROS production 
(b) Total liver ROS production in response to ex-vivo LPS challenge 
(c) Total Kupffer cell ROS production 
(d) Total liver ROS production in response to ex-vivo LPS challenge 
(e) Total hepatic neutrophil ROS production 
(f) Total hepatic neutrophil ROS production in response to ex-vivo LPS challenge 
* denotes p<0.05 
7.3.8.2.2 Portal Venous Populations 
7.3.8.2.2.1 Portal venous neutrophil ROS production 
(a)      (b) 
  
(c) 
 
 
Figure 7.31  
 
(a) Total Portal Venous Neutrophil ROS production  
(b) Total Portal Venous Neutrophil ROS production in response to ex-vivo LPS challenge 
(c) % Increase in Portal Venous Neutrophil ROS production as a marker of cellular priming to 
endotoxin challenge (n=4/group)  * denotes p<0.05 
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7.3.8.2.2.2 Portal Venous Monocyte ROS production 
(a)      (b) 
  
(c) 
   
 
Figure 7.32 
 
(a) Total Portal Venous Monocyte ROS production  
(b) Total Portal Venous Monocyte ROS production in response to ex-vivo LPS challenge 
(c) % Increase in Portal Venous Monocyte ROS production as a marker of cellular priming to 
endotoxin challenge (n=4/group)  * denotes p<0.05 
ROS production by Portal Venous Monocyte Subpopulations 
(a)     (b) 
 
(c)     (d) 
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Figure 7.34 
(a) Total Portal Venous CD43 hi Monocyte ROS production  
(b) Total Portal Venous CD43hi Monocyte ROS production in response to ex-vivo LPS 
challenge 
(c) Total Portal Venous CD43 lo Monocyte ROS production  
(d) Total Portal Venous CD43lo Monocyte ROS production in response to ex-vivo LPS 
challenge (n=4/group)  * denotes p<0.05 
 
 
Bile duct ligation was associated with a significant increase in portal venous 
neutrophil and monocyte constitutive ROS and LPS-induced ROS production. When 
expressed as a ratio of LPS-induced ROS:constitutive ROS, a significant increase 
was observed suggestive of increased endotoxin sensitivity. Significant increases in 
LPS-induced ROS production were observed in both CD43 hi and lo monocyte 
subpopulations. Constitutive ROS was significantly raised in CD43hi with an upward 
trend observed with CD43lo monocyte constitutive ROS production.  
 
7.3.8.3 Phagocytosis 
(a) Kupffer Cell    (b) Liver Neutrophils 
  
Figure 7.35  Percentage population actively phagocytosing a minimum of 3 particles 
(n=4/group) 
(a) Kupffer cell 
(b) Liver neutrophils 
 
ROS production from the non-parenchymal fraction of liver-derived cells was found to 
be significantly raised in BDL rats compared to sham control. Of this fraction, both 
constitutive and LPS-ROS production from hepatic neutrophils were found to be 
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significantly raised in BDL rats compared to control. An upward trend in Kupffer cell 
ROS production was observed in BDL rats with borderline significance achieved with 
regards to LPS-induced ROS production.  No significant difference in Kupffer cell or 
liver neutrophil phagocytosis was observed. 
 
7.3.9 Portal Venous Cytokines 
 
(a)      (b) 
 
(c) 
 
Figure 7.36 
 
(a) Portal Venous plasma TNFα levels 
(b) Portal Venous IL-4 levels 
(c) Portal Venous IL-10 levels 
(n=4/group) 
 
No significant differences in portal venous TNFα, IL4 or IL10 concentrations were 
observed between sham and BDL. Upward trends were observed with IL4 and IL10 
in BDL rats.  
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7.4 Discussion 
7.4.1 Structural phenotype 
Intestinal permeability is known to be increased in cirrhosis and an important factor 
promoting bacterial translocation. Despite this, the exact site of bacterial 
translocation remains poorly understood. Therefore, studies along the length of the 
small and large intestine in a model of cirrhosis were performed. The first study 
evaluated light microscopy appearances of duodenum, jejunum, ileum and colon with 
full thickness sections and associated mesentery. This was complemented by 
studies looking at tight junction and jap junction protein expression and correlated 
with functional studies to evaluate intestinal permeability using sugar probes studies. 
Mucosal integrity was preserved throughout the small and large intestine with subtle 
vascular changes at the level of the sub-mucosa in BDL rats. Perivascular 
inflammation was observed in the mesenteric vessels close to the peritoneal surface.  
With no clear breach in the mucosal surface, studies were conducted to evaluate 
ultra-structural changes in the duodenal and colonic mucosa. At both sites, integrity 
of the epithelial barrier was observed. Tight junctions, responsible for modulating 
paracellular intestinal permeability, were intact. A slight reduction in mitochondrial 
density was observed in duodenal mucosa in BDL rats. The duodenal microvilli in 
BDL rats was found to be slightly blunted compare to control and a slight increase in 
inter-villus distance was observed in disease models.  
Connexin-43 expression was found to be significantly increased in BDL rats. One 
potential explanation would be a required for increased enterocyte restitution. 
Certainly it is known that the oxidative stress in the gut of portal hypertensive rats is 
increased which is likely to result in heightened enterocyte turnover. For the time that 
restitution allows for compensation of any GI insult such as portal hypertension, 
apparent epithelial integrity is observed. It may be that in the context of more 
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advanced disease, this is not fully achieved and may contribute to the much higher 
rates of bacterial translocation observed in more advanced disease states.  
A significant increase in the relative expression of defensins 5 and 8 and lysozyme 
was observed in the terminal ileal tissue of BDL rats as compared to sham. No 
significant difference in TNFα gene expression was observed. Antimicrobial peptides 
derived from Paneth cells play a key role in the maintenance of homeostasis with the 
intestinal flora at the gut barrier interface. Paneth cells have also been implicated in 
the process of bacterial translocation in rat models of cirrhosis in context of carbon 
tetrachloride-induced liver injury and portal venous ligation. This study evaluates the 
role of the paneth cell function in a cholestatic model of liver cirrhosis. The data 
suggests that there is an association with cirrhosis and increased production of 
antimicrobial peptide production from Paneth cells. Whether this is causal or 
consequential is unclear.  
A significant increase in urinary lactulose excretion was observed in BDL rats 
compared to sham controls. Regrettably discrimination between rhamnose and 6-o-
methyl-glucose on mass spectroscopy was not possible which may have been 
secondary to trace contamination in the original sugar probes. Urinary 5 hour 
lactulose excretion, a reflection of paracellular permeability, was standardised to 
creatinine levels to control for renal function. Without the rhamnose data, we were 
unable to standardise for other factors which may confound the results such as 
gastric emptying rates and intestinal transit times. It is a crude measure of intestinal 
permeability but is consistent with previously published data.  
Finally, a significant increase in duodenal iNOS protein expression was observed in 
BDL rats compared to sham controls. No significant difference in eNOS protein 
expression was observed however. This is an interesting and novel observation and 
has since been confirmed in duodenal biopsy tissue from cirrhotic patients. iNOS is 
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produced by monocyte/macrophage populations as nitric oxide is a key factor in 
innate immune defence against bacteria. iNOS expression is largely induced rather 
than present constitutively and is responsive to IRF1 and NFkB-dependent signalling 
pathways. By this means, it produces nitric oxide, often in large quantities, in 
response to inflammatory cytokines often in the context of high oxidative stress. Nitric 
oxide itself can inhibit elements of the respiratory chain driving an increase in 
glycolysis. ATP depletion ultimately results in necrotic cell death. NO-mediated cell 
death requires first the production of peroxynitrite from NO and ROS with high 
cellular toxicity conferring potent anti-microbial properties but with the potential for 
host organ damage in the context of a dysregulated inflammatory response. 
Heightened reactive oxidant species derived from both circulating and tissue resident 
monocyte and macrophage populations is a cardinal feature of the disease state.  
 
7.4.2 Gut Microbiota 
A significant shift in microbiome composition is observed in BDL rats compared to 
sham controls associated with a distinct shift in urinary metabolomic profile. Bile salts 
are known to exert a differential bacteriostatic effect on the intestinal microflora and 
indeed bile salt deficiency secondary to cholestasis has been shown to be 
associated with dysbiosis. This shift in microbiome composition may be responsible 
for inducing the observed upregulation of paneth cell antimicrobial peptide 
production.  
Urinary NMR analysis is a reflection of the combined metabolic status of both host 
and microbiota. The bile duct ligated rat model is a model of cholestasis and is 
associated with a significant increase in urinary bile acid level concentration 
compared to sham controls. A significant reduction in urinary creatinine was also 
observed in BDL rats indicative of reduced renal function.  
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A significant increase in urinary lactate is observed in BDL rats. This parallels the 
observed increase in plasma lactate indicative of increased anaerobic metabolism. A 
heightened catabolic state in BDL rats is suggested by low plasma glucose levels 
and significant weight loss in the context of pair feeding. This is further exacerbated 
by impaired hepatocellular mitochondrial metabolism known to occur in this model.  
Microbial origin lactate production is unlikely to be a major contributory source in 
context of the microbiome results  
Trimethylamine oxidase (TMAO) and betaine are both breakdown products of dietary 
phosphatidylcholine. TMAO is formed from the oxidation of trimethylamine (TMA) 
and is a common metabolite in animals and humans. The key role of gut microflora in 
metabolism was demonstrated by a reduction in TMAO levels with selective gut 
decontamination with a quinolone. There has been considerable interest in TMAO as 
a pathogenic marker in atherosclerosis. This data highlights the importance in 
cirrhosis also. A significant rise in urinary betaine was observed in BDL rats. Betaine 
is a metabolic product of gut bacteria and is indicative of the increased dysbiosis 
evident in the BDL model.  
A significant reduction in urinary citrate was observed in BDL rats compared to sham 
operated animals. Urinary citrate concentrations are influenced significantly by the 
integrity of the proximal convoluted tubules and degree of acidosis, both of which are 
observed in the BDL model.  
 
7.4.3 Immunological Phenotype 
The phenotype of the innate immune response in the BDL rat is one of a heightened 
primed state to endotoxin challenge most markedly with regards to ROS production. 
This phenotype is observed across the different vascular and tissue compartments. 
Total liver ROS production was increased in BDL rats compared to sham controls. 
Both Kupffer cell (CD163+ gated non-parenchymal cells) and liver neutrophils 
exhibited a trend towards increased ROS production in BDL compared to sham but 
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no significant difference in phagocytosis. Portal venous monocytes and neutrophils 
exhibited a state of heightened endotoxin sensitivity with regards to ROS production. 
This may be due to a heightened primed state due to previous endotoxin exposure.  
A significant increase in liver neutrophil population was observed with BDL compared 
to sham. In contrast, only an upward trend in Kupffer cell populations was observed 
with cirrhotic rats. This data suggests that infiltrating innate immune populations from 
the gut play a greater role in pathogenesis than tissue resident populations.  
Phenotypically, the trafficking innate immune cell populations within the portal vein of 
BDL rats are characterised by an endotoxin-primed state resulting in a significant 
increase in ROS production. This effect is further compounded by the observation 
that the absolute populations of neutrophils and monocytes are significantly 
increased in the disease state compared to control. These cells are likely to have a 
significant impact on hepatocellular injury. 
Mesenteric lymph node studies were conducted to evaluate the local innate immune 
response to determine whether the innate immune phenotype of heightened 
endotoxin sensitivity was conditioned at the gut-barrier interface or in more proximal 
lymphatics. A non-significant increase in CD80+/CD68+ populations were observed 
in mesenteric lymph node populations of BDL rats suggesting a skew toward the pro-
inflammatory Th1 phenotype. This data suggests that the pro-inflammatory 
phenotype observed in BDL rats may be conditioned in part at the level of the gut.  
In conclusion, multiple elements of the gut-liver axis are modulated in a model of 
cirrhosis. A phenotype of enhanced endotoxin sensitivity is observed in association 
with a shift in microbiome composition and metabolomic profile. Subsequent work will 
focus on the biological effects of modulating the gut liver axis with Yaq-001, a 
powerful non-absorbable endotoxin and bacterial metabolite adsorbant in a model of 
cirrhosis and non-alcoholic fatty liver disease. 
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Chapter 8 
Biological Effects of Oral Administration of Yaq-001 Carbon Therapy in 
Bile Duct Ligated Rats 
 
8.1 Introduction 
Bacterial translocation plays a key role in the pathogenesis of liver disease. 
Modulation of the gut microflora with oral antibiotics has been shown to improve 
outcome but attendant risks of resistance and super-infection limits their role. Yaq-
001 is a non-absorbable activated carbon with a tailored bimodal porosity conferring 
optimal adsorptive properties to bind pathologically relevant gut-derived factors 
including endotoxin and bacterial metabolites. These in vitro properties render oral 
Yaq-001 a good candidate to modulate clinically relevant end-points in cirrhosis. 
 
8.2 Aims 
The aim of this study was to characterise the biological effects of oral administration 
of Yaq-001 in bile duct ligated rats. The primary end-points were reduction in organ 
injury and portal pressure. The secondary end points were improvement in gut 
barrier function and attenuation in primed innate immune phenotype. Microbiome 
composition and function was evaluated to ascertain whether the carbons, despite 
not exhibiting an antibiotic effect in vitro, were able to shape the microbiome 
composition and function towards a more autocthonous phenotype.  
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8.3 Results 
8.3.1 Biochemical Profile 
As previously described, bile duct ligation was observed to be associated with a 
significant increase in ALT, a biochemical marker of liver injury. A significant 
reduction in alanine transaminase (ALT) was observed in the carbon treated BDL 
and BDL+LPS groups compared to untreated groups. Carbon treatment was 
associated with a reduction in ALT from 73.95 + 4.10 IU/ml to 61.02 + 3.71U/ml 
(p<0.05) in BDL rats.  
 
  
 
Figure 8.1 Biochemical response to oral Yaq-001 carbon therapy  
(a) Alanine transaminase (Sham n=23, Sham+C n=19, BDL n=25, BDL+C n=25) 
(b) Alkaline phosphatase (Sham n=21, Sham+C n=16, BDL n=25, BDL+C n=26) 
(c) Albumin (Sham n=22, Sham+C n=16, BDL n=24, BDL+C n=25) 
(d) Creatinine (Sham n=23, Sham+C n=18, BDL n=24, BDL+C n=25) 
* denotes p<0.05 
***  denotes p<0.001 
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8.3.2 Haemodynamic Profile 
(a)         
(b)  
Figure 8.2 Haemodynamic Response to oral Yaq-001carbon therapy 
(a) Portal Pressure (Sham n=21, Sham+C n=22, BDL n=14, BDL+C n=25) 
(b) Mean Arterial Pressure (Sham n=13, Sham+C n=15, BDL n=12, BDL+C 
n=14) * denotes p<0.05 ***  denotes p<0.001 
 
 
A significant reduction in portal pressure was observed in BDL rats from 12.23 + 0.45 
mmHg untreated to 11.10 + 0.23 mmHg with carbon, p<0.05) groups following 
carbon treatment. No significant change in mean arterial pressure was observed.  
The effect size, as evidenced by Cohen’s d, is 0.996 and therefore represents a large 
biological effect of Yaq-001 in this context.  
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8.3.3 Immunological Phenotype 
8.3.3.1 Population studies 
8.3.3.1.1 Liver 
Kupffer cell population 
 
Figure 8.3 CD163+ gated liver non-parenchymal cell fraction as expressed as a 
percentage of the parent population in sham, bile duct ligated and carbon treated bile 
duct ligated rats (n=4/group)  * denotes p<0.05 
 
Liver Neutrophil Population 
   
Figure 8.4 Liver neutrophil populations as expressed as a percentage of the 
parent liver non-parenchymal cell population in sham, bile duct ligated and carbon 
treated bile duct ligated rats. (n=4/group)  * denotes p<0.05 
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 Sham    BDL    BDL+C 
Figure 8.5 Plots demonstrating gating strategy for populations of liver non-
parenchymal cells in sham, bile duct ligated and carbon treated bile duct ligated rats  
 
Bile duct ligation was associated with a significant increase in liver neutrophil 
population with an upward trend in Kupffer cell (CD163+) populations. Oral Yaq-001 
therapy resulted in a significant reduction in CD163+ populations in BDL rats with no 
impact on liver neutrophil populations.  
8.3.3.1.2 Arterial and Portal Venous blood populations 
(a)      (b) 
 
(c)      (d)  
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(e)      (f) 
 
Figure 8.6 Absolute arterial and portal venous total, neutrophil and monocyte 
populations in sham, carbon treated sham, bile duct ligated and carbon treated bile 
duct ligated rats(n=4/group)  * denotes p<0.05 
a) Absolute leucocyte count in arterial blood (x107 cells/ml) 
b) Absolute leucocyte count in portal venous blood (x107 cells/ml) 
c) Absolute neutrophil count in arterial blood (x107 cells/ml) 
d) Absolute neutrophil count in portal venous blood (x107 cells/ml) 
e) Absolute monocyte count in arterial blood (x107 cells/ml) 
f) Absolute monocyte count in portal venous blood (x107 cells/ml) 
 
Monocyte subpopulations 
(a)     (b) 
 
(c)     (d) 
 
 
Figure 8.7 Arterial and portal venous monocyte subpopulations as expressed as 
a percentage of total monocyte count in sham, carbon treated sham, bile duct ligated 
and carbon treated bile duct ligated rats. (n=4/group) * denotes p<0.05 
a) Portal venous CD43hi monocyte populations 
b) Arterial CD43hi monocyte populations 
c) Portal venous CD43lo monocyte populations 
d) Arterial CD43lo monocyte populations 
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Significant expansions in total leucocyte, neutrophil and monocyte counts were 
observed with BDL rats compared to sham controls. Oral carbon therapy resulted in 
a significant reduction in neutrophil count with non-significant downward trends 
observed with total leucocyte and monocyte counts. No significant differences in total 
leucocyte, neutrophil or monocyte populations were observed between arterial and 
portal venous blood.  
Monocyte subpopulations were evaluated to determine whether bile duct ligation 
resulted in polarisation of monocyte subpopulations and if so, whether carbon 
therapy could modulate this. Bile duct ligation was associated with a significant 
increase in the CD43hi  sub-population at the expense of CD43lo. Carbon therapy had 
no significant effect on the composition of monocyte subpopulations.  
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8.3.3.2.3 Mesenteric Lymph Node populations 
(a) Mesenteric Lymph Node CD68+ population 
      
(b) Mesenteric Lymph Node CD68+ absolute population 
 
Figure 8.8 CD68+ gated mesenteric lymph node populations in sham, carbon 
treated sham, bile duct ligated and carbon treated bile duct ligated rats 
a) Relative populations (%total mesenteric lymph node cells) 
b) Absolute populations (cells/ml) 
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(a) Mesenteric Lymph Node CD68+CD80+ population 
          
(b) Mesenteric Lymph Node absolute CD68+CD80+ populations
 
Figure 8.9 CD68+/CD80+ gated mesenteric lymph node populations in sham, 
carbon treated sham, bile duct ligated and carbon treated bile duct ligated rats. 
(n=4/group)  * denotes p<0.05 
a) Relative populations (%total mesenteric lymph node cells) 
b) Absolute populations (cells/ml) 
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(a) Mesenteric Lymph Node CD163+ population 
        
(b) Mesenteric Lymph Node absolute CD163+ population 
 
Figure 8.10 CD163+ gated mesenteric lymph node populations in sham, carbon 
treated sham, bile duct ligated and carbon treated bile duct ligated rats. (n=4/group) 
* denotes p<0.05 
a) Relative populations (%total mesenteric lymph node cells) 
b) Absolute populations (cells/ml) 
 
No significant shifts in mesenteric lymph node populations were observed although 
bile duct ligation does appear to be associated with an upward trend in absolute 
CD163+ and CD68+ population. Carbon therapy appears to result in a downward 
trend in absolute CD163+ CD68+ mesenteric lymph node populations in BDL rats 
towards untreated sham controls.  
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8.3.3.2 ROS production 
8.3.3.2.1 Liver 
Total Liver ROS 
 
Figure 8.11 Total reactive oxidant species production in liver non-parenchymal cell 
fraction as expressed as a percentage of the parent population in sham, bile duct 
ligated and carbon treated bile duct ligated rats. (n=4/group)        * denotes p<0.05 
 
Kupffer cell ROS production 
Constitutive ROS 
 
Figure 8.12 Constitutive reactive oxidant species production in CD163+-gated liver 
non-parenchymal cell fraction as expressed as a percentage of the parent population 
in sham, bile duct ligated and carbon treated bile duct ligated rats. (n=4/group)  
* denotes p<0.05 
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LPS-induced ROS production 
 
Figure 8.13 Lipopolysaccharide-induced reactive oxidant species production in 
CD163+-gated liver non-parenchymal cell fraction as expressed as a percentage of 
the parent population in sham, bile duct ligated and carbon treated bile duct ligated 
rats (n=4/group).   * denotes p<0.05 
 
Liver neutrophil ROS production 
Constitutive ROS production 
 
Figure 8.14 Constitutive reactive oxidant species production in neutrophil-gated 
liver non-parenchymal cell fraction as expressed as a percentage of the parent 
population in sham, bile duct ligated and carbon treated bile duct ligated rats. 
(n=4/group) 
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LPS-induced ROS production 
 
Figure 8.15 Lipopolysaccharide-induced reactive oxidant species production in 
neutrophil-gated liver non-parenchymal cell fraction as expressed as a percentage of 
the parent population in sham, bile duct ligated and carbon treated bile duct ligated 
rats. (n=4/group) * denotes p<0.05 
 
Bile duct ligation was found to be associated with a significant increase in total ROS 
production within the liver total non-parenchymal cell (NPC) fraction with an upward 
trend in constitutive ROS production in CD163+-gated non-parenchymal cells. Oral 
carbon therapy was associated with a significant attenuation in constitutive ROS 
production in the NPC fraction of BDL rats. Whilst a downward trend in constitutive 
ROS was observed in CD163+-gated populations, this did not achieve statistical 
significance. No significant differences were observed in liver neutrophil constitutive 
ROS. The discordance may be accounted for by non-parenchymal liver cell 
populations other than Kupffer cells and neutrophils. These include stellate cells, 
cholangiocytes, sinusoidal endothelial cells and intrahepatic lymphocytes.  
Despite these observations, Yaq-001 therapy was associated with a significant 
reduction in LPS-induced ROS production in BDL rats. This is suggestive that the 
carbon therapy has a particular effect on LPS-sensitivity, diminishing the primed 
state observed in BDL rats. No significant differences were observed in LPS-induced 
neutrophil ROS between sham and BDL and untreated and Yaq-001-treated BDL 
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rats. Marked heterogeneity in neutrophil LPS-induced ROS production were 
observed in BDL rats contributing to the broad standard error values. In the light of 
such heterogeneity and small group numbers, statistical significance was not 
observed.  
8.3.3.2.2 ROS production (Portal Venous blood) 
Monocyte populations 
 
Figure 8.16 Constitutive and lipopolysaccharide-induced reactive oxidant species 
production in portal venous monocytes as expressed as a percentage of total 
monocyte count in sham, carbon treated sham, bile duct ligated and carbon treated 
bile duct ligated rats. (n=4/group)  * denotes p<0.05 
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Monocyte subpopulations 
  
Figure 8.17 Constitutive and lipopolysaccharide-induced reactive oxidant species 
production in portal venous monocyte subpopulations as expressed as a percentage 
of total monocyte count in sham, carbon treated sham, bile duct ligated and carbon 
treated bile duct ligated rats. (n=4/group) * denotes p<0.05 
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Neutrophil populations 
 
Figure 8.18 Constitutive and lipopolysaccharide-induced reactive oxidant species 
production in portal venous neutrophils as expressed as a percentage of total 
monocyte count in sham, carbon treated sham, bile duct ligated and carbon treated 
bile duct ligated rats. (n=4/group) * denotes p<0.05 
 
Functionally, bile duct ligation was associated with a significant increase in 
constitutive and LPS-induced ROS production from portal venous monocytes and 
neutrophils. Carbon therapy resulted in a significant attenuation of portal venous 
monocyte LPS-induced ROS production in BDL rats suggestive of a diminished 
primed state to endotoxin challenge. This effect was observed within the CD43hi 
monocyte sub populations.  In contrast, no significant differences in portal venous 
neutrophil phenotype were observed with carbon therapy in BDL rats although 
downward trends towards sham controls were observed. Regulation of endotoxin 
sensitivity is regulated most stringently in monocyte/macrophage populations. They 
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are considered the cellular mediators of endotoxin tolerance and phenotype most 
responsive to changes in endotoxin concentrations. This may account for the 
differential effect of Yaq-001 on LPS-induced ROS production in portal venous blood.  
 
8.3.3.2.3 Phagocytosis 
Kupffer Cell Phagocytosis 
 
Figure 8.19 Phagocytosis of bead particles in CD163+-gated liver non-
parenchymal cell fraction as expressed as a percentage of the parent population in 
sham, bile duct ligated and carbon treated bile duct ligated rats. (n=4/group) 
 
Liver Neutrophil Phagocytosis 
P3-gated 
 
Figure 8.20 Phagocytosis of bead particles (P3-gated) in neutrophil-gated liver 
non-parenchymal cell fraction as expressed as a percentage of the parent population 
in sham, bile duct ligated and carbon treated bile duct ligated rats. P3=phagocytosis 
of 3 or more beads. (n=4/group) 
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Total Phagocytosis 
 
Figure 8.21 Phagocytosis of bead particles in neutrophil-gated liver non-
parenchymal cell fraction as expressed as a percentage of the parent population in 
sham, bile duct ligated and carbon treated bile duct ligated rats. (n=4/group) 
 
No significant differences in phagocytosis were observed between sham , BDL and 
carbon-treated BDL rats. A downward trend towards sham control values were 
observed with carbon-treated BDL rats. 
Gating strategy for phagocytosis assays 
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Figure 8.22 Plots demonstrating gating strategy for populations of whole blood in 
sham, carbon treated sham, bile duct ligated and carbon treated bile duct ligated rats  
 
 
 
 
 
 
193 
 
 
 
Figure 8.23 Histograms demonstrating gating strategy for populations of whole 
blood in sham, carbon treated sham, bile duct ligated and carbon treated bile duct 
ligated rats  
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8.3.3.4 Inflammasome activation 
 
 
Figure 8.24 (a) Inflammasome activation with arterial plasma in HEK reporter cells 
  (b) TLR4 activation with arterial plasma in HEK reporter cells 
(n=4/group) * denotes p<0.05 
 
Bile duct ligation was associated with a significant increase in inflammasome 
activation which was attenuated with carbon therapy. Similar trends were observed 
with TLR4 reporter cell lines but did not achieve statistical significance.  
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8.3.3.5 Terminal Ileal TNFα gene expression 
 
Figure 8.25 Relative expression of TNFα in terminal ileal tissue of sham, sham+ 
carbon, BDL, BDL+carbon (n=4/group)   * denotes p<0.05 
 
No significant increase in terminal ileal TNFα gene expression was observed. Carbon  
therapy resulted in a borderline significant reduction increase in terminal ileal TNFα 
gene expression. 
 
8.3.4 Gut Barrier Integrity 
8.3.4.1 Intestinal Permeability Assays 
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Figure 8.26 5 hour urinary excretion of lactulose, rhamnose and 6-OMG in sham, 
sham+LPS, BDL, BDL+LPS, BDL+carbon, BDL+LPS+carbon. (n=4/group) 
* denotes<0.05  
 
Progressive increases in intestinal permeability as evidenced by increased excretion 
of lactulose, rhamnose and 6-o-methyl-glucose is observed with bile duct ligation and 
BDL with intraperitoneal LPS challenge. Carbon therapy resulted in a significant 
reduction in urinary excretion of lactulose, rhamnose and 6-o-methyl-glucose. Yaq-
001 exhibits preferential adsorption for hydrophobic compounds. In principal 
therefore, Yaq-001 should not bind the sugar probes in this study. 
 
8.3.4.2 Paneth Cell Gene Expression Data 
(a) 
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(b) 
 
(c) 
 
Figure 8.27  Relative gene expression in the terminal ileum of sham and BDL rats 
with and without carbon therapy regards to: 
a. defensin 8 
b. defensin 5 
c. lysozyme 2 
 
Significant increases in gene expression Paneth cell markers defensins 5,8 and 
lysozyme 2 was observed in terminal ileal tissue of BDL rats compared to sham 
controls. Downward trends in defensin 5 and 8 gene expression were observed with 
carbon-treated BDL rats although no significant changes were observed with 
lysozyme expression. 
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8.3.4.3 Nutrition 
8.3.4.3.1 Weight 
 
Figure 8.28 Final body weight in sham, carbon treated sham, bile duct ligated and 
carbon treated bile duct ligated rats. . (n=4/group)  * denotes<0.05 
 
8.3.4.3.2 Micronutrients and electrolytes 
 
Figure 8.29 Plasma folate concentrations in sham and carbon treated sham rats 
(n=6/group)  * denotes<0.05 
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Figure 8.30 Plasma micronutrient and electrolyte concentrations in sham and 
carbon treated sham rats (n=6/group) * denotes<0.05 
 
Bile duct ligation was associated with a significant reduction in final body weight. 
Carbon treatment results in a significant improvement in 4 week body weight. No 
significant effect on micronutrient and electrolyte profile was observed with the 
exception of folate.  
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8.3.4.3.2 Primary Bile acid profile 
Cholic acid 
 
Glycocholic acid   Taurocholic acid 
  
 
Figure 8.31 Arterial concentrations of cholic acid and derivatives in sham, carbon 
treated sham, BDL and BDL+carbon rats at 4 weeks post-surgery (n=6/group) 
* denotes<0.05 
  a) Cholic acid 
  b) Glycocholic acid 
  c) Taurocholic acid 
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Chenodeoxycholic acid 
 
Glycochenodeoxycholic acid  Taurochenodeoxycholic acid 
   
Figure 8.32 Arterial concentrations of chenodeoxycholic acid and derivatives in 
sham, carbon treated sham, BDL and BDL+carbon rats at 4 weeks post-surgery 
(n=6/group)  * denotes<0.05 
 
  a) Chenodeoxycholic acid 
  b) Glycochenodeoxycholic acid 
  c) Taurochenodeoxycholic acid 
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Secondary Bile acids 
Deoxycholic Acid 
 
Glycodeoxycholic acid   Taurodeoxycholic acid 
   
Figure 8.33 Arterial concentrations of deoxycholic acid and derivatives in sham, 
carbon treated sham, BDL and BDL+carbon rats at 4 weeks post-surgery 
(n=6/group)  * denotes<0.05 
 
  a) Deoxycholic acid 
  b) Glycodeoxycholic acid 
  c) Taurodeoxycholic acid 
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Lithocholic acid 
 
Glycolithocholic acid   Taurolithocholic acid 
   
Figure 8.34 Arterial concentrations of lithocholic acid and derivatives in sham, 
carbon treated sham, BDL and BDL+carbon rats at 4 weeks post-surgery 
(n=6/group)  * denotes<0.05 
 
  a) Lithocholic acid 
  b) Glycolithocholic acid 
  c) Taurolithocholic acid 
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Ursodeoxycholic acid 
 
Glycoursodeoxycholic acid Tauroursodeoxycholic acid 
   
Figure 8.35 Arterial concentrations of ursodeoxycholic acid and derivatives in 
sham, carbon treated sham, BDL and BDL+carbon rats at 4 weeks post-surgery 
(n=6/group)  * denotes<0.05 
  a) Ursodeoxycholic acid 
  b) Glycoursodeoxycholic acid 
  c) Tauroursodeoxycholic acid 
 
 
Muricholic acid 
 
Figure 8.36 Arterial concentrations of muricholic acid in sham, carbon treated 
sham, BDL and BDL+carbon rats at 4 weeks post-surgery (n=6/group) 
 * denotes<0.05 
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Bile duct ligation was found to be associated with a marked reduction in several 
unconjugated plasma bile acids. Significant reductions were observed with primary 
bile acids cholic acid, chenodeoxycholic acid and secondary bile acids 
ursodeoxycholic acid, lithocholic acid and a near significant reduction with 
deoxycholic acid (p=0.05). Alpha muricholic acid, a rodent FXR antagonist was also 
found to be significantly depleted with bile duct ligation as compared to sham.  
A significant reduction in deoxycholic acid was observed in carbon-treated sham rats 
compared to untreated controls. Non-significant downward trends in several bile 
acids were observed in carbon-treated sham rats compared to sham controls (albeit 
in context of wide standard error margins).  
A significant 16 fold increase in urinary bile acids was observed with bile duct ligated 
rats compared to sham controls. No significant increases were observed with carbon 
treated sham or BDL compared to untreated controls.  
One potential explanation for differential bile acid adsorption is that Yaq-001 has 
preferential adsorption for hydrophobic compounds. Bile acids differ in their 
hydrophobicity as illustrated in figure x with more hydrophobic compounds implicated 
in hepatotoxicity, cholestasis, necrosis and apoptosis of hepatocytes. We did 
observe significant reductions in arterial secondary bile acids LCA, DCA but not total 
primary bile acids CA and CDCA in sham operated rats. Against this argument is the 
observation that Yaq-001 did also bind the more hydrophilic bile acids aMCA and b-
MCA. More hydrophilic compounds are generally hepatoprotective and hydrophobic 
more hepatotoxic. The net effect on liver injury is a function of the combination and 
size of the bile acid pool. FXR signaling is an important component of the gut-liver 
axis. Adsorption of bile acids has the potential to alter this however, biochemically a 
net improvement in liver injury is observed with Yaq-001 which is the most important 
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end point. Further studies are required to determine the effect of Yaq-001 on FXR 
pathways and total bile acid pool. 
 
 
Figure 8.37 Hydrophobicity Index of Bile Acids 
 
 
 
 
 
 
 
 
 
 
 
 
αMCA  Hydrophilic   Hepatoprotective 
βMCA    
UCDA    
CA     
CDCA    
DCA     
LCA   Hydrophobic       Hepatotoxic 
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8.3.5 Stool Microbiome (Phylogenic Studies) 
8.3.5.1 Phyla Level 
 
 
Figure 8.37  Phylogenic profile of stool (phyla level) 
a) Sham rats untreated 
b) Bile duct ligated rats untreated 
c) Sham rats with carbon treatment 
d) Bile duct ligated rats with carbon treatment 
 
Bile duct ligation was associated with an expansion in the relative population of the 
Firmicutes phyla compared to sham rats (Sham 38.0+9.2% vs BDL 59.0+7.2%, 
p>0.05). A reciprocal reduction in the Bacteroides phyla was observed (Sham 
59.0+9.6% vs BDL 39.0+7.3%, p>0.05). Yaq-001 treatment was associated with near 
significant increases in Firmicutes (BDLC 74.3+4.4% vs BDL 59.0+7.2%, p=0.05) 
and reductions in Bacteroides (BDLC 23.4+4.0% vs BDL 39.0+7.3%, p=0.07) in BDL 
rats. No effect was observed with Yaq-001 in sham controls.  
Bacteroides Firmicutes Proteobacteria Other 
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8.3.5.2 Order level 
 
    
Figure 8.38 Phylogenic profile of stool (order level) 
a) Sham rats untreated 
b) Bile duct ligated rats untreated 
c) Sham rats with carbon treatment 
d) Bile duct ligated rats with carbon treatment 
 
Yaq-001 treatment was associated with significantly lower Bacteroidia populations in 
BDL rats (BDLC 22.1+3.9% vs BDL 36.4+7.1% p=0.049). No significant difference in 
Bacteroidia populations was observed with carbon-treated sham rats (ShamC 
48.6+11.4 vs Sham 57.5+9.7%, p>0.05). Yaq-001 treatment was not associated with 
any significant differences in BDL or Sham rats (BDLC 71.6+4.7% vs BDL 57.5+7.3, 
p>0.05), (ShamC 36.3+9.5 vs Sham 36.3+9.6, p>0.05).  
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8.3.5.3 Family level 
 
 
Figure 8.39 Phylogenic profile of stool (family level) 
a) Sham rats untreated 
b) Bile duct ligated rats untreated 
c) Sham rats with carbon treatment 
d) Bile duct ligated rats with carbon treatment 
 
Bile duct ligated rats were found to have significantly higher populations of 
Porphyromonadaceae compared to sham controls (BDL 15.4+1.7% vs Sham 
9.0+1.4%, p=0.004). Yaq-001 significantly lowered the Porphyromonadaceae 
populations in BDL rats compared to untreated controls (BDLC 10.1+3.5% vs BDL 
15.4+1.7%, p=0.02). A downward trend towards reduction in Prevotellaceae and 
increase in Ruminococcaceae populations were observed in BDL compared to sham 
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rats (Sham 42.6+12.9% vs BDL 6.3+1.8%, p=0.07 and Sham 28.5+9.8% vs BDL 
49.3+6.6%, p=0.09 respectively) but no significant changes with Yaq-001 in either 
sham or BDL rats were observed. No significant differences in Lachnospiraceae 
populations were observed between BDL and sham rats, Yaq-001-treated and 
untreated BDL or sham rats. Peptostreptococcaceae populations collapsed in BDL 
rats compared to sham controls (BDL 0+0% vs Sham 8.2+1.7%, p=0.005). No 
significant differences were observed with Yaq-001 treatment in either BDL or sham 
rats.  
 
8.3.5.4 Genus Level 
a.      b. 
 
c.      d. 
 
e. 
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Figure 8.40 Geni in which significant differences between groups (sham, sham 
carbon treated, bile duct ligated and carbon treated bile duct ligated rats) were 
observed: 
a) Peptostreptococcaceae 
b) Clostridium XI 
c) Clostridium XVIII 
d) Clostridium XIVb 
e) Marvinbryantia 
 
Bile duct ligation is associated with a relative expansion in firmicutes at the expense 
of bacteroides populations. Carbon treatment in context of both sham and BDL is 
associated with a further expansion of firmicutes populations. At order level, bile duct 
ligation is associated with an increase in clostridia at the expense of bacteroidia. This 
is further increased with sham and most markedly in BDL carbon treated rats. At 
family level, untreated BDL, carbon treated sham and BDL rats are observed to have 
a collapse of prevotellaceae. BDL is associated with an expansion in bacteroidaceae 
and autochthonous lachnospiraceae and ruminococcaceae populations. The latter 
two families predominate in carbon treated BDL rats at the expense of 
bacteroidaceae. BDL was found to be associated with a significant collapse in 
peptostreptococcaceae, clostridium XI and XIVb populations. Near significant 
changes were observed at the level of the clostridium XVIII genus (p=0.05) and 
marvinbryantia (p=0.07). Carbon therapy was associated with significant shifts in 
marvinbryantia and clostridium XIVb populations.  
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8.3.6 Urinary 1NMR analysis 
Principal Component Analysis 
   
 Sham Sham+Carbon BDL BDL+Carbon 
Sham  0.79 1.71 1.20 
Sham+Carbon 0.79  1.36 1.64 
BDL 1.71 1.36  0.12 
BDL+Carbon 1.20 1.64 0.12  
 
Figure 8.41 Principal Component Analysis 
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BDL/Sham 
 
Figure 8.42 Relative urinary concentrations of metabolites in BDL compared to 
sham (n=6/group). Red columns denote higher concentrations in BDL vs sham. Blue 
columns denote lower concentrations in BDL vs sham * denotes statistically 
significant difference between BDL and sham 
 
Carbon treated BDL/BDL 
 
Figure 8.43 Relative urinary concentrations of metabolites in BDL+C compared to 
BDL (n=6/group). Red columns denote higher concentrations in BDLC vs BDL 
Blue columns denote lower concentrations in BDLC vs BDL denotes statistically 
significant difference between BDLC and BDL 
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Carbon treated sham/Sham 
 
Figure 8.44 Relative urinary concentrations of metabolites in Sham= carbon 
compared to sham (n=6/group).  Red columns denote higher concentrations in 
ShamC vs sham. Blue columns denote lower concentrations in ShamC vs sham 
* denotes statistically significant difference between ShamC and sham 
 
Carbon therapy is associated with a significant increase in urinary formate and 
creatinine with significant reductions in glycine, benzoate and acetate. No significant 
differences in urinary metabolomic profile between untreated and carbon-treated 
sham rats were observed.  
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8.3.7 Markers of Bacterial Translocation 
(a)  
     
(b) 
            
(c) 
            
Figure 8.45  
(a) Portal venous endotoxin (LAL assay) (n=4/group) 
(b) Bacterial DNA positivity in portal venous plasma (n=4/group) 
(c) Mesenteric lymph node culture positivity (n=5/group) 
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Oral Yaq-001 administration is associated with a reduction in portal venous 
endotoxin, portal venous plasma bacterial DNA positivity but no significant difference 
in mesenteric lymph node culture. This is consistent with the known in vitro 
properties of carbon in which bacterial ligands are adsorbed but no significant effect 
on bacterial growth kinetics is observed. 
 
8.3.8 ACLF Data  
    
 
       
Figure 8.46 Biochemical response to oral Yaq-001 carbon therapy  
(a) Alanine transaminase (Sham n=13, Sham+C n=15, Sham+LPS n=8, 
Sham+LPS+C n=10, BDL n=12, BDL+C n=14, BDL+LPS n=10, BDL+LPS+C 
n=10) 
(b) Alkaline phosphatase (Sham n=21, Sham+C n=16, BDL n=25, BDL+C n=26) 
(c) Albumin (Sham n=22, Sham+C n=16, BDL n=24, BDL+C n=25) 
(d) Creatinine (Sham n=23, Sham+C n=18, Sham+LPS n=8, Sham+LPS+C 
n=4,BDL n=22, BDL+C n=25, BDL+LPS n=12, BDL+LPS+C n=9) 
* denotes p<0.05 ***  denotes p<0.001 
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Figure 8.47 Portal Pressure (mm Hg)  
(Sham n=21, Sham+C n=22, Sham+LPS   n=8, Sham+LPS+C n=10, BDL n=15, 
BDL+C n=26, BDL+LPS n=9, BDL+LPS+C n=9) 
 
       
Figure 8.48 Mean Arterial Pressure  
(Sham n=13, Sham+C n=15, Sham+LPS  n=8, Sham+LPS+C n=10, BDL n=12, 
BDL+C n=14, BDL+LPS n=10, BDL+LPS+C n=10) 
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Liver Histology  
Bile duct ligation was associated with nodule formation, cholangiocyte proliferation 
and inflammatory infiltrate. Yaq-001 therapy did not significantly alter fibrosis as 
evidenced by surrogate collagen proportionate area as described in section 6.3. This 
suggests that the effect of Yaq-001 on portal pressure is at the level of the 
inflammatory component of portal hypertension. Intraperitoneal LPS challenge was 
associated with an exacerbation of the inflammatory infiltrate in BDL rats, an effect 
attenuated with Yaq-001 therapy.  
(a)      (b) 
 
(c)       (d)    
Figure 8.49  Liver histology (Haemaoxylin and Eosin)  
(a) Sham+LPS   (b) sham+LPS+Yaq-001  (c) BDL+LPS   (d) BDL+LPS+Yaq-001 
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Oral administration of Yaq-001 in a model of ACLF is associated with a significant 
reduction in organ injury and improvement in portal pressure, important prognostic 
determinants in the clinical context. The BDL+LPS model assesses in vivo endotoxin 
sensitivity and therefore the observed improvement with carbon therapy is indicative 
of a diminished primed state to endotoxin challenge. This is an identical phenotype to 
that observed in in vitro studies of circulating and tissue resident innate immune 
populations.  
 
8.4 Discussion 
The primary aim of this study was to evaluate the efficacy of oral administration of 
Yaq-001 in the bile duct ligated model of cirrhosis particularly with regards to 
clinically relevant end-points such as markers of organ injury, portal haemodynamics 
and innate immune function.  
Two weeks of oral Yaq-001 therapy was found to be associated with a significant 
reduction in alanine transaminase as a marker of hepatocellular liver injury in bile 
duct ligated rats. The most marked effects were observed with BDL +LPS rats 
suggesting a reduction in in vivo endotoxin sensitivity conferred by the carbon.  
A significant reduction in portal pressure in BDL and BDL+LPS rats was observed 
following oral administration of Yaq-001 carbon. Carbon therapy however had no 
significant impact on mean arterial pressure demonstrating that the haemodynamic 
effects are confined locally within the portal circulation. Collagen proportionate area 
as a measure of fibrosis was not found to be significantly different following carbon 
treatment suggestive that the effects of Yaq-001 were exerted at the level of the 
dynamic modifiable component of portal hypertension driven by inflammation rather 
than a modulation of fibrosis and fixed intrahepatic resistance.  
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Kupffer cells play a key role in regulation of endotoxin-sensitivity and thus are a key 
cell type responsible for integration of inflammatory and portal haemodynamic 
signals. Kupffer cell population and function were observed to be modulated by 
carbon-treatment. Normalisation of Kupffer cell populations towards sham levels was 
observed in carbon-treated BDL rats. A significant reduction in LPS-induced Kupffer 
cell ROS activity was observed with Yaq-001 suggestive that Kupffer cells in carbon-
treated BDL rats are less primed to subsequent endotoxin challenge. Biochemically 
this finding was paralleled by a significant reduction in alanine transaminase 
suggesting diminished ROS-induced liver injury.   
An important consideration in the study was determining the relative contribution of 
trafficking portal venous monocyte and neutrophil populations within the portal vein to 
total liver ROS and subsequent organ injury and portal hypertension. A significant 
increase in absolute neutrophil count and population in both portal venous and 
arterial blood was observed in bile duct ligated rats compared to sham control. 
Phenotypically, bile duct ligation was associated increase in portal venous 
constitutive ROS and LPS-induced ROS production. Yaq-001 therapy resulted in a 
significant reduction in portal venous monocyte LPS-induced ROS production, most 
markedly within the CD43hi subpopulation. Significant reductions in total leucocyte 
and neutrophil counts were observed with carbon therapy with trends towards 
reduction in monocyte populations.  
No significant shifts in mesenteric lymph node populations were observed with 
carbon therapy albeit in context of a small sample size. Expansions in CD68+ and 
CD163+ populations observed with bile duct ligated rat mesenteric lymph nodes 
appear to be non-statistically reduced with carbon therapy. Further studies are 
required to augment this dataset to ascertain whether this is significant observation. 
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In light of the observation of diminished endotoxin sensitivity with carbon therapy, 
evaluation of TLR4 and inflammasome activation was performed using rodent 
plasma co-incubated with HEK reporter cell lines. A significant increase in 
inflammasome activation was observed with BDL rats which was significantly 
attenuated with carbon therapy. Similar but non-significant trends were observed with 
the TLR4 reporter cell lines. Of note only small numbers were used for this 
experiment. This data suggests a strong inflammasome activation associated with 
cellular ROS production both in the portal vein, liver and arterial monocyte/ 
macrophage populations. TLR4 signalling may be playing a contributory role and 
warrants further evaluation in larger studies although endotoxin sensitivity is not a 
solely mediated via TLR4 expression. Furthermore, the reporter cell line is an 
artificial and does not account for preconditioning of these pathways by weeks of 
endotoxin exposure in the animal model system. Cell sorting and gene expression 
data would serve to complement this data set well and further determine the 
molecular mechanisms of action of the carbons, most markedly on the monocyte / 
macrophage cell lines of the gut-liver axis. 
Sugar probe-based assays were used to evaluate intestinal permeability in BDL rats. 
Progressive increases in intestinal permeability were observed with progressive 
disease. In contrast, carbon therapy was associated with a significant improvement 
in intestinal permeability. Technical limitations in ability to discriminate 6-o-methyl-
glucose and rhamnose resulted in urinary concentrations of these sugars as a 
composite figure. This compromises the evaluation of intestinal permeability to 
smaller solutes but interestingly follows the same trend as the lactulose/creatinine 
ratios. Replication of the studies using lactulose and rhamnose only represents the 
best next step to assess this further.  
Paneth cell gene expression has been implicated in susceptibility to bacterial 
translocation in a CCl4 model of cirrhosis. Bile duct ligation was associated with a 
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significant increase in defensin 5 and 8 and lysozyme gene expression within 
terminal ileal tissue. Carbon therapy has no significant impact on Paneth cell gene 
expression data although downward trends were observed with defensins 5 and 8. 
Of note a borderline significant reduction in TNFα gene expression was observed 
with carbon therapy in context of bile duct ligation. Augmentation of this dataset is 
required to further validate these observations. Of note, TNFα and defensins act 
synergistically and so the biological effect of these observations may be functionally 
more significant than evidenced by the single datasets.  
Bile duct ligation was found to be associated with a marked reduction in several 
unconjugated plasma bile acids. Significant reductions were observed with both 
primary bile acids cholic acid, chenodeoxycholic acid and secondary bile acids 
ursodeoxycholic acid, lithocholic acid and a near significant reduction with 
deoxycholic acid. Alpha muricholic acid an FXR antagonists in rodents was also 
found to be significantly depleted with bile duct ligation as compared to sham.  
Whilst the bile duct ligated rat model is one of extra-hepatic cholestasis, this data 
suggests that by week 4, there is a significant depletion of the total bile acid pool 
associated with an increase in urinary bile acid excretion. The increased urinary bile 
acids may therefore be the mechanism by which the total bile pool is depleted over 
the course of 4 weeks. BDL mice have been shown to have an increased renal 
expression of MRP4, a bile acid export protein in the proximal convoluted tubule. 
Renal excretion of bile acids may be a protective mechanism in context of bile duct 
ligation to minimize toxicity of high levels of circulating unconjugated bile acids in 
context of cholestasis. 
A significant reduction in deoxycholic acid was observed in carbon-treated sham rats 
compared to untreated controls. Non-significant downward trends in several bile 
acids were observed in carbon-treated sham rats compared to sham controls (albeit 
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in context of wide standard errors). No significant differences in renal excretion of 
total bile acids was observed with carbon treated compared to non-carbon treated 
sham rats. This suggests that the intraluminal adsorption of carbon rather than 
enhanced renal excretion of bile acids underlies the observations.   
One potential explanation for differential adsorption of bile acids by Yaq-001 may be 
a preferential adsorption of hydrophobic compounds. The only significant difference 
in bile acid concentration was observed with deoxycholic acid which is relatively 
more hydrophobic. In vitro studies are also required to ascertain differential 
adsorption kinetics of carbon for individual bile acids.  
A significant reduction in lithocholic acid and chenodeoxycholic acid was observed 
with carbon treatment of bile duct ligated rats. It must be noted however, that despite 
the statistical significance identified, the percentage reduction with carbon therapy 
was very low. Urinary bile acid excretion was not found to be significantly increased 
in carbon-treated BDL rats as compared to untreated BDL controls. This suggests 
the site of action is likely in the intestine rather than promotion of renal excretion but 
further studies are warranted to augment the dataset and determine differential 
urinary bile acid profile.  
Oral carbon therapy in sham animals did not significantly influence arterial 
concentrations of standard electrolytes and micronutrients. A significant reduction in 
folate levels were however observed. This may be a function of intraluminal carbon 
adsorption or due to a shift in microbiome composition with carbon treated sham 
animals.  
A significant improvement in final body weight was observed in carbon-treated 
compared to untreated BDL rats. No significant difference in final body was observed 
between the sham groups. Weight loss in cirrhosis is attributed to an increased 
catabolic state particularly in the context of systemic inflammatory response. The 
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animals in this experiment were pair-fed and it seems likely that the weight gain in 
the BDL rats is due to a reduction in the systemic inflammatory response observed 
and an improvement in organ injury. 
 
Significant shifts in stool microbiome composition were observed with carbon therapy 
both in context of sham or bile duct ligated carbon-fed rats despite the apparent lack 
of impact on bacterial growth kinetics. Carbon therapy both in contact of sham rats 
and bile duct ligated rats results in a relative expansion of firmicutes phyla and a 
reciprocal contraction in bacteroides populations. The predominant shifts in 
firmicutes phyla are due to an expansion in clostridia populations and reduction in 
bacteroides. Carbon therapy resulted in similar shifts in a progressive manner with 
sham and subsequently BDL rats. 
Analysis at genus level is perhaps more informative still. BDL is associated with a 
collapse of peptostreptococcaceae, clostridium XI and XVIII. Bile duct ligation is 
significantly associated with an expansion of clostridium XIVb and upward trend in 
marvinbryantia. Given the small sample size, it is suggestive that the signal change 
with disease and carbon therapy is strong.  
 
Urinary NMR analysis is a reflection of the combined metabolic status of both host 
and microbiota. Carbon treatment was associated with a distinct shift in metabolomic 
profile in BDL rats. In contrast, no significant differences were observed in urinary 
metabolomic profile with carbon treatment in sham rats. The most marked difference 
in profile was a significant increase in urinary formate with a near two-fold increase in 
concentration. Formate together with lactate, acetate and succinate are products 
generated by mixed acid fermentation (MAF) typically by bacteria such as 
enterobacter. MAF is not the preferred metabolic pathway for facultative anaerobes 
and may be indicative that enterobacter populations may be under conditions of 
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metabolic stress in carbon treated BDL. Given these are the type of bacteria which 
are often pathogenic in cirrhosis with a heightened propensity to translocate, this 
may represent a beneficial change. Formate itself exhibits antibacterial properties 
and has been used in feed to diminish carriage of facultative anaerobes such as 
salmonella in poultry. This may further shape the microbial population.  
A significant increase in urinary creatinine was observed in carbon-treated BDL rats 
compared to untreated BDL. This may be indicative of an improvement in renal 
function as evidenced by a significant reduction in plasma creatinine in these 
animals. Significant reductions in urinary glycine and benzoate were observed with 
carbon treatment. Benzoic acid is a fungistatic compound produced by bacteria as a 
byproduct of phenylalanine and polyphenol metabolism. It is conjugated to glycine in 
the liver and excreted as hippuric acid. Significant reductions in urinary benzoate and 
glycine were observed with carbon treatment although hippurate levels were not 
significantly different. Further analysis is required to determine the relative 
contribution of host and microbial metabolism to these observations.  
 
In summary, oral administration of Yaq-001 to cirrhotic rats is associated with a 
significant reduction in organ injury and improvement in portal pressure, important 
clinical prognostic determinants. Carbon therapy attenuates the heightened 
endotoxin sensitivity observed in the BDL model and is associated with a 
normalisation of population and functional status in tissue resident and trafficking 
innate immune populations in the gut-liver axis with diminished inflammasome 
activation. These changes are associated with a distinct shift in metabolomic 
phenotype associated with an improvement in body weight and expansion of 
autochthonous bacterial populations in the microbiome. Further studies are required 
to more fully ascertain the mechanisms of action of Yaq-001 in more detail but the 
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observed changes in vivo demonstrate that the carbon is safe and efficacious and is 
a good candidate for translation to clinical studies.  
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Chapter 9 
Oral nanoporous carbons attenuate disease pathogenesis in models of 
Non-alcoholic fatty liver disease 
 
9.1 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is an important cause of cirrhosis and 
hepatocellular carcinoma. Exponential rises in prevalence have been observed 
affecting 15% of the developed population, attributed to a worldwide increase in 
obesity. Emerging evidence however has implicated the gut as a driver of disordered 
lipid metabolism in NAFLD a target for which there is no effective interventional 
strategy.  
Gut-derived endotoxin has been shown to be an important pathogenic factor driving 
progression to steatohepatitis, cirrhosis and hepatocellular carcinoma. Intraluminal 
acetaldehyde derived from gut bacteria causes mucosal injury and increased portal 
endotoxaemia. This results in Kupffer cell activation, ROS and TNFα production 
promoting liver injury, stellate cell activation and fibrosis. Removal of these 
intraluminal gut-derived factors represent an unmet clinical need with the potential to 
impact significantly on disease progression, morbidity and mortality. 
Having established that oral administration of Yaq-001 results in an improvement in 
organ inury, haemodynamic profile and normalisation of populations and phenotype 
of innate immune function in a model of cirrhosis, the final and exploratory stage of 
the project was to determine efficacy of oral Yaq-001 therapy in model systems of 
non-alcoholic fatty liver disease in particular as Yaq-001 has a high adsorptive for 
acetaldehyde in addition to endotoxin. Several models of non-alcoholic fatty liver 
disease utilise dietary methods such as high fat high carbohydrate compositions. As 
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Yaq-001 carbons are non-selective adsorbants with the possibility of removing a 
dietary insult, the models studied were the dietary deficient and knock-out models of 
leptin deficient and methionine choline deficient mice. 
 
9.2 Aims 
The aim of this pilot study were to establish whether oral administration of Yaq-001 
carbon therapy was associated with a significant attenuation of liver injury in two 
complementary models of non-alcoholic fatty liver disease.  
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9.3 Leptin deficient mice (obob-/-) 
9.3.1 Markers of liver Injury 
Male genetically leptin deficient (ob/ob) obese mice were randomized to receive 
standard powdered chow with or without carbon supplementation for four weeks. 
Heterozygote mice were used as the control population and also randomized to 
receive standard powdered chow with or without carbon supplementation for four 
weeks. 
 
Figure 9.1  Plasma alanine transaminase levels at 4 weeks (n=5/group) 
  * denotes p<0.05 
 
 
In accordance with previous literature, the leptin deficient mouse model was 
associated with a significant deterioration in liver biochemistry as evidenced by an 
increase in alanine transaminase from 38+ 2.83 IU/ml in heterozygote control 
animals to 889 IU/ml in ob/ob mice. 4 weeks of carbon therapy was found to be 
associated with a significantly lower ALT in Yaq-001-treated compared to untreated 
ob/ob mice with values of 889 IU/ml (+/-280) and 408 IU/ml (+/-42) respectively.  This 
is indicative of an abrogation of liver injury in obese mice by Yaq-001. 
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Figure 9.2 Liver histology (Haematoxylin & Eosin) (40x) 
(a) Ob- heterozygote untreated 
 
(b) Ob- heterozygote + carbon 
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 (c) Ob-/Ob- untreated 
 
(d) Ob-Ob- + carbon 
 
 
Marked steatosis was evident in both untreated and treated leptin-deficient mice. 
Inflammatory infiltration was also evident in both groups but less marked in Yaq-001 
treated ob-ob- mice.  
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9.3.2 Kupffer Cell Populations 
 
Figure 9.3 Kupffer cell populations in leptin deficient mice as determined by 
F4/80+-gated non-parenchymal cell fraction (n=5/group)   ** denotes p<0.005 
 
Kupffer cell populations were determined using F4/80+-gated liver non-parenchymal 
cell fraction. A significant increase in F4/80+ cell population (expressed as a fraction 
of total non-parenchymal cell fraction) was observed between untreated 
heterozygote controls and untreated ob/ob mice. Carbon therapy was associated 
with a significant reduction in this population in heterozygote controls but not ob/ob 
mice.  
(a)        (b) 
 
 
 
(c)       (d) 
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Figure 9.4 Kupffer cell (F4/80+) subpopulations (n=5/group) 
  (a) CD11b+CD68- populations 
  (b) CD11b-CD68+ populations 
  (c) CD11b+CD68+ populations 
  (d) CD11b-CD68- populations 
 
Kupffer cell subpopulations were determined by CD11b and CD68 surface 
expression. Previous studies demonstrate that F4/80+/CD11b+ populations produce 
higher TNFα in response to TLR2 and 9 ligand exposure with the capacity to 
differentiate to CD68+/CD11b+ cells (Nakashima et al). F4/80+/CD68+/CD11b+ 
populations typically represent a small percentage of the non-parenchymal cell liver 
fraction and differentiate from F4/80+/CD11b+ cells in response to endotoxin 
exposure. Clearly there are significant shifts in Kupffer cell sub-populations with 
carbon therapy in which there appears to be an expansion in CD68+ Kupffer cell 
populations at the expense of CD11b+ subpopulations perhaps suggesting a shift 
away from a more pro-inflammatory phenotype. Current understanding regarding the 
role of these sub-populations of Kupffer cells is limited and therefore correlation with 
phenotype is important. 
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9.3.3 Kupffer cell ROS production 
(a)     (b) 
  
Figure 9.5 Kupffer cell (F4/80+) ROS production 
 
  (a) Constitutive ROS production 
  (b) LPS-induced ROS production 
 
Analysis of Kupffer cell ROS production was technically limited by Kupffer cell yield in 
the heterozygote control populations in which liver size was considerably smaller 
than the ob/ob groups. A significant reduction in LPS-induced ROS production was 
observed in carbon treated compared to untreated ob/ob mice. This phenotype is 
identical to carbon treated BDL kupffer cell populations suggesting that the 
mechanisms are similar in both model systems. This diminished primed state to 
endotoxin challenge provides a potential explanation for the observed improvement 
in liver biochemistry despite small sample size.  
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9.3.4 Urinary NMR Profiling 
  
Figure 9.6 Principal Component Analysis (n=6/group)  
  (Black =ob+Yaq-001; Dark blue =obob+Yaq-001; Light blue ob  
  untreated; Green = ob/ob untreated) 
 
With regards to urinary metabolomic profile, ob/ob mice were characterized by a 
glycosuria, a typical phenotype of metabolic syndrome. In contrast, carbon treatment 
resulted in a significant metabolic shift in leptin-deficient mice resulting in a 
predominant lactate and acetate spikes in carbon treated leptin-deficient mice. Ob- 
heterozygote controls were characterized by TMA whereas carbon treated 
heterozygote controls were characterised by a predominant acetate spike. 
 
9.3.5 Body Weight 
 
Figure 9.7  Final body weight (n=5/group) 
glucose acetate lactate+acetate TMA
2.94 6.13 18.77
2.94 2.12 1.76
6.13 2.12 6.01
18.77 1.76 6.01
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A trend towards reduction in final body weight was observed in carbon treated ob/ob 
(42.28 + 1.24 g) mice compared to untreated control (46.34 + 1.39 g) (p=0.066) 
whereas no significant effects were observed with heterozygote mice. This is in 
contrast to the significant weight increase in BDL mice. Of note, the group sizes were 
small (n=5) and the study was underpowered. Further studies are required to validate 
these findings and augment the dataset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
237 
 
9.4 Methionine choline deficient mice 
The effects of oral carbon therapy methionine choline deficient mouse model was 
also evaluated in methionine choline deficient mice. Whilst lacking some features of 
the full metabolic syndrome, it is a good model of hepatic oxidative stress with 
marked inflammatory phenotype and therefore was a good complementary model to 
evaluate the efficacy of Yaq-001.  
Female C57/B mice were randomized to receive a diet of control powdered chow or 
powdered chow deficient in methionine choline (IPS Irradiated Baker Amino Acid Diet 
without Choline or Methionine (578B – 1811438) for 4 weeks. These feeds were 
randomized to be supplemented with carbon or not. The carbon was administered at 
a dose of 0.4g/100g body weight per day. The diet and treatment was continued for 4 
weeks.  
  
Figure 9.8 Plasma alanine transaminase  
(Wild type/Wild type+carbon n=5) 
(MDC/MCD+carbon, n=8) 
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Group WT 
(Mean) 
SEM WT+C 
(Mean) 
SEM MCD 
(Mean) 
SEM MCD+C 
(Mean) 
SEM 
ALT (IU/ml) 16.94 1.4 32.66 20.08 313.5 38.96 119.51 28.59 
AST (IU/ml) 74.14 19.45 93 36.12 286.83 26.78 139.56 23.71 
Bilirubin (μmol/L) 3.96 0.58 5.56 2.5 23.8 5.72 17.58 4.77 
ALP (IU/L) 55.46 3.17 92 23.93 75.48 4.32 70.91 9.41 
Albumin (g/L) 25.93 1.12 28.15 1.16 19.72 2.89 22.67 3.74 
Creatinine (μmol/L) 9.38 0.26 8.02 0.57 8.86 0.93 9.81 0.68 
 
Table 9.1 Plasma biochemistry  
(Wild type/Wild type+carbon n=5) 
(MDC/MCD+carbon, n=8) 
 
(a)              (b) 
 
(c)              (d) 
 
Figure 9.9 Liver histology (H&E) 
  (a) MCD fed mice 
  (b) MCD+carbon fed mice 
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Figure 9.10 NAS score  
(Wild type/Wild type+carbon n=5) 
(MDC/MCD+carbon, n=8) 
 
A highly significant near three-fold reduction in alanine transaminase were observed 
with carbon therapy in MCD mice. MCD mice had a non-significantly lower NAS 
score than untreated MCD mice. This may reflect the significantly lower ALT in Yaq-
001 treated mice but further studies are required to ascertain the mechanisms of 
action of Yaq-001 in this model.  
 
 
 
 
 
 
 
9.5 Discussion 
Oral Yaq-001 therapy is associated with a significant improvement in liver 
biochemistry in two complementary models of non-alcoholic fatty liver disease. This 
is associated with a significant attenuation in Kupffer cell ROS production in 
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response to LPS challenge indicative of a diminished endotoxin-primed state. An 
identical phenotype was observed with carbon therapy in cirrhotic rats suggestive of 
common mechanisms of action of the carbon in both model systems. Furthermore, 
carbon therapy significantly altered the Kupffer cell total populations and 
subpopulations both in ob/ob mice and heterozygote controls. The most significant 
reduction in liver injury was observed in methionine choline deficient mice, a model 
characterized by oxidative stress and pro-inflammatory phenotype. This suggests 
that Yaq-001 therapy results in an attenuation of oxidative stress and inflammation, 
consistent with the current flow cytometry data. Further work is required to 
characterise these mechanisms.  
Oral carbon therapy was also associated with a distinct shift in metabolomic 
phenotype in ob/ob and heterozygote control populations. Reductions in final body 
weight were also observed in carbon-treated leptin-deficient mice with no significant 
effects on heterozygote controls. Further work is required to ascertain the 
mechanisms of action with a particular emphasis on stool microbiome analysis. 
Future studies will be conducted on more physiologically relevant NAFLD models 
with longitudinal analysis of metabolomic profile and stool microbiome metagenomic 
studies. Liver, terminal ileum and colon tissue microarrays will be performed to 
characterise the relative local and distant effects of carbon therapy, of particular 
importance given the non-selective adsorptive properties of Yaq-001. Of particular 
interest will be the effects on TLR4-dependent pathways and markers of fibrosis.  
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Chapter 10 
Conclusions 
 
The gut-liver axis plays a central role in disease progression in cirrhosis. Bacterial 
translocation plays an important role in the pathogenesis of complications of cirrhosis 
and, in particular, ACLF, associated with multi-organ failure and a high mortality. This 
study describes the contribution of the gut-liver axis to the clinical phenotype in 
cirrhosis and describes the associated dysfunctional innate immune response. 
Characterisation of changes at the gut-barrier interface and innate immune 
populations along the gut-liver axis were described in a model of ACLF. Evaluation of 
the effiicacy of Yaq-001, a non-absorbable endotoxin adsorbant in a model of 
cirrhosis and NAFLD was determined.  
 
Data from the clinical study described the differential endotoxin concentrations and 
associated innate immune response within the splanchnic territories in patients with 
refractory variceal haemorrhage undergoing TIPSS insertion. In so doing, the relative 
contribution of the gut and liver to systemic endotoxin concentrations and innate 
immune response was determined.  Portal-derived endotoxaemia and associated 
neutrophil dysfunction was observed with apparent preserved integrity of endotoxin 
surveillance mechanisms within the liver despite advanced disease.  This trans-
hepatic gradient of endotoxin, neutrophil dysfunction and cytokine profile was found 
to be disrupted upon TIPSS insertion.  
Neutrophil function has previously been identified as of prognostic worth in patients 
with cirrhosis and alcoholic hepatitis. In this study, neutrophil dysfunction was 
significantly worse in patients who developed ACLF compared uncomplicated acute 
decompensation. The presence of ACLF in this context was found to be associated 
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with a significantly worse prognosis. Portal venous neutrophil ROS was found to 
significantly correlate with portal pressure reinforcing the importance of the dynamic 
inflammatory-driven component of portal hypertension in this context.  
 
To further evaluate characterise the mechanisms underlying the observed high 
bacterial translocation rates clinically, the bile duct ligated rat model, a model of 
cirrhosis was studied. The BDL rat model is one of increased liver injury, portal 
hypertension with a pro-inflammatory phenotype. Data from this project has 
demonstrated in the bile duct ligation model that a significant difference in phenotype 
at the gut-barrier interface, innate immune function along the gut-liver axis and portal 
haemodynamic status is observed. This is associated with a distinct alteration in 
microbiome composition and function.  Phenotypically this is associated with a 
significant increase in endotoxin sensitivity both in vivo and in vitro.  
 
 
Figure 10.1 Pathogenesis of bacterial translocation and role in the natural history of cirrhosis 
Alcohol 
NAFLD 
Cholestasis 
Cirrhosis 
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Modulation of the gut liver axis remains an unmet clinical need. Selective intestinal 
decontamination is the only strategy currently in clinical practice which impacts on 
this process but antibiotic resistance and superinfection limits their role. Yaq-001, an 
activated carbon with tailored bimodal porosity has been shown to exhibit favourable 
adsorption kinetics in vitro with regards to intraluminal bacterial factors such as 
endotoxin and acetaldehyde without exerting an effect on bacterial growth kinetics.  
Oral administration of Yaq-001 therapy is associated with a significant reduction in 
liver and renal injury associated with a significant improvement in portal 
haemodynamic status. Locally, carbon therapy results in an improvement in gut 
barrier function as evidenced by intestinal permeability and nutritional status. 
Despite the lack of effects on bacterial growth kinetics, oral carbon therapy was 
found to be associated with a distinct shift in microbiome composition and function. 
This is paralleled by a significant normalization in both tissue resident and circulating 
innate immune populations and phenotype characterised by a reduction in oxidative 
stress. HPLC data suggests that these carbons are capable of binding bile acids and 
influencing folate availability which may be a function of microbiome composition or 
may be a function of adsorption. Despite this most other nutritional factors such as 
common electrolytes and trace elements remain unchanged.  
Preliminary work in complementary models of non-alcoholic fatty liver disease 
suggest that a similar phenotype of diminished organ injury and oxidative stress is 
observed with oral administration of carbons of bimodal porosity. There is some 
suggestion of potential to impact on elements of the metabolic syndrome but further 
work is required to further characterize these effects in more physiologically relevant 
model systems.  
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Figure 10.2  Effects of Yaq-001 on pathogenesis of cirrhosis 
Future pre-clinical experiments will be conducted to ascertain the underlying cellular 
mechanisms of action of Yaq-001 in models of liver disease. The nature of the 
underlying liver injury and cell death requires further characterisation.  Further work 
will be conducted to determine whether Yaq-001 carbons confer a protective effect 
via reduction in apoptosis, autophagy or necrosis. Markers of endoplasmic reticulum, 
mitochondrial and oxidative stress will be performed on liver, terminal ileal and 
colonic tissue. Further characterisation of nutritional profile including fat soluble 
vitamins is required together with an assessment of the effects of carbon on 
nutritional uptake.  Further assessment of mechanisms of reduced endotoxin 
sensitivity will be conducted assessing TLR4 pathways in liver, intestine, kidney and 
brain using gene and protein expression. Phylogenic studies of caecal luminal 
microbiome composition will be complemented by metagenomic studies to assess a 
functional shift in the microbiome. Microbiome composition will also be evaluated in 
caecal mucosal associated microflora populations. 
Alcohol	
NAFLD	
Cholestasis	
Cirrhosis	
Yaq-001 
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Activated carbon Yaq-001 therefore exhibits many favourable adsorptive properties 
which makes it an excellent candidate product for translation to clinical studies. 
Consideration of a colonic release preparation will help obviate concerns regarding 
bile salt absorption and potential drug interactions. Nonetheless, this technology 
represents a novel interventional strategy to modulate the gut-liver axis without being 
associated with any of the attendant risks of oral antibiotics. In these series of 
experiments, we demonstrate that Yaq-001 has the ability to impact on many 
clinically relevant end-points both in cirrhotic and non-cirrhotic models. Whilst further 
studies are required to more fully ascertain all of the molecular pathways influenced 
by the carbons, considerable potential has been shown in the experiments described 
in this thesis. Translational clinical studies to evaluate efficacy in NAFLD and cirrhotic 
patients are scheduled with the potential to impact on natural history of a disease 
process with a currently unacceptable mortality with an otherwise unmet clinical 
need.  
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